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Abstract
Background: Although depression can affect anyone at any time, the first year after the
birth of a child appears to be a time when both parents are more likely to experience de-
pression. Research has mainly focussed on maternal perinatal or early depression which
has an estimated incidence of 10-15%. Less is known about early paternal depression or
early comorbid depression, where both parents experience depression.
Methods: I conduct a systematic review on the prevalence of early comorbid parental
depression and associated childhood outcomes. Next, I explore adolescent depression re-
cording in UK primary care, and trends over time. Finally, I use structural equation
modelling to provide a quantitative analysis of the association between early comorbid
parental depression and adolescent outcomes, focussing on the effects of recurrent par-
ental depression and internalizing behaviours in childhood. I examine depression and its
intergenerational transmission using data from a large UK primary care database, The
Health Improvement Network (THIN).
Results: Prevalence of early comorbid depression in parents ranged from 0 to 20%.
However, it was not feasible to perform a meta-analysis due to measurement variation
and study quality. I identified only two studies assessing child outcomes. Diagnoses
of adolescent depression and antidepressant prescribing have increased in recent years
despite a temporary drop in 2002-2005. Symptom recording increased steadily between
1995-2009. I did not find evidence for an association between early comorbid parental
depression and adolescent depression (OR: 2.02, 95% CI: 0.42-9.67). Early maternal
depression does increase the risk of adolescent depression. The effect is mainly indirect,
mediated by recurrent parental depression (OR: 1.54, 95% CI: 1.26-1.87), as opposed to
direct (OR: 1.06, 95% CI: 0.69-1.63). Childhood internalizing behaviour might be an
early indicator of depression risk.
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Conclusion: Early parental depression increases the risk of adolescent depression,
but the effect is strongly mediated by recurrent parental depression.
Samenvatting van de thesis
Summary in Dutch
Achtergrond: Hoewel depressie een aandoening is die iedereen op elk moment kan
treffen, lijkt het eerste jaar na de geboorte van een kind een tijd te zijn waarin beide ouders
een verhoogd risico op depressie hebben. Tot dusver heeft onderzoek zich vooral gericht
op depressie in moeders rond de geboorte (perinatale of vroege depressie), een stoornis
die in 10-15% van nieuwe moeders voorkomt. We weten minder over vroege depressie
in vaders en comorbide depressie, waarbij beide ouders een depressive episode ervaren.
Methoden: In mijn thesis presenteer ik een literatuurstudie naar het vrkomen (pre-
valentie) van comorbide vroege depressie in ouders en gezondheidsgerelateerde gevolgen
in hun kinderen. Daarnaast onderzoek ik de registratie van depressie in kinderen in de
elektronische patintendossiers van huisarten in het Verenigd Koninkrijk, en kijk of en hoe
dit is veranderd tussen 1995 en 2009. Tenslotte gebruik ik Structural Equation Modelling
(SEM) voor een kwantitatieve analyse van de associatie tussen vroege comorbide de-
pressie in ouders en depressie in hun kinderen. Hierbij richt ik mij vooral op de effecten
van chronische depressie in ouders en symptomen die kunnen wijzen op internaliserend
gedrag (gedrag waarbij men in zichzelf keert en een schadelijke uitwerking heeft waarbij
een person zichzelf i.p.v. anderen schade kan berokkenen) in kinderen. Ik onderzoek
depressie en de overdracht deze stoornis van de ene op de andere generatie met behulp
van The Health Improvement Network (THIN) database, een grote Britse database van
elektronische patintendossiers van huisarten.
Resultaten: Schattingen van het aantal ouders dat beide vroege depressie ervaart
variren van 0 tot 20%. Het was niet mogelijk om middels een meta-analyse een punt-
schatting te maken doordat de geı¨ncludeerde studies sterk verschilden in hoe en wanneer
depressie gemeten werd, en in studie kwaliteit. Ik kon slechts twee studies identificeren
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die gevolgen voor de gezondheid van kinderen hadden gemeten. Diagnoses en recepten
voor antidepressiva voor adolescenten zijn de afgelopen jaar sterk toegenomen, ondanks
een tijdelijke dip tussen 2002 en 2005. Registratie van symptomen van depressie steeg
gestaag tussen 1995 en 2009. Ik heb geen bewijs gevonden voor een associatie tussen
vroege comorbide depressie in ouders en depressie in adolescenten (OR: 2.02, 95% BI:
0.42-9.67). Vroege depressie in moeders verhoogt het risico of depressie in adolescenten.
Dit effect is voornamelijk indirect en wordt gemedieerd door recidiverende depressie
(OR: 1.54, 95% BI: 1.26-1.87). Het directe effect van vroege depressie op depressie in
adolescenten is verwaarloosbaar (OR: 1.06, 95% BI: 0.69-1.63). Internalisatie sympto-
men in kinderen lijken een belangrijke vroege indicator te zijn van een verhoogd risico
op depressie als adolescent.
Conclusie: Vroege depressie in ouders verhoogt het risico op depressie in adoles-
centen. Echter, dit effect speelt slechts voor kinderen van ouders met recidiverende de-
pressie.
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In this thesis, I provide a quantitative analysis of the association between parental
depression in the first postpartum year and depression in adolescent offspring, with in-
ternalizing behaviour in children as a mediator. I examine depression and its intergen-
erational transmission in a large UK primary care database, The Health Improvement
Network (THIN), using one of the largest birth cohorts currently available worldwide.
Depressive disorders are common, serious, and treatable [Regier et al., 1988]. In the
World Health Organization’s Global Burden of Disease Study, unipolar major depression
was predicted to be the second most common cause of disability worldwide by 2020,
and the leading cause for developing countries [Murray and Lopez, 1997]. Although
depression can affect anyone at any time, the first year after the birth of a child appears to
be a time when both men and women are at an increased risk of depression [Dave´ et al.,
2010].
Research has mainly focussed on maternal perinatal depression. The incidence of
depression onset in the first five weeks after delivery was threefold higher in postnatal
women compared to control women [Cox et al., 1993]. The incidence of maternal post-
natal depression has been estimated at 10% in the early weeks postpartum, with episodes
typically lasting two to six months [Cooper and Murray, 1998].
Although early parental depression (EPD) is generally associated with mothers, de-
pression rates are also increased for fathers in the first year after the birth of a child [Dave´
et al., 2010]. Several studies have found that maternal and paternal depression in the first
year postpartum are highly correlated [Paulson and Bazemore, 2010]. Leading on from
this, the incidence of comorbid early parental depression (where both the mother and the
father are depressed simultaneously) might be increased during the first year postpartum
as well.
Comorbid parental depression could have detrimental effects on childhood out-
comes. Research focussing on maternal postnatal depression has found that children
(especially daughters) of mothers who were depressed after childbirth were more likely
than children of non-depressed mothers to develop depression themselves in adolescence.
A similar effect, though less pronounced, has been found for children of depressed fath-
ers.
Research on the effect of comorbid parental depression is sparse. The current hypo-
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thesis is that in the case of single parental depression, the non-depressed parent can form
a buffer to the effects of depression on the child. However, as this shielding opportunity
is not present in families with comorbid parental depression, the effects on children are
hypothesised to be much more severe.
The time span between early parental depression and adolescent depression is very
long, and although previous studies have found the two to be correlated, many children of
parents with early depression will not develop depression themselves. Therefore, an inter-
mediate variable or mediator measured during childhood could provide more information
on risk of depression and identify high risk groups as a target for prevention. Studies have
assessed a variety of internalizing behaviours in children aged from a few months old to
adolescence to examine effects of postnatal depression on child outcomes in studies with
short follow-up times. In this thesis, I propose a model in which early parental depression
is associated with adolescent depression, mediated by childhood internalizing behaviour.
The main research question I try to answer is whether children of parents who both
had depression in the first year after childbirth (early comorbid parental depression) are
more likely to develop depression in adolescence compared to children of non-depressed
parents or families in whom only one parent was depressed.
I aim to answer this question by exploring the following sub-questions:
1. What is the prevalence of early comorbid parental depression?
2. How has adolescent depression been recorded in UK primary care over time?
3. What is the association between early comorbid parental depression and adolescent
depression?
In the first part of my thesis, I will provide background information. In Chapter 1,
I will present a literature review on depression: how it is defined and measured, what is
known on parental depression, how it could be transmitted across generations, and what
childhood outcomes are linked to parental depression. In Chapter 2 I will introduce The
Health Improvement Network (THIN) database, which I will use for the analysis in my
thesis.
In part II, I will explore the first two subquestions, exploring the main exposure
(early comorbid parental depression) and outcome (adolescent depression) of my thesis.
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Chapter 3 will present a systematic review on the prevalence of early comorbid parental
depression and associated child outcomes. Chapter 4 will detail trends in the recording
of adolescent depression in UK primary care.
In part III I will present my main analysis. First, in Chapter 5, I will introduce the
family cohort by explaining how families were linked together in THIN and describe the
characteristics in the cohort. Next, I will explore the association between sleep disorders
and depression in Chapter 6. I have included this chapter as I will investigate internalizing
behaviours in childhood as a potential mediator in the association between parental and
adolescent depression and will test whether this is possible by using sleep disorders as an
example. Finally, I will present my main analysis in Chapter 7.
The final part of my thesis, Chapter 8, will provide a summary of my thesis, list
implications on conclusions resulting from the work presented in earlier chapters.
Chapter 1
Introduction and literature review
1.1 Objectives of the chapter
In this chapter I aim to provide an introduction by discussing background literature on
early parental depression, which will be the exposure in my main analysis. I will provide
various definitions for depression, discuss the literature on parental postnatal depression,
explore mechanisms for intergenerational transmission of depression and child outcomes
associated with parental depression.
1.2 Definition of depression
As early as 1621, Robert Burton attempted to describe what we now call depression in
his magnum opus ’The Anatomy of Melancholia’ [Burton and Jackson, 1827]:
”Melancholy, the subject of our present discourse, is either in disposition
or in habit. In disposition, is that transitory melancholy which goes and
comes upon every small occasion of sorrow, need, sickness, trouble, fear,
grief, passion, or perturbation of the mind, any manner of care, discontent, or
thought, which causes anguish, dulness, heaviness and vexation of spirit, any
ways opposite to pleasure, mirth, joy, delight, causing frowardness in us, or
a dislike. In which equivocal and improper sense, we call him melancholy,
that is dull, sad, sour, lumpish, ill-disposed, solitary, any way moved, or
displeased. And from these melancholy dispositions no man living is free,
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no stoic, none so wise, none so happy, none so patient, so generous, so godly,
so divine, that can vindicate himself; so well composed, but more or less,
some time or other, he feels the smart of it. Melancholy in this sense is the
character of mortality.
Although Robert Burton was not the first person to try and define what we now
call depression1 , his early description of melancholy through a list of symptoms bears a
striking resemblance to the present day method of classifying mental health disorders.
Today, depression is often diagnosed using criteria set by the Diagnostic and Statist-
ical Manual of Mental Disorders (DSM). The DSM uses lists of symptoms to identify a
range of mental disorders. Although the fifth version of the DSM was published in May
2013, I will use the 4th revised version (IV-TR, published in 1994 [American Psychiatric
Association, 2000]) to define depression in this thesis as the period during which clinical
diagnoses of depression were made by GPs relates to a period before 2013.
The diagnosis of Major Depressive Disorder according to DSM requires the pres-
ence of one or more Major Depressive Episodes (see Table 1.1). Also, the episode should
not be better accounted for by other diagnoses such as schizoaffective disorder and should
not be superimposed by other mental disorders. Finally, persons who have ever exper-
ienced a (hypo)manic episode, are classified as suffering from bipolar disorder rather
than depressive disorder. In this thesis, I will focus on major depressive disorder; related
disorders such as bipolar disorder and seasonal affective disorder are not included.
Another commonly used set of diagnostic criteria is the International Statistical
Classification of Diseases and Related Health Problems 10th Revision (ICD-10) [World
Health Organisation, 2007]. ICD-10 differs slightly from the DSM-IV-TR in its defini-
tion of depression. Whereas DSM-IV-TR has one entry for ’Major Depressive Disorder’,
with specifiers for a single episode or a recurrent disorder, ICD-10 has separated them
in an entry ’Depressive episode’ for a single episode and ’Recurrent depressive disorder’
for repeated episodes. A second difference appears in the main symptoms used to define
1The Greek founder of medicine, Hippocrates (460-377 BCE), described melancholia in his Aphorisms
as a distinct disease. The word is derived from the ancient Greek words µλασ (melas - black) and χ oλη
(chole - bile), indicating the humours Hippocrates thought to be imbalanced in melancholia.
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depression. While the DSM-IV-TR requires both a depressed mood and anhedonia to be
present, ICD-10 requires two of three possible main symptoms (depressed mood, anhe-
donia, and reduced energy) to be present for the diagnosis of a depressive disorder.
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Table 1.1: DSM-IV-TR diagnosis for a Major Depressive Episode
Present during the same 2-week period and represent a change from previous functioning;
At least one of the symptoms:
- Depressed mood
Note: In children and adolescents, can be irritable mood
- Loss of interest or pleasure
Note: In children, consider failure to make expected weigth gain
Plus four or more of the following symptoms:
• Significant weight loss when not dieting or weight gain (e.g., a change of more than
5% of body weight in a month), or decrease or increase in appetite nearly every day
• Insomnia or hypersomnia nearly every day
• Psychomotor agitation or retardation nearly every day (observable by others, not
merely subjective feelings of restlessness or being slowed down)
• Fatigue or loss of energy nearly every day
• Feelings of worthlessness or excessive or inappropriate guilt (which may be delu-
sional) nearly every day (not merely self-reproach or guilt about being sick)
• Diminished ability to think or concentrate, or indecisiveness, nearly every day (either
by subjective account or as observed by others)
• Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation
without a specific plan, or a suicide attempt or a specific plan for committing sui-
cide
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It is important to distinguish depression from low mood, which is part of the nor-
mal spectrum of mood, and is thought to be useful in certain situations such as after a
bereavement when it can indicate a need for caring [Nesse, 2000]. However, when low
mood is excessive, prolonged, or expressed in the wrong situation it becomes patholo-
gical depression. Lifetime prevalence of major depressive disorder has been estimated at
16.6% [Kessler RC, 2005].
1.2.1 Measuring depression
The gold standard for measuring depression is through a structured clinical interview with
a trained professional. However, due to time and financial constraints, depression is often
measured using questionnaires in research.
One of the most commonly used clinical interviews is the Structured Clinical Inter-
view for DSM-IV Axis I Disorders (SCID-I) [Spitzer RL, 1992]. It is a semi-structured
interview, originally based on DSM-III but updated for DSM-IV. The SCID is designed
to both measure current (in the past month) and lifetime occurrence of any of the DSM
axis I disorders (clinical disorders and other conditions that may be a focus of clinical
attention). A full SCID-I assessment can take between 1-2 hours and is designed to be
administered by a clinician. However, many epidemiological studies have used the World
Health Organisation Composite International Diagnostic Interview (CIDI) [Robins LN,
1988], designed to be administered by a lay person, instead. The CIDI was used most
notably in the US National Comorbidity Survey [Kessler RC, 1994], which used the ques-
tionnaire to provide estimates of the prevalence of mental disorders in the US general
public.
There is a multitude of validated questionnaires that are designed to measure de-
pressive symptoms without the need of an interviewer. One of the most commonly used
rating scales, especially in clinical trials, is the Hamilton Rating Scale for Depression
(HAM-D) [Hamilton, 1960]. The score on this scale can range from 0 to 52, and it is
commonly used to classify severity of depression. The HAM-D was developed over 50
years ago, in 1960, based on a study of major depressive disorder in patients confined
to asylums. As few trial participants now suffer from that level of illness, some experts
wonder if what pharmaceutical companies now refer to as depression is the same disease
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that the HAM-D was designed to diagnose [Kriston and von Wolff, 2011].
Another criticism of the HAM-D is its focus on somatic symptoms such as insomnia,
rather than suicidal behaviour and thinking. Because of this emphasis it is possible for
patients to show improvement on the HAM-D while suicidal behaviour and thinking has
increased [Bagby et al., 2004]. Moreover, there are several standards for interpreting the
score (Figure 1.1) [Kriston and von Wolff, 2011]. The differences between HAM-D in-
terpretations can have effects on inclusion of patients into clinical trials and interpretation
of trial outcomes, as well as the ability to compare studies in meta-analyses.
Figure 1.1: Levels of depression in relation to the HAM-D according to different recom-
mendations, figure adapted from Kriston et al [Kriston and von Wolff, 2011, Neuroskep-
tic, 2010]
Observational studies tend to use shorter questionnaires to assess depression. Com-
monly used questionnaires are the Beck Depression Inventory (BDI) [Beck et al., 1961],
consisting of 21 items, and the Center for Epidemiological Studies Depression Scale
(CES-D) [Radloff, 1977], consisting of 20 items. Both questionnaires have been valid-
ated and are estimated to take only five to ten minutes to complete [Sharp and Lipsky,
2002]. However, similar to the HAM-D, studies employing the BDI or CES-D have used
different cut-offs to define depression and depression severity. Moreover, updated ver-
sions of these questionnaires have become available over the years (e.g. the BDI-II [Beck
et al., 1996], updated to correspond to DSM-IV), as well as shortened versions to use in
specialised settings such as primary care (e.g. the BDI for Primary Care or BDI-PC [Beck
et al., 1997]), making it more difficult to compare estimates for depression from studies
using different questionnaires, or different versions of the same questionnaire.
Furthermore, specialised questionnaires have been developed for some populations,
such as perinatal women and children and adolescents, as these groups might express
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symptoms of depression differently. One of these questionnaires, the Edinburgh Postnatal
Depression Scale (EPDS), was developed in the 1980s specifically for women in the
postpartum period as these women were known to be at an increased risk of developing
depression [Cox and Holden, 2003, Cox et al., 1987]. The available questionnaires at
the time gave a high number of false-positives as parts of these questionnaires focussed
on somatic symptoms (e.g. sleep difficulty) which are considered normal for postpartum
women. The EPDS has since also been validated for detecting depression in antenatal
women [Murray and Cox, 1990], non-postnatal women with older children [Cox et al.,
1996], and men [Matthey et al., 2000].
Few other questionnaires have also been used that measure psychiatric disorder or
symptoms, rather than depression specifically. The General Health Questionnaire (GHQ)
is an example of such a general questionnaire. It was developed in the 1970s to detect
psychiatric disorder in the general population and within community or non-psychiatric
clinical settings such as primary care [Goldberg and Williams, 2006, Goldberg and Hil-
lier, 1979]. The GHQ focusses on both physical and psychiatric symptoms.
1.2.2 Depression in primary care
Questionnaires are often used to assess patients newly diagnosed with depression. Ac-
cording to NICE guidelines [National Institute for Health and Clinical Excellence, 2009],
patients who may have depression should be screened by asking two questions:
• During the last month have you been feeling down, depressed or hopeless?
• During the last month have you often been bothered by having little interest or
pleasure in doing things?
If patients answers ’yes’ to either question further investigation is required, often by
administering the PHQ-9 [Kroenke et al., 2001] or one of the questionnaires metnioned
in the previous section. A general practitioner (GP) who is experienced in mental assess-
ment can perform this assessment his/herself, though they can also refer the patient to an
appropriate professional. Most patients with depression are treated in primary care. The
GP considers the degree of functional impairment and duration of the episode, as well
as factors that may have affected the development, course and severity of the depression
1.3. Parental postnatal depression 34
(e.g. history of depression, comorbid mental health or physical disorders, response to
previous treatment, living conditions and social isolation).
In order to diagnose depression, a longitudinal assessment is needed and GPs tend
to monitor patients and assess their depression symptoms over time. Depression dia-
gnoses, symptoms and referrals are entered in a patient’s medical records by using Read
codes [Chisholm, 1990], which will be further explored in the next chapter. Prescriptions
for antidepressants will also be coded in electronic medical records. GPs can also enter
notes in free text areas (more on electronic medical records in Chapter 2).
1.3 Parental postnatal depression
Depression is a common mental disorder affecting 121 million people worldwide [WHO,
2011]. In the US, about 1 in 10 individuals older than 12 are taking antidepressant drugs,
according to a recent report from the US Centers for Disease Control and Preventions
(CDC) National Center for Health Statistics [Kuehn, 2011]. Women appear more likely
than men to develop depression: a gender imbalance in prevalence, incidence and morbid-
ity risk develops in adolescence and persists throughout adult life [Piccinelli and Wilkin-
son, 2000]. In the perinatal period, 10-15% of mothers are affected by depression [Cox
et al., 1993, Dave´ et al., 2010, Kumar and Robson, 1984, O’Hara and Swain, 1996].
Although postnatal depression is generally thought of as a disorder affecting mothers, I
will use the term ’postnatal’ as a specifier of time of onset (relating to the first year after
childbirth) and as such use it for depression in both mothers and fathers.
1.3.1 Maternal early depression
There is long history of research into maternal mental illness around childbirth. For cen-
turies, ’female hysteria’ was thought to be caused by disturbances of the uterus, such as
during childbirth [King, 1993]. Louis Victor Marce´ was the first to write a book2 en-
2Although Louis Victor Marce´ was the first to devote an either work to puerperal illness, there are
earlier references. For instance, Gerard van Swieten, a Dutch physician, mentions puerperal sadness in
his Commentaria in Hermanni Boerhaave aphorismos de cognoscendis et curandis morbis (page 601) from
1764. He writes that in the Dutch city of Haarlem, women were required by law to put a sign on their doors
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tirely devoted to puerperal mental illness in 1858 [Marc, 1858]. In it, he attempted to
estimate the number of women afflicted by ’puerperal madness’ (la folie puerprale) by
counting women who had become ’mad’ after giving birth in hospital, and the number of
women who had been admitted to asylums during pregnancy or shortly after childbirth.
Although the numbers he found were very low (e.g. only 9 out of 3500 women in the
General Lying-in Hospital in Westminster were identified as cases, while most other hos-
pitals reported never having observed puerperal madness), Marce´ did stress the influence
of maternal mental illness on the child.
A large meta-analysis of the rates of postpartum depression found an average rate of
12.8% (95%CI: 12.3-13.4%) [O’Hara and Swain, 1996]. This meta-analysis also found,
by including data from 59 studies on a total of 12,810 women, that the prevalence of early
maternal depression varied with the method of assessment. Studies in which women had
been assessed for depression using a questionnaire reported higher prevalence rates than
studies using interviews. Women who had been assessed with the EPDS had depression
rates of 18.0% (95%CI: 16.1-19.9%) on average, compared to 7.2% (95%CI: 3.7-10.7%)
for women assessed by an interview based on DSM-III.
Studies have found little evidence for a biological basis of maternal postnatal de-
pression, and the main risk factors are the same as those for major depressive dis-
orders [Cooper and Murray, 1998]. These risk factors include lower social class, negative
life events, marital difficulties, lack of social support, and a history of depression (par-
ticularly antenatal depression) [Cooper and Murray, 1998, Milgrom et al., 2008, O’Hara
and Swain, 1996]. Some pregnancy-specific risk factors have also been identified, such
as unplanned pregnancy, complications during pregnancy or childbirth, and not breast-
feeding [Milgrom et al., 2008, Warner et al., 1996].
Rates of early depression for mothers are not necessarily higher than prevalence
rates outside of the perinatal period [Cox et al., 1993]. However, the incidence of new
after they had given birth. This would prevent ’officers of justice’ from coming into their homes and giving
them bad news (Haarlem was a city of sailors and merchants who travelled between Europe and Asia),
which Van Swieten thought would lead to puerperal sadness. He recommended women to carefully avoid
all emotions after childbirth.
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depressive episodes might be higher in the first few weeks after delivery. Moreover,
although the prevalence of depression is not increased, the effects of maternal depression
on the child are thought be most potent during the first months postpartum (see section 1.4
on page 37 for more detail).
1.3.2 Fathers and early depression
Although most research on psychiatric morbidity during the perinatal period has fo-
cussed on mothers, there are some studies that have included fathers as well. As early as
1931, Zilboorg described several case studies of ’depressive reactions related to parent-
hood’ [Zilboorg, 1931]. The fathers described in his article experienced severe depressive
reactions resulting in hospitalisations, and Zilboorg classified them as manic-depressives.
In the Freudian spirit of the time, he attributed their psychopathology to suppressed inces-
tuous thoughts about their mothers (and occasionally sisters), hatred or jealousy towards
their fathers, and passive homosexuality.
In the following decades, case studies on mental illness in men around the perinatal
period appeared sporadically in the scientific literature [Ballard and Davies, 1996]. From
the 1980s onwards, small studies started to assess psychiatric morbidity in fathers. Most
of these were biased in that they assessed partners of mothers with severe mental illness,
or partners of mothers who were being treated in mother-baby units. As such, these
studies often found high rates of paternal morbidity, ranging from 40% to 50% [Harvey
and McGrath, 1988, Lovestone and Kumar, 1993].
Paternal early depression has received more attention in recent years. A large meta-
analysis estimated that 10.4% (95%CI: 8.5-12.7%) of fathers experienced depression dur-
ing their partners’ pregnancy or in the first year after childbirth [Paulson and Bazemore,
2010], which is slightly higher than the estimated 12-month prevalence of 5-7% for de-
pression in men in general [Kessler RC, 2005, Kessler et al., 2003, 1993]. The study
included information on 28,004 participants from 43 studies. The highest rate was ob-
served in the 3- to 6-month postpartum period, with an estimated rate of 25.6% (95%CI:
17.3-36.1%) of fathers experiencing depression. However, there was a large amount of
heterogeneity between studies, with estimates ranging from 0.7% [Thorpe et al., 1992] to
46.2% [Dudley et al., 2010], which is likely due to differences in study populations, types
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of measurements (e.g. interview or questionnaire), and criteria used to define depression.
Studies that have followed parents up longitudinally tend to find lower estimates of
paternal postnatal depression compared to depression in mothers. For instance, a study
in Spain that followed up 769 parents from pregnancy to 12 months postpartum found
that 3.4% and 4.0% of fathers were depressed at 3 and 12 months postpartum [Escriba`-
Agu¨ir and Artazcoz, 2011]. A study using a UK primary care database (THIN) found
a postnatal depression rate of 3.56 per 100 person-years for fathers [Dave´ et al., 2010].
These rates could be lower than the meta-analysis estimate due to fathers with depression
being more likely to drop out of longitudinal studies, and because studies using diagnoses
rather than questionnaires to define depression tend to find lower estimates.
The risk factors for early depression in fathers are similar to those for mothers:
younger age, low income, low level of education, poor partner relationship quality, and
worries about the economy and employment [Bergstrøm, 2013].
1.4 Intergenerational transmission of depression
As shown in section 1.3, parental depression in the first year postpartum is common in
both parents. This section will explore different mechanisms for transmission of parental
depression onto their children, and will look into potential intermediate child outcomes
such as internalizing behaviour.
1.4.1 Developmental origins of health and disease: genes, epigenetics
& environment
1.4.1.1 Developmental origins of health and disease
Developing organisms adapt themselves to their environment [Bateson et al., 2004]. This
observation has been found in fields of research ranging from evolutionary ecology to
medical epidemiology, leading to the theory of developmental programming [Barker
et al., 1993]. During programming, environmental adversity is transmitted to the foetus
and acts on specific tissues during sensitive periods in their development to change devel-
opmental trajectories and thus their organisation and function [Harris and Seckl, 2011].
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According to this theory, a given genotype - the genetic constitution of an individual or-
ganism - can give rise to different phenotypes - the set of observable characteristics of an
individual - depending on environmental conditions. Put more briefly: the impact of the
environment experienced by one generation can shape the development and behaviour of
the next.
The varied developmental pathways triggered by environmental events may be in-
duced during sensitive, often brief, periods in development. Outside these sensitive peri-
ods an environmental influence that sets the characteristics of an individual may have
little or no effect. If the effects of past conditions produce mismatches with current,
changed conditions, developmental plasticity may have an adverse effect on survival and
reproductive success.
In humans, the idea of developmental plasticity has been shown with regards to the
relation between adult health and nutritional level during later development with pheno-
types that were initiated during pregnancy. A pregnant woman in poor nutritional con-
dition may unwittingly signal to her unborn baby that is about to enter a harsh world.
If so, this ’weather forecast’ from the mother’s body may result in her baby being born
with characteristics, such as a small body and a modified metabolism, that help it to cope
with a shortage of food. When sufficiently high levels of nutrition are available after the
development of a ’small’ phenotype has been initiated, marginal benefits of rapid growth
may offset the costs, but they may also trigger the health problems arising in later life.
The bigger the disparity between the ’forecast’ received in the womb and the level of
nutrition available, the larger the health problems are thought to be.
Evidence from the Dutch famine of 1944-45 showed that glucose intolerance, a
prodrome of diabetes type 2, is induced by maternal malnutrition during the final three
months of pregnancy [Ravelli et al., 1998]. The study compared 702 people who were
born between November 1943 and February 1947 in Amsterdam, and for who detailed
prenatal and birth records were available. People who were born during or in the months
immediately following the hunger winter of 1944-45 had decreased glucose tolerance.
The effect of famine was especially important in people who became obese, further
strengthening the idea of developmental plasticity.
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1.4.1.2 Epigenetics: Glucocorticoids and the HPA-axis
Similarly, maternal stress during pregnancy can have permanent effects on the child by
disrupting hormonal balances. Stress is mediated by the hypothalamic-pituitary-adrenal
(HPA) axis, and cortisol - a glucocorticoid hormone produced by the adrenal cortex -
is its main hormonal mediator. Some researchers believe that stress-induced HPA-axis
activation can directly cause depressive symptoms [Pariante, 2003]. When a mother ex-
periences stress during pregnancy, for instance as a consequence of antenatal depression,
blood cortisol levels will increase and can affect the offset of the foetus’ HPA axis as it is
prepared for a life in a stressful world.
The foetus’ HPA axis can be affected as certain glucocorticoid-sensitive genes can be
activated or repressed by cortisol, which can lead to lasting epigenetic effects in placental
and foetal glucocorticoid target tissues such as the brain [Harris and Seckl, 2011, Hogg
et al., 2012].
Animal studies have shown how prenatal stress can alter the function of the HPA axis
in offspring. However, as detailed in a review by Glover and colleagues [Glover et al.,
2010], there is a lot of variation in the possible effects. Importantly, rodent experiments
have also shown that the effects of prenatal stress can be moderated, and even reversed,
by positive postnatal rearing [Maccari et al., 1995].
Studies assessing the link between prenatal stress and child outcomes in humans are
rare and observational, as opposed to animal studies. Although this complicates the mak-
ing of causal inferences, results from human studies are similar to experimental animal
data, strengthening the belief in a causal relationship.
Several childhood outcomes have been linked to prenatal stress, ranging from atten-
tion deficit hyperactivity disorder (ADHD) to effects on cognitive development [Glover
et al., 2010]. A number of studies have also assessed the link between prenatal stress
and cortisol levels in children ranging in age from 1 week to 15 years. These studies
consistently found that cortisol levels were increased for children of mothers who had
experienced prenatal stress (either through depression, or exposure to stressful life events
such as 9/11 or Chernobyl) [Glover et al., 2010]. Therefore, maternal stress due to de-
pression in the prenatal period could be a possible mechanism for the transmission of
depression.
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1.4.1.3 Epigenetics: Antidepressants in pregnancy - the SSRI paradox
A second possible mechanism of transmission of depression from parents to offspring is
the SSRI paradox: while these drugs are used to treat depression in adults, they could
have the opposite effect when a foetus is exposed to it in utero. As SSRI use during
pregnancy has increased in both the US [Huybrechts et al., 2013] and the UK [Petersen
et al., 2011] this potential transmission mechanism could have become more important
in recent years.
SSRIs can reach the foetus via the placenta and can thus have an effect on serotonin
levels in the foetal brain during critical phases of neurodevelopment [Rampono et al.,
2004]. The serotonin transporter, one of the targets of SSRIs, is transiently expressed in
many brain areas during development, and blocking this transporter (one of the mechan-
isms of action of SSRIs) during development can cause wiring defects. Animal research
suggests that SSRIs could have paradoxical effects when administered prenatally: rather
than decreasing depression levels, it appears to increase them in rodents (see for example
this review by Homberg and colleagues [Homberg et al., 2011]).
SSRI use in pregnancy has been linked to many outcomes: pregnancy complica-
tions, birth defects, persistent pulmonary hypertension, neurodevelopmental outcomes,
and stress regulation [Olivier et al., 2011a]. However, it is difficult to distinguish the
effects of antidepressants from the effects of the underlying depression in humans. An-
imal research has replicated many of the effects of prenatal SSRI exposure, particularly
neurodevelopmental outcomes. Increases in internalizing behaviour have been found in
early adulthood in humans, and anxiety- and depression-like behaviour has also been
found to be increased in rodents exposed to prenatal SSRIs [Oberlander TF, 2010, Olivier
et al., 2011b].
1.4.1.4 Environment: early brain development and parent-child attach-
ment
A third mechanism for depression transmission is via environmental transmission through
parenting behaviour. A depressed parent may interact with their infant in ways that dis-
rupt the child’s emotional and/or cognitive development.
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A number of studies have assessed whether parental depression, maternal depres-
sion in particular, affects parent-child attachment. A meta-analysis based on seven stud-
ies found that 1-3 year old children of depressed mothers were less likely to show secure
attachment, and more likely to show avoidant or disorganised forms of attachment com-
pared to infants of non-depressed mothers [Martins and Gaffan, 2000]. However, the
number of children included in each study was small, ranging from 26 to 99, and families
were relatively well off, making the representativeness of the studies unclear.
A larger UK study that sampled 10,438 children found that parenting strategies were
associated with child mental health [Vostanis et al., 2006]. The quality of parenting,
and abusive parenting of young children in particular, has been shown to have lasting
biological effects [Scott, 2012].
1.4.1.5 Is there a gene for depression?
A final important potential transmission mechanism is genetic susceptibility. Adoption
studies have provided some support for a role of genetic factors in the intergenerational
transmission of depression [Levinson, 2006]. In these studies adopted children share
their genes with their biological parents, but they do not share their environment, and
thus researchers are able to distinguish between the effects of the two. It seems that
children whose biological parents had depression are more likely to become depressed
themselves compared to adopted children of non-depressed parents.
Similarly, twin studies have been used that compare monozygotic twins (who are
genetically almost entirely identical) to dizygotic twins (who share half their DNA on
average). By comparing how often both siblings are depressed, it is possible to estim-
ate the role of genetics: if monozygotic twins are more often both depressed, this is a
sign that genes are important in depression. If, on the other hand, there is no difference
between monozygotic and dizygotic twins, environmental factors or shared adversity are
more important. From twin studies, heritability has been estimated to be about 40-50%
in depression, and might be even higher for severe depression. The role of familial trans-
mission is further strengthened by the increased risk of depression for first-degree family
members of a person with depression. Compared to the general population, this group
has two- to threefold increase in risk of depression.
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Several specific genes have been linked to an increased risk of depression. Most
notable is SLC6A4, a gene on chromosome 17 that encodes the serotonin transporter (5-
HTT). The promotor region of this gene, known as the 5-HTT-linked polymorphic region
(5-HTTLPR), comes in different lengths. The short version of this region is linked to
a higher risk of depression, especially when an individual has inherited the short allele
from both parents [Caspi et al., 2003]. The gene appears to increase the risk of depression
after negative life events - a gene-environment interaction. However, a more recent meta-
analysis shows only a small effect of the polymorphism on susceptibility to depression
and the authors warn the effect could be an artifact [Clarke et al., 2010].
Some studies have found that environmental factors also play an important
role [Lewis et al., 2011]. A study an assisted conception design3 found that associ-
ations between parental and child and adolescent depression were equally strong between
genetically related and genetically unrelated parent-child pairs.
1.4.2 Sensitive period versus chronic exposure
As detailed in the previous section, many of the proposed mechanisms for the intergen-
erational transmission of depression appear to depend on a sensitive period around the
time a child is born. However, some studies have suggested that parental depression in
the perinatal period on its own is not associated with adverse child outcomes, but rather
it is chronic exposure to a depressed parent that could facilitate transmission of the dis-
order [Hammen et al., 2004].
However, research in this area is sparse and methodologically flawed. Parental de-
pression throughout a child’s life is likely to be associated with depression in the perinatal
period and thus could be seen as a mediator or intermediate variable on the causal path-
way from early parental depression to child outcomes (Figure 1.2). As described by
Baron and Kenny in their seminal paper on mediation analysis [Baron and Kenny, 1986],
the strict assumptions required for a mediation analysis where a mediator is simply added
to a regression model are rarely valid. However, this method has been used in papers
attempting to assess whether early or chronic parental depression is more important for
3The assisted conception design uses children that are conceived with the help of donor sperm, donor
eggs or donor embryos. In this design, children share their genotype with one or neither parent.
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transmission.
Figure 1.2: Causal diagram of the hypothesized effects of early parental depression on
child outcomes
As chronic depression is on the causal pathway and potentially correlated with early
parental depression (EPD), just adding chronic depression to a regression model assessing
the effect of early parental depression on child outcomes can lead to biased results. In
addition, mediation analysis requires special attention to possible confounders. In order
to get an unbiased estimate of the direct effect (EPD to child outcomes) and indirect effect
(EPD to child outcomes, via chronic parental depression) confounders of the association
between the exposure and mediator, exposure and outcome, and mediator and outcome
need to be considered. Unfortunately, the latter group of confounders (represented by risk
factor in Figure 2) are often neglected as they were not explicitly mentioned in Baron and
Kenny’s paper despite an earlier paper by David Kenny stressed their importance [Judd
and Kenny, 1981].
I will explore the effects of chronic exposure to depression and mediation analysis
more in Section 5.2.2 on page 120 and Appendix D.1.
1.4.3 Childhood outcomes: internalizing behaviour
Early parental depression has been linked to many child outcomes [Grace et al., 2003].
Maternal postnatal depression has been associated with child cognitive development, be-
haviour, sleep, crying and motor behaviour. As the exposure (early parental depression)
and outcome (adolescent depression) for my main analysis are at least 13 years apart in
time, I will also explore internalizing behaviour in childhood as a potential intermediate
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variable. I will introduce some of research on child outcomes in this section, but will
come back to them in Section 5.2.1 on page 119.
1.4.3.1 Child behaviour problems
Child behaviour can be affected by parental depression as early as in the first few months
of life. Larger studies, most notably the Avon Longitudinal Study on Parents And Chil-
dren (ALSPAC) study, have tried to assess the effects of parental depression on child
behaviour. ALSPAC has followed up over 14,000 families from the Avon area in the UK
from pregnancy in the early ’90s. The study found that behavioural problems at age 3.5
years were associated with both maternal and paternal early depression [Ramchandani
et al., 2005a]. Maternal depression was particularly associated with emotional problems
in girls (OR 2.24, 95% CI: 1.62-3.11) and conduct problems in boys (OR 2.18, 95% CI:
1.58-3.01), while paternal depression was linked to conduct problems (OR 2.66, 95% CI:
1.67-4.25) and hyperactivity (OR 2.06, 95% CI: 1.16-3.66) in boys. A review of the ef-
fects of parental psychiatric disorders on children’s psychosocial development found that
the effect of paternal and maternal depression were of similar magnitude [Ramchandani
and Psychogiou, 2009]. However, paternal psychiatric disorders, depression in particular,
appeared to have a larger effect on boys, while maternal depression was more likely to
affect girls.
A small study including 48 fathers found that paternal negative mood was associated
with infant fussiness at six months as measured by the Infant Characteristics Question-
naire [Dave´ et al., 2005]. However, men who were depressed at screening (4-6 weeks
after childbirth) did not participate in the follow-up. Hence, none of the 17 fathers in-
cluded in the final analysis linking negative mood to infant behaviour scored over the
depression threshold.
1.4.3.2 Cognitive development
Child cognitive development has been tested extensively in a cohort of 59 women re-
cruited in the Cambridge area by Prof Lynne Murray [Murray, 1992, Murray et al., 1993,
1996a,b, Sinclair and Murray, 1998]. At 9 and 18 months, children of mothers with post-
natal depression (as assessed at 2-3 months postpartum by interview) performed worse on
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Piaget’s object concept task than children of non-depressed mothers [Murray, 1992]. Pia-
get’s object concept task tests infants’ abilities to recognise the independent existence of
objects. In this study, objects were hidden under opaque plastic cups. Infants passed the
test if they (tried to) recover the objects by removing the plastic cup, indicating they’ve
progressed from the ’out of sight, out of mind’ stage. At 9 months, 2 (13%) children of
mothers with postnatal depression passed the object concept test, compared to 10 (59%)
of children of non-depressed mothers (p<0.04). Results were similar at 18 months.
Follow-up studies found that the association between maternal depression and the
child’s cognitive development was mediated by mother’s speech to her infant during play
interactions at age 2-3 months [Murray et al., 1993], life adversity, infant sex [Murray
et al., 1996a]. Mothers who were depressed at the time of speech assessment were much
less infant-focussed than the non-depressed mothers and displayed more negative effect.
Also, boys of mothers who had postnatal depression performed significantly more poorly
than boys of non-depressed mothers, while there was no such effect for girls.
The children were reviewed again at age 5 years. At this time point, cognitive devel-
opment was neither associated with maternal depression at any time point, nor with the
length of maternal depression [Murray et al., 1996b]. Maternal postnatal depression was
also unrelated to readiness for school, personal maturity, prosocial behaviour, adaptabil-
ity, emotional intensity, and persistence at age 5 [Sinclair and Murray, 1998]. However,
both postnatal and recent maternal depression were associated with significantly raised
levels of child disturbance, particularly among boys and children from lower social class
families.
A study from Germany found similar results [Kurstjens and Wolke, 2001]. The study
followed 1,329 families from South Bavaria, Germany, from birth up to age six years and
focussed on the effects of maternal depression on cognitive development of children.
They found no significant main effects of depression severity, timing of onset, duration,
or chronicity on the child’s cognitive development. However, similar to the study by
Murray et al., Kurstjens and Wolke found that cognitive development was affected by
maternal depression when the depression was chronic, and for lower social class boys.
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1.4.3.3 Clinical outcomes
Few studies have assessed the association between early parental depression and clinical
child outcomes. Ramchandani and colleagues assessed the association between early
parental anxiety - a measure closely related to depression - and recurrent abdominal pain
(RAP) in school age children (6-7 years) [Ramchandani et al., 2006]. They found that
both maternal and paternal anxiety were independently associated with RAP (OR 1.53,
95% CI: 1.24-1.89, and OR 1.38, 95% CI: 1.12-1.71, respectively). In an earlier study on
the same cohort, it was shown that RAP is associated with anxiety in children, suggesting
it is a psychosomatic symptom in children [Ramchandani et al., 2005b].
1.4.4 Adolescent depression
Depression is less common in children compared to adolescents or adults: prevalence
rates range between 0.4% and 2.5% in children and between 0.4% and 8.3% in adoles-
cents [Birmaher, 1996]. In prepubescent children, where prevalence rates are reported to
be very low, boys appear more likely to be depressed than girls [Anderson et al., 1987, Co-
hen and Brook, 1987], although there is also some literature reporting no difference [An-
gold, 1992, Kashani et al., 1983]. However, between the ages of 11 and 13 this gender
gap reverses and by the age of 15 girls are twice as likely to have experienced depression
compared to boys [Angold, 1992, Angold et al., 1998, Cyranowski et al., 2000].
Although some studies suggest that there has been an increase, or even an epidemic,
of childhood and adolescent depression [Collishaw et al., 2004], reviews show that this
is not the case [Costello et al., 2006]. The apparent increase in childhood depression
seems to be due to an increase in antidepressant prescriptions. However, rather than more
children taking these drugs, prescriptions are for shorter lengths of time making, con-
tributions to a inflation in the number of prescriptions but not the number of children
taking them. Moreover, the prevalence of any disorder always involves some arbitrary
decisions concerning where to place the cut points between sick and well. For depres-
sion this is particularly the case as it is defined by the presence of a certain number of
symptoms which have changed repeatedly over the development of different versions of
the Diagnostic and Statistical Manual of Mental Disorders (DSM).
A multitude of factors can affect an adolescents vulnerability to depression (Fig-
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ure 1.3).
Figure 1.3: Factors affecting vulnerability to depression in adolescence. Adapted from
The depressed child and adolescent [Goodyer, 2000].
A quarter of all lifetime cases of depression have started by age 19 [Kessler et al.,
2005]. Moreover, internalizing disorders (anxiety and depression) in adolescence ap-
pear to be a risk factor for adult psychiatric outcomes. Using the 1946 British cohort,
about 70% of adolescents who had internalizing disorder at both ages 13 and 15 had
a mental disorder at age 36, 34, or 53, compared with about 25% of mentally healthy
adolescents [Colman et al., 2007].
1.5 How does this chapter inform my thesis?
As detailed in this chapter, parental postnatal depression is common in both new mothers
and fathers and many studies have shown that it can negatively affect children in the
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short and long term. However, many questions remain to be answered. Although the
prevalence of maternal and paternal depression during the first year postpartum has been
studied separately, there appears to be no consensus on the prevalence of comorbid or
comorbid early parental depression, despite the meta-analysis by Paulson and colleagues
concluding that the two are correlated. Therefore, I have undertaken a systematic review
of the literature (Chapter 3) to try to determine an estimate of the prevalence of comorbid
parental depression, as well as its effects on child outcomes as research in this area seems
sparse.
In addition, most studies examining parental depression and its effects on child out-
comes are small and focussed on ’soft’ non-clinical outcomes (with ALSPAC as a notable
exception). Hence, I will use a large UK primary care database (as detailed in Chapter 2)
to assess whether early parental depression has an effect on clinically relevant child out-
comes. Finally, the few studies that have tried to assess whether the postnatal period
is a sensitive period for the transmission of parental depression, or whether exposure to
chronic depression is more likely to facilitate this have suffered from methodological
flaws and small sample sizes. I will use novel methods for mediation analysis and struc-
tural equation modelling to assess this question.
Chapter 2
The Health Improvement Network
primary care database
2.1 Objectives of the chapter
In this chapter, I will provide an overview of The Health Improvement Network (THIN)
primary care database, which I have used as a data source for my thesis. I will go over
the history of THIN, the data quality and structure, how I have identified diagnoses and
prescriptions, limitations of THIN, and I why I used THIN as data source.
2.2 The Health Improvement Network (THIN) database
characteristics
2.2.1 The history of THIN: five decades of primary care databases
The Health Improvement Network (THIN) is a large UK primary care database contain-
ing electronic medical records on approximately 6% of the UK population. The devel-
opment of the database started in the mid-1970s with Dr Alan Dean (Figure 2.1). Dr
Dean was a general practitioner (GP) from Essex who wanted to develop a program to
computerise his records and become paperless [Health Service Journal, 1999]. With the
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help of the IT staff from a shoe factory located near his practice he built such a program
and started selling it to other practices in 1979.
At the end of the 1980s, the need for large databases to undertake pharmacoepidemi-
ological research was highlighted by the Committee on the Safety of Medicines [Hall,
1992]. The two systems in place at the time in the UK, the Yellow card system and
prescription event monitoring1 [Rawson et al., 1990] were criticised for having a low
response rates and being too slow to inform regulatory decisions. Large database of
routinely collected data were being set up in the US (by insurers) and Canada at the
time and with an increasing proportion of UK GPs working in computerised practices, a
general practice research database seemed like the solution.
In 1987, Dr Alan Dean set up Value Added Information Medical Products Ltd
(VAMP) with the aim to recruit 950 practices covering five million patients. With the
help of Dr Gillian Hall, they started building the first primary care database with the
aim to find a way to detect adverse drug reaction signals [Walley and Mantgani, 1997,
Hall, 1992]. This first database was called the Vamp Research Databank (VRD). The UK
database would have the added advantage of containing a representative sample of the
population as the majority of the population is registered with a GP.
At the time Dr Gillian Hall started work on the VRD, under 100 practices had com-
puterised medical records, and over 50% of those who used a computer, used home
written programs [Gillian Hall, personal communication]. The development of a data-
base was further complicated by the way GPs used computers. Dr Hall identified three
’phases’ for GPs to convert from using paper medical records to computerised record. In
the first phase, GPs use the computer system for prescriptions only; in the second phase,
they also use it for recording consultation details; and finally, they will use it for storing
all medical records, including secondary care outcomes and medical history. In order to
1The Yellow card system (which is still in place today) allowed doctors to report adverse events by
filling out a yellow card at the back of the British National Formulary (BNF). Prescription Event Monitoring
(PEM) identified all prescriptions by compiling lists from all pharmacies in England. From these lists, the
drug of interest and individual patients prescribed this drug were identified. The prescribing doctor was
then send a personalised questionnaire to ask about potential adverse events
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contribute to analyses of the database, practices needed to be in phase three.
A second problem was data storage. Soon after GP practices started sending in data,
the VRD started exceeding the available storage capacity at the time. In order to solve the
problem, an computing engineer had to be flown in from California to daisy chain2 several
hard-drives together in other to be able to store the data from the ten initial practices that
formed the VRD.
To incentivise others to join, GPs were offered free computer equipment in exchange
for entering clinical data in a standard manner and providing anonymised data to VAMP
(if practices chose not to provide data, the costs for computers and software was about
£25,000). The initial database was compiled to be used in post-marketing studies. One
such study, with Dr Alan Dean as co-author, examined the risk of suicide among people
taking 10 commonly prescribed antidepressants [Jick et al., 1995]. At that time, data
was available from 495 practices comprising 172,598 people who had at least one anti-
depressant prescription between 1988 and 1993.
In 1993 at the peak of VAMP’s popularity with 6,000 GPs using it, Dr Dean sold the
company to Reuters. Unfortunately, Reuters was only interested in the computer systems,
not in the VRD database and was considering shutting the database down. However, Re-
uters donated the VRD ’for the public good’ to the Department of Health, who renamed it
the General Practice Research Database (GPRD) [Ogdie et al., 2012]. To allay GP anxi-
ety the Department of Health would use the database to monitor their activity and link it
to funding, the Office of National Statistics (ONS) was put in charge of the database. The
GPRD moved again in 1999 from ONS to the Medicines and Healthcare products Regu-
latory Agency (MHRA) which still manages it today (although the name has changed to
Clinical Practice Datalink - CPRD - in April 2012).
In 1994, EPIC, a new non-profit company set up by Dr Alan Dean, aquired a license
to use the GPRD by the Department of Health. Meanwhile, VAMP had changed its name
to In Practice Systems Ltd (INPS) and had bought back the practice management software
from Reuters, calling it Vision. Despite the early setback with the VRD, INPS and EPIC
teamed up in 2002, when EPIC’s licence to the GPRD database expired, to form The
2Daisy chaining is a wiring scheme in which multiple devices are wired together in a sequence or ring
to boost power, analog signals, or data storage capacity.
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Figure 2.1: How THIN came to be. Yellow: VRD database (managers); blue: CPRD
database (managers); green: THIN database (managers)
Health Improvement Network (THIN). The aim of this collaboration was to set up a new
’real life’ database, while at the same time improving the quality of data recording by
providing feedback and training to GPs. INPS dispersed and supported Vision software
while EPIC managed data extraction and database use [Ogdie et al., 2012]. THIN started
data collection in 2003, but data goes back to the 1980s for some practices. A final change
happened in 2005 when Cedegim, the company owning INPS, acquired EPIC. EPIC was
renamed to Cedegim Strategic Data (CSD) Medical Research UK.
2.2.2 THIN today
Apart from sharing a common history, THIN and the CPRD also share practices. Both
databases collect similar data from practices using Vision software, and as a result, some
practices appear in both databases [Lewis et al., 2007]. The most recent estimate, from
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2009, is that 30% of GPRD practices also contribute to THIN [Ogdie et al., 2012].
When a practice first joins the THIN scheme, an initial Full Data Collection (FDC)
is performed. This FDC includes all retrospective data available at the practice, going
back to when the practice first started using Vision/VAMP software (1988 for the first
practices) or switched to Vision, and is collected for THIN. Following this first data col-
lection, incremental data are collected automatically and downloaded electronically each
month. The data collection software used by Vision practices allows for data collection
without interruption to the running of the GPs system. This method ensures minimal
disruption to daily practice activities and maximises data security.
Each year, THIN GPs record information on 3-5 million patients, accounting for 5-
7% of the population [Lewis et al., 2007]. The latest version of the database (updated to
December 2012) included data on 559 practices, covering 11,350,933 patients, 3,802,018
of whom were ’active’ patients who can be followed prospectively. This latest data cut
covers 6% of the UK population [UK, 2012].
The overall majority of people living in the UK (the usually resident population)
is registered with a GP: in April 2011, the NHS Patient Register contained records on
58,471,500 individuals in England and Wales. The Patient Register bases its counts on
numbers reported by each Primary Care Trust (PCT). The 2011 Census, carried out on 27
March 2011, estimated the population to be 56,075,912 at that time (Office for National
Statistics 2012). The difference between the two estimates (the NHS Patient Register
estimate is 4.3% higher than the Census estimate) is likely due to both over and under
coverage.
Patients could be counted twice if they are registered in multiple locations, which
can happen temporarily when a patient is transferring GPs, or permanently if their new
practice fails to identify a person as already being on the register and provides them with
a new NHS number (e.g. if they spell their name differently). These so-called ’ghost
patients’ could also erroneously remain registered with their original practice if they do
not notify their GP of their move. Furthermore, lags in the recording of births and deaths,
immigrations and embarkations (especially if patients choose to stay registered in order to
access healthcare in the UK) can influence the number of records in the Patient Register.
The number of individuals on the Patient Register has been slightly higher than
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Figure 2.2: Differences between the usually resident population and the NHS Patient
Register
estimates of the usually resident population in every year since 1961. Some groups of
the usually resident population are known not to be registered with a GP practice, such as
armed forces personnel, prisoners and non-registered immigrants. However, some people
not included in the usually resident population such as short term migrants (for instance
some students on language courses) might register with a GP and be recorded in the
Patient Register (Figure 2.2). For the reasons outlined above, it is difficult to provide an
accurate number on what proportion of the population is registered with a GP.
As an estimate of the theoretical proportion of the GP registered population, the
armed forces made up 0.3% of the UK population on 1 April 20113, and prisoners ac-
counted for 0.2%, also on 1 April 20114. A study by the LSE estimated the number of
3192.330 trained and untrained personnel (Defence Statistics 2013) / 63,182,175 UK population on 1
April 2011 according to Census data (Office for National Statistics 2013)
485,447 prisoners in England and Wales (Ministery of Justice 2012) / 56,075,912 England and Wales
population on 1 April 2011 according to Census data (Office for National Statistics 2012)
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illegal immigrants at 618,000 at the end of 2007 (estimate range: 417,000 - 863,000)
(Gordon et al. 2009), making up 1.0% (0.7% - 1.4%) of the population5. Excluding these
groups of people leads to an estimate that approximately 98.5% of the UK usually res-
ident population is registered with a GP, suggesting that the GP-registered population is
highly representative of the total UK population. It is likely that some other vulnerable
populations, such as homeless people, are also less likely to be registered with a GP.
GPs use electronic medical records to document information about their patients’
health and prescriptions. Data is collected on patient demographics (date of birth, date
the patient registered with and left the practice, and a household identifier number), dia-
gnoses (including details on hospital admissions, discharge medication and diagnosis),
prescribing, additional health data (tests, laboratory results, lifestyle factors such as alco-
hol and smoking), free text comments, and socioeconomic data.
As shown in Figure 2.3, not all health events that occur in the community are recor-
ded in primary care and hence in THIN. Health events need to be reported by patients to
GPs, and GPs need to record them. Events could be lost if GPs do not record them, if
patients do not deem events important enough to warrant a GP visit, or if they choose to
go to a walk-in centre or hospital instead. In the case of hospital visits, the GP will of-
ten receive a discharge letter. However, discharge letters are now often received digitally
and can be saved as (scanned) attachments or free text. As a result, these might not be
directly available to researchers using THIN, unless participating practices also enter any
diagnoses made directly into the patient’s medical records.
Before data is available to researchers, it is quality checked (see section 2.3, page 56
for more details) and anonymised by CSD: date of birth is changed into year of birth
(although children up to the age of 15 will have both year and month of birth available)
and any names or addresses (from both patient records and free text comments) are re-
moved. The data collection for THIN was approved by the NHS South-East Multi-centre
Research Ethics Committee in 2003. In order to gain approval for individual studies,
study protocols are reviewed by an Independent Scientific Review Committee (SCR) led
by CSD Medical Research UK.
5Estimates based on a mid-2007 UK population estimate of 60,985,700 individuals (Office for National
Statistics 2011)
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The UCL Research Department Primary Care & Population Health has acquired a
full license for access to THIN data for the purposes of conducting large-scale epidemi-
ological, clinical and health care utilisation studies.
Figure 2.3: Recording of health events in THIN
2.3 Data quality and structure
2.3.1 Acceptable Mortality Reporting and Acceptable Computer Us-
age
For the first 100 practices that joined the THIN scheme, preliminary audits of consulta-
tions and prescriptions were compared to national figures. Incremental data collection
undergoes consistency and integrity checks. This information is used to provide feed-
back to the GPs regarding UK quality metrics performances, medical history recording,
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and comparison of prevalence of disease with national levels where available.
An extra check performed by CSD is the calculation of the Acceptable Mortality
Reporting (AMR) date [Maguire et al., 2009]. The AMR date is the year from which
the practice is deemed to be reporting all-cause mortality based on predicted numbers of
deaths derived from National statistics given the practices’s demographics (Figure 2.4).
When practices first switch to using electronic medical records, there might be a
period when they use both the electronic record system and physical records. This would
lead to an underestimate of the incidence of some health events.
Figure 2.4: Example practice for determining the Acceptable Mortality Recording
(AMR) year
Thus, practices might have started by using the electronic system for the most ba-
sic recording (e.g. registration, demographics, death) and continue to use paper-based
recording for diagnoses and writing prescriptions. To correct for this, the Acceptable
Computer Usage (ACU) date was developed by the research team at UCL [Horsfall et al.,
2013]. The ACU date marks the date by which a practice was continuously entering on
average at least two therapy records, one medical record and one additional health record
per patient per year (see Section 2.3.2 on page 59 for information on THIN data files),
and is 3.3 years later than the AMR date, on average. Applying the ACU date as a cut-off
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for selecting high quality data resulted in incidence rates that were more comparable to
external sources, as compared to just using the AMR date [Horsfall et al., 2013].
Table 2.1: Main file types of THIN data
File name Information contained in file
Patient records age, sex, registration date when entering the practice, and
date when leaving the practice
Medical records medical diagnoses, date of diagnosis, and location (e.g.,
GPs office, hospital, consultant) of the event and an option
for adding free text; referrals to hospitals and specialists
Therapy records all prescriptions along with the date issued, formulation,
strength, quantity, and dosing instructions, and events lead-
ing to withdrawal of a drug or treatment
Additional Health Data
(AHD)
vaccinations and prescription contraceptives; miscellaneous
information such as smoking, height, weight, immuniza-
tions, pregnancy, birth, death, and laboratory results
Postcode Variable In-
dicators (PVI)
postcode linked area based socio-economic, ethnicity and
environmental indices
Consultation records date, time and duration (time patient record remained
opened) of consultation
Staff records gender and roles of staff who entered data
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2.3.2 Data structure
THIN data is structured in seven standardised files that are available for each individual
practice (Table 2.1), and one file containing basic information on each practice included
in THIN.
Although the file types are intended to record different information, there is some
redundancy between the files. For instance, suicides can be recorded in different places. It
could be recorded in a patient’s medical records using a diagnosis code, in the Additional
Health Records which has a specific field for recording cause of death, or it could be
recorded as free text. These different types of suicide records are entered in different
sections of the Vision system, and it depends on a GP’s personal preference where a
record will be recorded. Because of this, it is important to consider multiple file types
and codes when identifying cases and covariates, as explained in the next section.
2.4 Identifying cases and confounders
2.4.1 Diagnoses: Read codes in THIN
Diagnoses and symptoms are recorded using a system of diagnosis codes called Read
codes [Booth, 1994, Chisholm, 1990]. The Read codes were developed by Dr James
Read in the 1980s and are used in general practice in the UK. Read codes form a hier-
archical system of codes, divided in chapters and structured similarly to the International
Classification of Diseases (ICD).
Currently, there are just over 100,000 different Read codes. As a result, one dia-
gnosis can usually be represented by several Read codes, ranging from very general to
very specific. For instance, a search for the word ’depression’ in Read code descriptions
gives 130 different hits. Some of these codes are generic (e.g. ’Eu32z11: [X]Depression
NOS’)6, while others are very specific (e.g. ’Eu32212: [X]Single episode major depres-
sion without psychotic symptoms’). As there are a variety of codes that could be used
to describe the same condition, and which code is used is to some degree up to a GPs
6The ’[X]’ at the start of the Read code description indicates that this a Read code added after ICD-10
came out, and thus maps directly onto an ICD-10 code.
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personal preference, it is preferable to use a code list to identify study populations.
A code list is a comprehensive set of condition-specific medical or drug codes which
can be used by researchers to search patient medical/clinical and therapy records in
primary care databases [Dave´ and Petersen, 2009]. Code lists are created by first identi-
fying a list of key words that will be used to identify the disease or illness of interest.
In the case of depression, words such as ’depressive’, ’affective disorder’, ’depressed’,
’unipolar’, and ’dysthymia’ would need to be searched for as well in order to identify all
relevant Read codes. Adding these key words to the initial search increases the yield to
319 Read codes.
However, some Read codes that relate to depression might not contain any of the key
words. Therefore it is necessary to have a look at the identified Read codes and identify
common stems. As the Read codes form a hierarchical system, codes relating to a similar
disorder will have similar stems. By browsing through the Read codes looking for these
common stems, codes such as ’Loss of interest in previously enjoyable activity’ or ’Low
mood’ can be identified as well.
The final step of creating a code list is excluding irrelevant codes. As the key words
used to identify relevant codes tend to be sensitive rather than specific, it is common that
irrelevant codes are also included at this stage. For depression, this also leads to codes
such as ’ECG: S-T depression’ or ’Bone marrow depression’ also being included. An
example code-list and Stata do-file are included in Appendix C on page 202.
Apart from diagnoses and symptoms, Read codes are also used to record patient
demographics (e.g. occupation, ethnicity or family structure), or administration (e.g. re-
ferrals, receipt of a hospital letter, or administered questionnaires). There is a group of
Read codes that relates to different questionnaires such as the HAM-D or EPDS (see
Section 1.2.1 on page 31). While these could be relevant when trying to identify patients
with depression, they are distinct from diagnoses: a patient could have filled out the ques-
tionnaire and not have any symptoms of depression. The result of a questionnaire could
either be the recording of a subsequent depression diagnosis (or no addition recording if
the patient is diagnosed as not depressed) or the score on the questionnaire can be entered
in the free text field. As free text is not available for all patients, these codes are generally
also excluded.
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Two systematic reviews have reviewed the validity of diagnoses in the GPRD [Her-
rett et al., 2010, Khan et al., 2010]. Both reviews conclude that most diagnoses are
well recorded in electronic databases, with the exception of acute conditions. The re-
view by Herrett and colleagues collected 212 papers that investigated 183 different dia-
gnoses [Herrett et al., 2010]. Most papers (85%) used external data to validate diagnoses.
On average 89% of cases were confirmed for the different types of diagnoses, though con-
firmation rates ranged from 24% to 100%. The second review found similar results. As
this review had slightly more strict inclusion criteria, only 49 papers were included [Khan
et al., 2010]. It found that most diagnoses were accurately recorded in electronic records,
with exception of acute conditions. Also, rates of diabetes and musculoskeletal condi-
tions were found to be underestimated.
2.4.2 Prescriptions in THIN
Prescriptions issued by GPs are recorded in THIN. However, there is no information
available whether prescriptions were dispensed by pharmacies, or whether patients take
their prescriptions.
Comparing prescription data in THIN to dispensing data from NHS Prescription
Services showed that the mean practice redemption rate (the percentage of recorded pre-
scription which were dispensed) was as high as 97.4% in 2008, with rates ranging from
89.9% to 113.9% [The NHS Information Centre and Services, 2011]. The study focussed
on 145 practices covering over 1 million patients and using data from 2004 to 2008.
Rates can be higher than 100% when prescriptions are redeemed that were not issued on
the GPs computer, for instance during home visits. When the redemption rate is less than
100%, it indicates the GPs have issued prescriptions that were not redeemed by patients.
Redemption rates for antidepressants were slightly lower at 96.7% (ranging from
88.2% to 112.5%) in 2008. This high redemption rate is surprising as a systematic review
of 12 studies has found that patients with depression were three times as likely as other
patients to be non-compliant with their medication [DiMatteo M et al., 2000]. This could
suggest that the non-compliance happens after redeeming a prescription.
In THIN, prescriptions were until recently coded using Multilex codes provided by
First Databank (FDB). There are just under 75,000 drug codes (as of 2012), and each
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drug code relates to a specific drug at a specific dose. On top of information about drug
name and dose, there is also information about which British National Formulary (BNF)
chapter the drug appears in. This is very useful information when creating drug code lists
as these can be solely based on the relevant BNF chapter (e.g. chapter 4.3 Antidepressant
drugs).
2.5 Limitations of THIN
Although THIN provides unique clinical information useful for epidemiological research
on a large number of people, it also has some limitations. As mentioned in the previ-
ous section, THIN only contains information on prescriptions, not whether these were
dispensed or whether patients take their medication. However, it is possible to get an
indication of whether patients are adhering to their medication by looking at repeat pre-
scriptions. If a patient receives a prescription for a drug that is intended to be taken long
term (or at least for more than one prescription), you would expect the patient to come
back for a repeat prescription. If a patient in this situation has only a single record of a
prescription, this probably indicates that the patient did not adhere to the prescription. If
there are multiple prescriptions (for instance, at least two within a certain time period),
it is more likely that the drug is actually being dispensed and being used by the patient.
Furthermore, THIN does not contain information on prescriptions that were issued in
secondary care such as by a psychiatrist (although some information might be available
in the free text as hospital discharge letters).
Secondly, patients are only followed as long as they stay registered with the same
practice within THIN. If patients move to another practice not contributing to the data-
base, they are lost to follow-up. However, it is possible that a few patients re-register with
another practice that contributes data to THIN. In that case these patients may be counted
twice, though this will be rare.
2.6 Why use THIN for this thesis?
To explore the intergenerational transmission of depression, a long follow-up time of at
least 15 years is necessary. This follow-up time is difficult and extremely costly to achieve
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in regular cohort studies, especially if the study is large. Hence, most epidemiological
studies assessing the effects of postnatal depression on child outcomes are small and have
short follow-up times. Moreover, as cohort studies tend to rely on questionnaires, child
outcomes are usually ’soft’ outcomes. Outcomes measured this way might not relate to
diagnoses and could thus not have an important impact on a child’s life.
With THIN, it is possible to follow a relatively large cohort of families over a pro-
longed period of time. With data up to 31 December 2011 available, children born before
1997 are eligible to be included in the THIN birth cohort I will use for my analysis. Over
this time period, many GP practices will have used electronic health records for a number
of years. Also, by using a primary care database, I can assess ’hard’ diagnostic outcomes.
Finally, loss-to-follow-up will be less of a problem in THIN compared to cohort studies.
In cohort studies, families with a lower socioeconomic status tend to be more likely to
drop out, while this will be less of an issue in THIN. However, families will be lost if
they move and transfer out of a practice. Finally, a birth cohort linking mothers, fathers
and their children has already been created in THIN [Dave´ et al., 2010].
In order to use THIN data, I have applied for and received scienitfic approval for all
studies included in this thesis (Appendix G).
Part II
Parental and adolescent depression
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In part II of my thesis, I explore my main exposure and outcome variables: comorbid
early parental depression and adolescent depression. As discussed in Chapter 1, depres-
sion during the first year after birth is common in both mothers and fathers. Throughout
my thesis I will use the term ’early depression’ to signify parental depression in the first
year after childbirth. I use this term in preference to ’postnatal’ depression as I also
include fathers’ depression and some argue that fathers’ depression is distinct from ma-
ternal postnatal depression that could be influenced by womens’ physical and hormonal
changes occuring after childbirth. As this discussion is beyond the scope of my thesis, I
have chosen to use the term ’early depression’ for both parents.
Several studies have found that depression in mothers and fathers is correlated [Dud-
ley et al., 2001]: if one parent is depressed, the other is more likely to be depressed
as well. A recent meta-analysis by Paulson and Bazemore found a moderately pos-
itive correlation between paternal and maternal depression (r=0.308; 95% CI: 0.228-
0.384) [Paulson et al., 2006]. Similarly, a narrative review by Goodman found that one
in four partners of postnatally depressed mothers were depressed themselves [Goodman,
2004]. Depression rates in fathers were significantly higher when mothers were severely
depressed, with levels in up to 50%.
Many studies have found that maternal [Brennan et al., 2000, 2002, Hanington
et al., 2011], and to a lesser extent, paternal postnatal depression [Goodman, 2004,
Ramchandani et al., 2005a, 2008b] can have adverse effects on childhood outcomes.
However, studies have generally only considered one depressed parent and ignored the
potentially additive or multiplicative effects of comorbid parental depression. Theoret-
ically, if one parent is depressed, the second non-depressed parent could form a ’buffer’
to the child, providing the stimulation and affection the depressed parent is limited in
giving. In the case of comorbid depression, where both parents experience depression
simultaneously, the child could be deprived of this stimulation and affection and could
experience more and more severe child outcomes.
However, few estimates of the prevalence of early comorbid parental depression are
found in the literature. Therefore, I have performed a systematic review to estimate the
prevalence and effects on childhood outcomes of early comorbid parental depression.
This review forms Chapter 3.
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In Chapter 4, I use THIN to explore childhood depression in more detail. As detailed
in chapter 1, the prevalence of major depressive disorder is estimated to be approximately
2% in children and 4% to 8% in adolescents, with a male-to-female ratio of 1:1 during
childhood and 1:2 during adolescence [Birmaher, 1996]. The risk of depression increases
by a factor of 2 to 4 after puberty, particularly in females [Angold et al., 1998], and the
cumulative incidence by age 18 is approximately 20% in community samples [Lewinsohn
et al., 1998, Birmaher et al., 2007].
Depression is treated with psychological therapy or antidepressants. However, there
have been doubts about the efficacy and safety of antidepressant use in children and ad-
olescents, which I detail in Appendix B. Next, I describe trends in the recording of depres-
sion diagnoses, symptoms and antidepressant prescriptions in children and adolescents.
Chapter 3
Systematic review
3.1 Objectives of the chapter
The objectives of this review are to:
1. estimate the prevalence of comorbid postnatal depression during first year post-
partum
2. assess the effects of comorbid parental postnatal depression on children
3.2 Methods
3.2.1 Criteria for considering studies for this review
3.2.1.1 Types of studies
Published and unpublished observational studies (cohort and cross-sectional studies)
were included in this review if they reported the prevalence or incidence of comorbid
parental postnatal depression. Studies were considered if they were published between
January 1980 and December 2012.
3.2.1.2 Types of participants
Parents aged 15 to 50 years old, who had a primary diagnosis of depressive disorder
according to DSM or ICD criteria assessed by a clinical interview, or who scored as
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depressed on a validated questionnaire, during pregnancy or within 1 year of the birth of
their child were included. Studies focussing solely on adolescent parents were excluded,
as well as studies that used parents from high-risk populations as these groups of parents
are likely to not be representative of the general population.
Parents who had suffered the loss of an infant, or parents of infants with chronic dis-
eases were excluded from the current study as they are very likely to suffer from reactive
depression in this situation which is distinct from depressive disorder. Studies including
the effects on children were included for any type of effect and any age of the child (<18
years).
Types of outcome measures
1. Prevalence/incidence of depressive disorder according to DSM or ICD criteria
2. Prevalence/incidence of heightened risk of depression according to a validated
questionnaire (e.g. Edinburgh Postnatal Depression Scale or Beck Depression In-
ventory), both as point prevalence or cumulative prevalence
3. Adverse outcomes in children
3.2.2 Search method for identification of studies
Computer searches for relevant studies were conducted on databases including PubMed,
Web of Science, PsycINFO, CINAHL and EMBASE; and by consulting the reference
lists of retrieved articles as well as relevant review articles and meta-analyses and a cited
reference search of relevant articles.
The database search consisted of three terms: Outcome (depression), Subjects (both
parents), and Timing (perinatal). The search strategies resulting from this method can be
found in Table 3.1.
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3.2.3 Data collection and analysis
3.2.3.1 Selection of studies
I selected studies for inclusion in the review after employing the search strategy described
previously. Where a title or abstract described a study eligible for inclusion, I obtained
the full article and inspected it to assess relevance to this review based on the inclusion
criteria. Study selection based on title and abstracts was performed independently by
Shuk-Li Man and Jenny Woodman, full article inspection was checked by Ruth Black-
burn, Jesca Brouwer and Hilary Davies.
3.2.3.2 Assessment of Study Quality
Studies were rated on the risk for selection bias (appropriate sampling method and clear
inclusion/exclusion criteria 1 point each), representativeness of the study population
(<60% of population in the same educational/socioeconomic group 1 point), response
rate (adequate if >60% - 1 point), objectivity of the measurement instrument (validated
questionnaire 1 point; or diagnostic interview/medical diagnosis 2 points), and report-
ing of ethical approval and funding disclosure (1 point). All assessment of the quality of
studies was performed independently by reviewers (LW, RB, JB and HD). These quality
measures were informed by the STROBE guidelines for observational studies [von et al.,
2007].
3.2.3.3 Data extraction
Information on each study including quality characteristics and details regarding parti-
cipants, comparisons, and outcomes was independently extracted by reviewers (LW, RB,
JB and HD). The description of the included studies provides a context for discussing the
reliability, internal and external validity of results.
I sought additional data from the principal authors of studies that appeared to meet
the eligibility criteria when aspects of methodology were unclear, or where the data were
missing, or were in a form unsuitable for meta-analysis. Study where the authors provided
the necessary information were included.
Discrepancies in the study selection, study quality assessment and data extraction
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phases were resolved by discussion or, if necessary, by a third reviewer.
3.2.3.4 Data analysis
Data analysis was undertaken using the meta-analytic methods available in Stata Statist-
ical software (version 12.1, StataCorp).
3.3 Results: Prevalence of comorbid early parental de-
pression
I identified 1554 studies, of which 690 were duplicates. Most remaining studies (n=761)
were excluded because they were not applicable to the present systematic review (e.g.
articles on other topics, depression only assessed in one parent, reviews or summaries,
infant death, teen parents). Of those that were reviewed in full text (n=103), most were
excluded because the diagnosis of depression was not ascertained (e.g. studies using
reporting average questionnaire-based depression scores), while seven studies were not
retrievable. Finally, 20 papers met the inclusion criteria for this systematic review (Fig-
ure 3.1) [Ballard et al., 1994, Bielawska-Batorowicz and Kossakowska-Petrycka, 2006,
Curro` et al., 2009, Dave´ et al., 2010, Escriba`-Agu¨ir and Artazcoz, 2011, Hanington et al.,
2010, 2011, Kerstis et al., 2012, Lane et al., 1997, Muscat et al., 2012, Nishimura and
Ohashi, 2010, Parfitt and Ayers, 2012, Paulson et al., 2006, 2009, Petitclerc et al., 2009,
Ramchandani et al., 2005a, 2008b, Raskin et al., 1990, Soliday et al., 1999]. Of these
studies, eight reported rates of comorbid depression at two or more time points and 11
reported a single observation. Apart from one study [Dave´ et al., 2010] that reported
cumulative prevalence over the first year, all studies reported point prevalence rates.
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Figure 3.1: Study selection for inclusion in systematic review
Details on the characteristics of the 20 included studies are shown in Table 3.2. Stud-
ies originated from 10 different countries, with the United Kingdom contributing the most
(n = 4 studies). Most studies used a validated self-report questionnaire as the primary
case definition: The Edinburgh Postnatal Depression Scale (11 studies), the Center for
Epidemiologic Studies Depression Scale (5 studies), and the Beck Depression Inventory
(1 study). One study used a structured interview, and one used GP diagnoses. Sample
sizes varied widely across studies (n = 40 - 72,861 couples), as did estimated rates of
couple depression comorbidity (0 - 20%, Table 3.3). Rates of maternal depression ranged
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from 4.5% to 39.2%, while rates for paternal depression were estimated between 0.9%
and 27.5%.
Figure 3.2: Prevalence of comorbid early parental depression in the perinatal period. As
the study by Paulson and Bazemore used 3 different cut-offs to determine depression, I
chose the cut-off (CES-D>15) that was most commonly used by other studies to represent
the study here. ES shows prevalence estimates with 95% confidence intervals, boxes
represent study weights, studies that had prevalence rates of 0% are excluded
As studies used various instruments to measure depressive symptoms, at various
time points, using different cut-off points (see Figure 3.2), it is not appropriate to sum-
marise the results using a meta-analysis.
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3.3.1 Study Quality
The quality of the included studies varied (Table 3.4 and Table 3.5). Most stud-
ies used appropriate sampling methods. However, Bielawska-Batorowicz and col-
leagues [Bielawska-Batorowicz and Kossakowska-Petrycka, 2006] used internet advert-
isements to recruit participants, which may be subject to selection bias as parents ex-
periencing depression may be more likely to participate. Similarly, Soliday and col-
leagues [Soliday et al., 1999] used secondary recruitment or snowball sampling (i.e.
participants recruited by other participants) to boost their sample size, again subject to
selection bias. Two studies did not report on their sampling method [Raskin et al., 1990,
Nishimura and Ohashi, 2010]. Most studies recruited participants in hospital after child
birth.
Most studies (85%) reported on inclusion and exclusion criteria. Overall, studies
were very inclusive, only excluding parents who did not speak the language used in the
study questionnaires and excluding adolescent parents. Two studies did not report any
inclusion/exclusion criteria [Raskin et al., 1990, Curro` et al., 2009] , one study was un-
clear [Nishimura and Ohashi, 2010]. Eight study populations had limited educational
or socioeconomic diversity, with 60% of participants at the same educational of SES
level [Ballard et al., 1994, Curro` et al., 2009, Kerstis et al., 2012, Parfitt and Ayers, 2012,
Paulson et al., 2006, Raskin et al., 1990, Soliday et al., 1999].
Response and cohort retention rates were high (80%) in most samples, although few
studies did not report on the number of people who were approached, so no response
rates could be calculated. Moreover, some studies were cross-sectional so retention rates
were not applicable to these studies.
All studies used validated measures of depression: validated questionnaires (18 stud-
ies), clinical interviews (1) and GP diagnoses (1). Although a few studies used the EPDS
to measure depression in fathers before this questionnaire was validated for men, I have
classified these as validated questionnaires as they used the cut-off score that was determ-
ined appropriate in the later validation. Only 7 (35%) of studies reported on receiving
ethical approval and disclosed who funded the study.
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Table 3.4: Risk of bias summary: review authors judgements about each risk of bias item
for each included study
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Ballard, 1994 + + - + + -
Bielawska-Batorowicz, 2006 - + + ? + -
Curro`, 2009 + + - + + -
Dave´, 2010 + + + + ++ +
Escriba`-Agu¨ir, 2011 + + + + + ?
Hanington, 2010 + + + + + +
Hanington, 2011 + + + + + +
Kerstis, 2012 + + - + + ?
Lane, 1997 + + ? + + ?
Muscat, 2012 + + + ? + +
Nishimura, 2010 ? ? + - + ?
Parfitt, 2012 + + - ? ++ +
Paulson, 2006 + + - + + ?
Paulson, 2009 + + - + + ?
Continued on next page
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Table 3.4: Risk of bias summary: review authors judgements about each risk of bias item
for each included study
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Petitclerc, 2009 + + + + + ?
Pinheiro, 2006 + + + ? + ?
Ramchandani, 2005 + + + + + +
Ramchandani, 2008 + + + + + +
Raskin, 1990 ? - - ? + ?
Soliday, 1999 - - - - + ?
3.4 Results: Childhood outcomes
Two studies reported on the association between couple depression comorbidity and
childhood outcomes (Table 3.6). One of these studies reported on couple depression pre-
valence [Paulson et al., 2006], while the second study only reports depression prevalence
for mothers and fathers separately [Mezulis et al., 2004].
The study characteristics of the study conducted by Paulson and colleagues [Paulson
et al., 2006] are represented in Tables 3.2-3.5. Paulson and colleagues found that couples
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Table 3.5: Risk of bias overview: review authors judgements about each risk of bias item
presented as percentages across all included studies. + means a study complies with that
measure, ? means compliance could not be assessed by the information in the paper, -
means the study does not comply
1 + + + + + + + + + + + + + + + + ? ? - -
2 + + + + + + + + + + + + + + + + + ? - -
3 + + + + + + + + + + + ? - - - - - - - -
4 + + + + + + + + + + + + + ? ? ? ? ? - -
5 + + + + + + + + + + + + + + + + + + + +
6 + + + + + + + ? ? ? ? ? ? ? ? ? ? - - -
1. Sampling method (selection bias)
2. Clear inclusion/exclusion criteria (selection bias)
3. Educationally/socio-economically diverse population
4. Adequate response rate
5. Objective measurement of parental depression
6. Report ethical approval & funding disclosure
Table 3.6: Characteristics of studies included in child outcomes systematic review
Source (study location) Child outcome measure N of children Child age at assessment
Paulson, 2006 (US)
Patient health behaviour
5089 9 months
Parent-child interaction
Mezulis, 2004 (US)
Internalizing behaviour
350 5 years
Externalizing behaviour
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where both parents were depressed were less likely to follow anticipatory guidance re-
commendations on health behaviours compared to both couples where only one parent
was depressed, and where both parents were non-depressed. Specifically, when both par-
ents were depressed, the child was less likely to be put to sleep on his/her back (41%
comorbid depressed versus 54% for both not depressed, p<0.001), was less likely to
have ever been breastfed (64% comorbid depressed versus 74% for both not depressed,
p<0.001), and was more likely to be put to bed without a bottle (62% comorbid depressed
versus 75% for both not depressed, p<0.001), or awake (54% comorbid depressed versus
61% for both not depressed, p<0.05). Parent-child interaction behaviours were also af-
fected as mothers were least likely to play peekaboo with their infants when both parents
were depressed (85% comorbid depressed versus 88% for both not depressed, p<0.01),
and fathers were least likely to play outdoor games (53% comorbid depressed versus 60%
for both not depressed, p<0.05), or sing songs (29% comorbid depressed versus 35% for
both not depressed, p<0.10) with their infants.
The study by Mezulis and colleagues [Mezulis et al., 2004] recruited women and
their partners during pregnancy through US obstetric and hospital clinics and is part of
the Wisconsin Maternity Leave and Health (WMLH) Project. To be included in the study,
at least one member of the couple had to be working for pay or profit, and mothers were
excluded if they were students, or unemployed and not looking for work. Of all eligible
women, 75% agreed to participate, and 77% of women who participated were followed
up to child age 5 years, compared to 64% of men.
The study by Mezulis used the CES-D questionnaire to assess depression in men and
women at 1 month, 4 months, 12 months postpartum and when the child was in kinder-
garten, but also assessed mother’s depression using the Diagnostic Interview Schedule
(DIS). Women were depressed between 3.7% and 4.6% in the first year after childbirth
according to the DIS, compared to between 5.9% and 11.6% as measured by the CES-D.
Men were only scored using the CES-D and between 10.2% and 15.6% of fathers were
depressed. Children’s behaviour problems were measured when children were in kinder-
garten (age 5-6 years) with the Health and Behavior Questionnaire (HBQ) which was
administered via the teacher by telephone interview. The mental health domain of the
questionnaire used in this study focussed on internalizing (depression and anxiety symp-
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toms) and externalizing behaviour (symptoms of conduct disorder, oppositional defiant
disorder, overt aggression and attention deficits).
Mezulis and colleagues found that paternal depression during a child’s infancy ex-
acerbated the effect of maternal depression. Paternal depression had little effect on the
children of non-depressed mothers. The highest levels of internalizing behaviours were
found in children of parents where both were depressed (estimate not provided, p<0.05),
especiallyin case when fathers spent a lot of time with the children. There were no effects
on externalizing behaviour.
3.5 Discussion
Studies reporting on comorbid early parental depression showed a wide variety of pre-
valence rates, ranging from 0 to 20%. This can be explained by variations in the meas-
urements instruments, cut-off scores, timing, and quality of the 20 included studies. A
meta-analysis could hence not be performed. The larger, better quality studies estimated
the prevalence of comorbid early parental depression between 0.8% and 4.0%. Only two
studies measured child-related outcomes in families with comorbid depressed parents and
found that these families were more likely to experience adverse outcomes compared to
families with one depressed parent or no depressed parents.
Two studies included in my review found a comorbid early parental depression rate
of 0% [Muscat et al., 2012, Parfitt and Ayers, 2012]. However, both studies were more
limited by small sample sizes (20 and 40 couples), which could explain these results. In
order to detect a prevalence rate of 4% (the higher end of the estimate based on the high
quality studies) one would require a sample size of at least 1475 couples (if estimated
with 95% power and a margin of error of 1%).
Two other studies found very high rates of comorbid parental depression (20% and
19.6%) [Soliday et al., 1999, Bielawska-Batorowicz and Kossakowska-Petrycka, 2006].
The first study used an internet advertisement that mentioned the study’s aim to recruit
couples. This may have biased the study participants to those with depression. The
second study asked participating couples to recruit additional couples, a technique known
as snowbal sampling. As couples would have been aware of the study aims at this time,
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they could have been more likely to recommend the study to other couples whom they
know were experiencing depression. If I only include studies with a sample size of at
least 1475 couples, and exclude the two outliers, couple comorbidity ranged from 0.6%
to 14.5%.
Overall, studies that assessed depression by using questionnaires appeared to find
higher rates of depression compared to studies using a diagnostic interview or medical
diagnosis. Since only two studies used interviews or diagnoses to assess depression, no
formal analysis was performed to confirm this finding. However, the study by Mezulis
and colleagues measured depression in mothers using both a diagnostic interview and the
CES-D questionnaire and consistently found higher rates of depression when using the
questionnaire (e.g. at 1 month postpartum, 4.6% of women were depressed according to
the interview, compared to 11.6% based on the CES-D).
As shown in Figure 3.2, there were no clear time trends of couple depression over
the first year postpartum. There is some indication that father’s depression peaks in the
period between 3-6 months after childbirth [Paulson and Bazemore, 2010], although I did
not observe this for couple depression. However, due to the heterogeneity of the included
studies, an existing time trend may have been obscured.
The relatively high rates of comorbid depressed parents could be explained by as-
sortative mating: the tendency for individuals with similar phenotypes to mate more
frequently than expected by chance. A meta-analysis has shown evidence for assortat-
ive mating in people with affective disorders, including depression [Mathews and Reus,
2001].
Couple depression comorbidity could be a significant public health concern if it leads
to a higher likelihood of adverse events in children. It is well documented that adverse
childhood experiences can have an impact on health outcomes in children (e.g. [Fla-
herty EG, 2013]), and that maternal and paternal depression individually can affect child
outcomes (see Chapter 1). The two studies included in this review assessing child-related
outcomes both found that these outcomes were increased in children of two depressed
parents: these parents were less likely to follow guidance on health behaviours, and chil-
dren were more likely to show internalizing behaviour.
This review was limited by the heterogeneity of studies reporting on couple de-
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pression comorbidity (I2=98.6%, p<0.001). This can be explained by the substantial
differences in the measurement instrument and cut-off scores used and timing of meas-
urement. It was hence inappropriate to perform a meta-analysis. Therefore, I am not
able to provide a point estimate of the prevalence of early parental comorbid depression.
Moreover, the point estimates from the individual studies could be biased by inappro-
priate sampling selections or non-representative populations. As couple comorbidity is
not routinely assessed, this review is unable to compare couple depression rates to time
outside the perinatal period. Finally, I was able to identify only two studies assessing the
effects of couple depression on child outcomes, severely limiting the evidence base for
drawing conclusions for this part of my review.
Despite these limitations, two conclusions can be drawn from this review. Firstly,
a substantial number of couples experience comorbid depression during the first year
after childbirth. Second, couple depression comorbidity appears to adversely affect child
outcomes, more so than individual parental depression.
Future research should focus on families as a whole and examine the course of de-
pression in both new parents as comorbid depression appears to exacerbate the effects
of individual parental depressio [Paulson and Bazemore, 2010]. Further investigation of
the long term outcomes of children of comorbid depressed parents, focussing on ’hard’
clinical based outcomes rather than ’soft’ questionnaire based outcomes is required.
3.6 How does this chapter inform my thesis?
Although I was not able to provide an overall estimate for the prevalence of early comor-
bid parental depression, the estimate from a previous THIN study [Dave´ et al., 2010] is in
line with other studies, particularly the studies using data from another large UK birth co-
hort (ALSPAC) [Hanington et al., 2010, 2011, Ramchandani et al., 2005a, 2008b]. This
finding shows that routinely collected health data is at least on par with the large UK birth
cohort studies on this topic and that THIN is an appropriate data source to investigate par-
ental depression.
Moreover, only two studies assessed child outcomes associated with early comorbid
parental depression. These studies were limited in follow-up time, only assessing out-
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comes in early childhood, but did find adverse effects of comorbid parental depression.
As a significant number of couples does experience depression simultaneously in the first
year after childbirth, a study focussed on long term clinical child outcomes, as I present
in the next part of my thesis, is overdue. Using THIN, I will be able to assess clinical
outcomes in both childhood and adolescence in a large and unselected population using
information on both parents. This type of study has not been performed before and will
provide novel inside into the effects of parental mental health on child outcomes.
As mentioned in this chapter, Shreya Dave´ has conducted a study on the prevalence
of parental depression in THIN [Dave´ et al., 2010]. She found that overall, 4% of parents
experienced depression in the same year. For mothers, 14% had a record of depression in
the first year after childbirth, compared to 4% of fathers.
I have repeated her analysis on the updated cohort (as described in Chapter 5) and
found that in 1994 - 1997, the years from which I will draw my cohort, rates for maternal
depression were between 12% to 15% (Figure 3.3). For fathers, depression rates were
around 1.5% (Figure 3.4). As described in the published THIN study [Dave´ et al., 2010],
rates for paternal depression have increased over time, which explains why the rates I
find in 1994 - 1997 are slightly lower compared to the rates drawing on data from 1993 -
2007.
Comorbid early depression was recorded for 0.5% of couples between 1994 - 1997,
which is substantially lower than the 4% reported in the earlier THIN paper. Again, this
will be at least partly due to the lower recording of paternal depression in that time period.
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Figure 3.3: Early maternal depression as measured by depression diagnoses and antide-
pressant prescriptions
Figure 3.4: Early paternal depression as measured by depression diagnoses and antide-
pressant prescriptions
Chapter 4
Trends in childhood depression
4.1 Objectives of the chapter
In this chapter I aim to describe trends in the recording of depression diagnoses, symp-
toms and antidepressant prescriptions in primary care in the UK in children from 1995
to 2009, with a focus on the effects on the Committee for Safety of Medicines (CSM)
advice in December 2003.
Adolescent depression is the outcome of my main analysis, presented in part III of
this thesis. Therefore, I aim to describe how it is recorded, and any trends over time
and by age in this chapter. A paper studying depression in adults in THIN has found
that, over time, GPs have become more likely to record depression symptoms rather than
depression diagnoses [Rait et al., 2009]. A similar study for people under the age of 18
has not been performed yet.
Apart from a trend towards symptom recording, depression recording could also be
affected by a CSM advice issued in December 2003. This advice warned against the use
of antidepressants (other than fluoxetine) in children and adolescents, as the balance of
benefits and risks was deemed unfavourable. I will outline the treatment options avail-
able for depression in children and adolescents, provide a brief overview of the safety
concerns, and evidence from trials and observational studies for these safety concerns.
Results from this chapter have been published in PLoS One (see Appendix F on
page 232), and parts of the background and introduction were published in Significance
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as a feature article that was runner-up in the annual writing competion organised by the
Young Statisticians section of the Royal Statistical Society (Appendix F on page 250).
4.2 Introduction
4.2.1 Depression in children and adolescents: treatment options
There are several treatment options for depression in childhood and adolescence. The
National Institute for Health and Clinical Excellence (NICE) guidelines on depression in
children (aged 5 - 11 years) and young people (aged 12 years up to their 18th birthday)
offer an overview of the available options [National Institute for Health and Clinical Ex-
cellence, 2005]. The recommendations for treatment are summarised in Table 4.1. In
the NICE guidelines, it is stressed that psychological therapies ought to be the first line
of treatment. Only children with moderate to severe depression who are unresponsive
to psychological treatment should be treated with antidepressants, often in conjunction
with psychological treatment. As there is limited evidence of the effectiveness of antide-
pressant treatment of young people, and especially children, NICE advises these should
only be used very cautiously in this age group. However, a survey in a Child and Ad-
olescent Mental Services (CAMHS) found that after publication of the NICE guidelines
28% of children and adolescents were receiving antidepressants without psychological
treatment [Perera et al., 2007].
Selective serotonin reuptake inhibitors (SSRIs) were first developed in the
1970s [Wong et al., 1974]. At the time, depression was believed to be a rare disorder,
while anxiety was much more frequent. As such, anxiolytics and tranquilizers such
as benzodiazepines were the most frequently prescribed drugs. However, early in the
1980s it appeared that patients could develop dependence on these drugs, even on low
or moderate doses, and suffer from withdrawal symptoms when benzodiazepines were
discontinued. In the light of these findings, prescriptions for benzodiazepines decreased
markedly and a market for antidepressants opened up.
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Table 4.1: Recommended treatment for depression in children and adolescents, adapted
from NICE guideline CG28
Depression severity Recommended treatment
Mild depression (including
dysthymia)
Watchful waiting
Non-directive supportive therapy or group cognitive be-
havioural therapy/guided self-help
Moderate to severe depression
Brief psychological therapy
± fluoxetine
Depression unresponsive to
treatment/ recurrent
depression/psychotic depression
Intensive psychological therapy
± fluoxetine, sertraline, citalopram, augmentation with
an antipsychotic
Selective serotonin reuptake inhibitors work upon the serotonin system in the central
nervous system. Their main point of action is thought to be the inhibition of serotonin
reuptake, making serotonin available for longer in the synapses between nerve cells, and
making it more likely for the post-synaptic cells to become excited. They are deemed
‘selective’, as compared to the older tricyclic antidepressants (TCAs) which work on the
serotonin, norepinephrine and dopamine systems, SSRIs work mainly on the serotonin
system. They were found to be comparable to TCAs with regards to efficacy, although
SSRIs did not seem as effective as TCAs in hospitalised patients [Anderson, 2000].
Antidepressants (ADs) are commonly prescribed to children and adolescents for de-
pression, anxiety, and a variety of other disorders [Murray et al., 2004]. SSRIs, first
marketed in the late 1980s, were prescribed to children for depression on the basis of
effectiveness data from trials on adult psychiatric disorders coupled with other trial data
demonstrating the ineffectiveness of TCAs [Stark and Hardison, 1985, Hazell et al., 2010,
Keller et al., 2001, Emslie et al., 2002]. In the early 2000s, SSRIs became the preferred
treatment for depression in children rather than TCAs [Paediatric Formulary Commit-
tee, 2010]. However, there are serious safety concerns regarding SSRIs, as detailed in
Appendix B.
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Up to now, time trends in antidepressant prescribing in children have been described
for periods leading up to the CSM advice [Murray et al., 2004, 2005], and up to 2006, just
3 years after it was issued [Bergen et al., 2009]. Moreover, these studies only assessed
antidepressant prescriptions, and did not take recording of depression diagnoses or symp-
toms into account. I therefore sat out to examine the full time trends over the time period
for which information on depression (diagnoses, symptoms and antidepressant prescrip-
tions) is available in THIN.
4.3 Methods: interrupted time series
4.3.1 Data source and population
4.3.1.1 Data source & study population
I identified a cohort of children aged up to 18 years who were registered with a Gen-
eral Practice which was a part of THIN for at least six months between January 1995
and December 2009. Children entered the cohort when they registered with a General
Practice, or, the date when their practice joined the THIN scheme and met standards for
acceptable levels of data recording. Children remained in the cohort until aged 18 years,
transfer out of the practice, date of death or date of last data collection from the practice.
4.3.2 Outcomes and confounders
4.3.2.1 Depression and antidepressants
I examined entries made of diagnoses and symptoms of depression by examining Read
codes. Depression diagnosis codes ranged from ‘dysthymia’ and ‘mild depression’ to ‘re-
current severe major depression’, but excluded codes that indicated other mental disorder
such as psychosis or anxiety. Depression symptoms relate to codes indicating depression
but are not certain enough to be classified as a diagnosis, such as symptoms of depression
or ‘C\O feeling depressed’. I also examined anti-depressants BNF codes prescribed by
the general practitioner at appropriate therapeutic doses for the treatment of depression.
I excluded antidepressant prescriptions for products dosed too high to be eligible for pre-
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scription as an antidepressant. This led to the exclusion of high dose TCAs that were
indicated for nocturnal enuresis. These code lists have been created and used in previous
studies and were developed in line with the method described in chapter 2. The do-file
used for creating this codelist and resulting codelist itself are detailed in Appendix C on
page 202.
4.3.2.2 Potential confounders
I included information on age, gender and social deprivation score (Townsend scores)
in my analysis as these are known to be associated with childhood depression and the
distribution of these variables may change over the 15 year study period.
4.3.3 Statistical analysis
I described the baseline socio-demographic characteristics of the cohort using frequency
tables. I calculated annual incidence rates and 95% confidence intervals (CI) for de-
pression diagnoses, symptoms and antidepressant prescriptions by dividing the annual
number of incident cases by the total person-years at risk (PYAR) for each year.
Incidence rate ratios adjusted for gender, age and quintiles of Townsend deprivation
score) were estimated using a Poisson regression model. The analyses were adjusted for
clustering at practice level.
A Lewis plot [Lewis et al., 2005] was used to explore the association between time
since registration and incidence rates as prior diagnoses might be registered at or near
the time of registration and these ought not to be included in the incidence rates. The
Lewis plots revealed that there was an increased rate of depression diagnoses, symptoms
and antidepressant prescribing in the first month after registration, after which the rate of
recording dropped to a steady state. To correct for this, I started follow-up one month
after registration. Unless otherwise specified, analyses were conducted in Stata, version
11.2 (Stata Corp, College Station, Texas).
4.3.4 Interrupted time series analysis
In order to assess the effects of the CSM advice on antidepressant prescribing, I used a
segmented regression analysis [Wagner et al., 2002]. The general formula for using this
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type of regression is as follows:
Yt = β0 + β1 × timet + β2 × interventiont + β3 × time after interventiont + t
Here, Yt is the outcome variable, in my case the incidence rate of depression in chil-
dren, in year t; time is a continuous variable indicating time in years at time t from the
start of the observation period; intervention is an indicator for time t occurring before
(intervention = 0) or after (intervention = 1) the event of interest; and time after inter-
vention is a continuous variable counting the number of years after the intervention at
time t, coded 0 before the event of interest and (time - timing of intervention) after the
event of interest. In this model, β0 estimates the baseline level of the incidence rate at
time zero; β1 estimates the change in the incidence rate per person that occurs with each
time increment before the intervention (i.e. the baseline trend); β2 estimates the level
change in the mean yearly outcome variable per person immediately after the interven-
tion, that is, from the end of the preceding segment; and β3 estimates the change in trend
in the mean yearly number of records per person after the intervention, compared with
the yearly trend before the intervention. The sum of β1 and β3 is the post-intervention
slope.
In assessing the trends in incidence rates in depression recording in children, the ad-
vice issued by the CSM could be seen as the event or intervention of interest. However,
doubt over the safety of SSRIs was raised a full year before the advice was issued by
a BBC programme. Therefore, it would be possible that incidence rates of particularly
antidepressant prescriptions changed before December 2003. To account for the uncer-
tainty in the timing of the intervention, I used the Joinpoint regression program (version
3.5.1) from the Surveillance Research Program of the US National Cancer Institute to
perform the segmented regression analysis [National Cancer Institute, 2011]. Joinpoint
is statistical software for the analysis of trends using Joinpoint models. This analysis al-
lows for identifying points where there is a change in the linear slope of the trend, rather
than defining them yourself. The analysis starts with the minimum number of jointpoints
(i.e., 0 joinpoints, which is a straight line), and tested whether one or more joinpoints (up
to 4) were statistically significant and should be added to the model [Kim et al., 2000].
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The models incorporates estimated variation for each point by using the standard error of
the rate estimate. After identifying the existence of a change in the trend, a segmented
regression is fitted and the result of the best model is shown graphically. Finally, the es-
timated annual percentage of change (APC) and its corresponding 95% CI is computed
for each of those trends by fitting a regression line to the natural logarithm of the rates,
using calendar year as a regression variable [Clegg et al., 2009].
Figure 4.1: Venn diagram showing children with records of depression diagnosis, symp-
toms and/or antidepressants in THIN
4.4 Results: Trends in GP recording of childhood de-
pression 1995 - 2009
In total, 1,502,753 children up to the age of 18 years were registered with their GP for at
least one year in The Health Improvement Network (THIN) UK primary care database.
Of these children, 45,723 (3%) children had at least one entry of a depressive symptom,
diagnosis or antidepressant prescription. Of these children, 17,124 (38%) had a diagnosis
of depression, 22,587 (49%) had a record of depressive symptoms, and 25,473 (56%)
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were prescribed antidepressants. Most of these antidepressant prescriptions were for SS-
RIs: 16,925 (66%), with TCAs representing 7,777 (31%) and other antidepressants 771
(3%) of prescriptions (Table 4.2). Of the children receiving SSRIs, 4,339 (26%) were not
diagnosed with depression or depression symptoms. Similarly, 7,211 (42%) of children
diagnosed with depression were not prescribed antidepressants (Figure 4.1).
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Table 4.2: Characteristics of first time users by antidepressant (AD). Values are numbers
(column percentages) unless otherwise indicated
Characteristics Individuals by AD drug group
SSRI TCA Other MAOI Any AD
Socio-demographic (n=16,925) (n=7,777) (n=769) (n=2) (n=25,473)
Girls 12,142 4,680 488 1 17,311
(71.7) (60.2) (63.5) (50.0) (68.0)
Deprivation quintile
1 (most affluent) 3,252 1,631 144 1 5,028
(19.2) (21.0) (18.7) (50.0) (19.7)
2 3,063 1,451 105 0 4,619
(18.1) (18.7) (13.7) (18.1)
3 3,456 1,646 139 0 5,241
(20.4) (21.2) (18.1) (20.6)
4 3,732 1,706 182 0 5,620
(22.1) (21.9) (23.7) (22.1)
5 (most deprived) 3,195 1,259 191 1 4,646
(18.9) (16.2) (24.8) (50.0) (18.2)
Age groups
3 - 10 years 179 1,577 7 0 1,764
(1.1) (20.3) (0.9) (6.9)
11 - 14 years 1,567 1,558 53 1 3,192
(9.3) (20.0) (6.9) (50.0) (19.4)
15 - 18 years 15,179 4,642 709 1 20,652
(89.7) (59.7) (92.2) (50.0) (80.7)
SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant;
MAOI = mono-amine oxidase inhibitor; other ADs are: mirtazapine, venlafax-
ine, flupentixol, duloxetine, nefazodone and reboxetine
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Rates for entries of diagnoses of depression increased from 2.2 (95% CI: 1.9 - 2.5)
per 1,000 PYAR in 1995 to 3.0 (95% CI: 2.8 - 3.1) per 1,000 PYAR in 2002, then dropped
to 2.0 (95% CI: 1.9 - 2.1) per 1,000 PYAR in 2005 and have since been relatively constant
at around 2.0 per 1,000 PYAR (Figure 4.2). Rates for antidepressant prescribing show a
similar pattern: they have gone up from 2.8 (95% CI: 2.4 - 3.1) per 1,000 PYAR in 1995
to 4.5 (95% CI: 4.3 - 4.6) per 1,000 PYAR in 2002, then dropped to rates similar to the
initial 1995 rates, but have been increasing again since 2005. Recording of symptoms has
seen a dramatic rise from 1.0 (95% CI: 0.8 - 1.2) in 1995 to 4.7 (95% CI: 4.5 - 4.8) per
1,000 PYAR in 2009.
Figure 4.2: Trends in the incidence of childhood depression, symptoms and antidepress-
ants from 1995 to 2010
TCAs were the most commonly prescribed antidepressant to children in 1995, but
by 1999 SSRIs had overtaken them and have been the preferred drug type ever since (Fig-
ure 4.3). However, since 2003 there has been a sharp decline in SSRI prescriptions, with
rates decreasing from 3.2 (95% CI: 3.0-3.3) per 1,000 PYAR in 2002 to 1.7 (95% CI: 1.7
- 1.8) per 1,000 PYAR in 2005. Since then, rates have gradually started increasing again.
TCA prescription rates have gradually decreased since 1995, but stopped decreasing in
2006. Rates for MAOIs and other antidepressants were negligible.
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In children aged 3 - 11 years, girls were less likely than boys to be diagnosed
as depressed (IRR=0.79, 95% CI: 0.67 - 0.92), have depression symptoms recorded
(IRR=0.90, 95% CI: 0.84 - 0.95) or be prescribed antidepressants (IRR=0.63, 95% CI:
0.58 - 0.69). In children aged 12 - 18 years, girls were more likely than boys to have
been diagnosed as depressed (IRR=2.87, 95% CI: 2.77 - 2.97), have symptoms recorded
(IRR=2.31, 95% CI: 2.23 - 2.39) or have been prescribed antidepressants (IRR=2.71, 95%
CI: 2.63 - 2.80). The incidence rates in children in the younger age group (3 - 11 years
old) were only a fraction of those in the older age group (12 - 18 years old, Figure 4.4).
Rates for all depression indicators increased with deprivation: children and adoles-
cents in the most deprived quintile were twice as likely to be diagnosed as depressed
(IRR=2.14, 95% CI: 2.03-2.26) or be prescribed antidepressants (IRR=1.91, 95% CI:
1.82-2.00) compared to children and adolescent in the least deprived quintile. For de-
pression symptoms, there was an almost 50% increase of recording in the most deprived
compared to the most affluent children and adolescents (IRR=1.43, 95% CI: 1.36-1.50).
Figure 4.3: Rates of prescription of Tricyclic Antidepressants (TCA) and Selective Sero-
tonin Reuptake Inhibitors (SSRI) in children
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Figure 4.4: Incidence rates of depression diagnoses, symptoms and antidepressant pre-
scriptions by age
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Table 4.3: Incidence rate ratios (IRR) for diagnosis and symptoms of depression and
antidepressant prescriptions stratified by gender, age group and deprivation
Multivariablea: Multivariablea: Multivariablea: Multivariablea:
stratified by age group: stratified by age group: stratified by deprivation: stratified by deprivation:
3 - 11 years 12 - 18 years Townsend 1 & 2c Townsend 4 & 5c
IRR (95% CI) P b IRR (95% CI) P b IRR (95% CI) P b IRR (95% CI) P b
Diagnosed depression
Gender
Boy Reference Reference Reference Reference
Girl 0.79 0.003 2.87 < 0.001 2.58 < 0.001 2.93 < 0.001
(0.67-0.92) (2.77-2.97) (2.44-2.73) (2.78-3.09)
Symptoms of depression
Gender
Boy Reference Reference Reference Reference
Girl 0.90 0.001 2.31 < 0.001 1.78 < 0.001 2.12 < 0.001
(0.84-0.95) (2.23-2.39) (1.67-1.83) (2.02-2.22)
Antidepressant prescription
Gender
Boy Reference Reference Reference Reference
Girl 0.63 < 0.001 2.71 < 0.001 2.26 < 0.001 2.57 < 0.001
(0.58-0.69) (2.63-2.80) (2.16-2.36) (2.47-2.69)
a. Adjusted for calendar year, gender, deprivation, age and for clustering by general practitioner practice
using robust standard errors. b. P based on Wald test. c. A Townsend score of 1 or 2 represents the most
affluent patients, while patients with a Townsend score of 4 or 5 live in the most deprived areas.
4.4.1 Segmented regression analysis
The Jointpoint analysis suggested for SSRIs as a group, there were two time points at
which prescription rates changed: 2002 and 2005. Up to 2002 prescription rates for SSRIs
had been significantly increasing nearly 16% from 1995 - 2002 (Table 4.3). However,
between 2002 and 2005 the rates plateaued, followed by a significant increase of nearly
11% from 2005 to 2009 (Table 4.3).
Individual SSRIs followed a similar pattern: fluoxetine, citalopram, paroxetine and
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sertraline rates all were increasing from 1995 to the early 2000s before showing a tempor-
ary decrease, or stall, in prescription rates. Paroxetine was the only SSRI which showed a
statistically significant decrease in prescription rates. Rates for citalopram and sertraline
started increasing again in 2005, while rates for fluoxetine and paroxetine remained stable
(Table 4.4 & Figure 4.5).
In contrast, rates for TCAs as a group showed a significant decrease between 1995
and 2006, after which there was no significant change. Rates for amitriptyline prescrip-
tions showed a moderate decrease between 1995 and 2006, but started to increase after
this point. Imipramine prescription rates showed a steady decline over the entire period.
4.5 Discussion
4.5.1 Key Findings
This is the first large paediatric database study to compare depression diagnoses, symp-
toms and antidepressant prescriptions (and the effects the CSM advice) over a longer time
period in the UK. I have found that prescription rates of SSRIs as a group decreased from
3.2 per 1,000 person-years in 2002 to 1.7 per 1,000 person-years in 2005. More spe-
cifically, rates for contra-indicated SSRIs, i.e. citalopram, paroxetine and sertraline, went
down during that period, while rates for fluoxetine remained stable and rates for TCAs
were not affected. The decline in prescription rates was sharpest for paroxetine. Rates
for depression diagnoses entries decreased from 3.0 per 1,000 person-years in 2002 to
2.0 per 1,000 person years in 2005. Depression symptom recording saw a steady increase
over the study period, increasing from 1.0 per 1,000 person-years in 1995 to 4.7 per 1,000
person-years in 2009. Finally, rates for SSRIs as group and citalopram in particular were
increasing after 2005.
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(a) SSRIs
(b) TCAs
Figure 4.5: Segmened regression trends for selective serotonin reuptake inhibitors (SS-
RIs) and tricyclic antidepressants (TCAs) as groups and individual drugs - y-axis differ
between graphs.
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Table 4.4: Annual percentage change (APC) for selective serotonin reuptake inhibitors
(SSRIs) and tricyclic antidepressants (TCAs) as groups and individual drugs
APC 1 (95% CI) Period APC 2 (95% CI) Period APC 3 (95% CI) Period
SSRIs 15.8* 1995-2002 -19.7 2002-2005 10.6* 2005-2009
(8.5-23.6) (-36.2-1.0) (3.1-18.8)
fluoxetine 11.6 1995-2001 -1.8 2001-2009
(-0.4-25.1) -4.8-1.3
citalopram1 37.7 1999-2002 -22.0 2002-2005 29.0* 2005-2009
(-4.7-98.9) (-51.1-45.4) (14.4-45.4)
paroxetine2 67.9 1995-1997 -2.2 1997-2002 -69.1* 2002-2005
(-27.1-286.9) (-12.2-9.1) (-84.2- -39.5)
sertraline3 20.5* 1996-2002 -29.4 2002-2005 4.3 2005-2009
(6.1-37.0) (-54.2-9.0) (-11.3-22.6)
TCAs -9.5* 1995-2006 6.5 2006-2009
(-10.3- -8.7) (1.0-12.2)
amitriptyline -1.8 1995-2006 11.9* 2006-2009
(-3.8-0.3)) (2.3-22.3)
imipramine -17.1* 1995-2009
(-18.6- -15.6)
*annual percentage change (APC) is statistically significant (p< 0.05) different from 0. 1Observations start in 1999 for
citalopram as prescription rates were negligible (< 10 prescriptions a year) before this year. 2Observations stop in 2005 for
paroxetine as it is only prescribed sporadically (< 5 prescriptions a year) after this time point. 3Observations start in 1996
for sertraline as prescription rates were negligible (< 10 prescriptions a year) before this year.
The decrease in recording of both depression diagnoses and antidepressant prescrip-
tions after 2002 could indicate caution on the part of GPs in diagnosing depression and
prescribing antidepressants following the CSM advice. There appears to be a general
consensus among GPs to not diagnose something that cannot be treated. In the case of
childhood depression, the options for treatment are very limited: TCAs have not been
proven to be effective in children, and have serious side effects; most SSRIs are contrain-
dicated; and there are waiting lists for psychotherapy.
An audit in 2002 found that waiting times for specialist psychotherapy were 11.5
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weeks on average for a first appointment, with 30% of patients waiting longer than 13
weeks. In 2003 an action plan was introduced, and in 2004 a re-audit found that the
average wait for a first appointment had decreased to 6.7 weeks, with only 2.3% of pa-
tients waiting more than 13 weeks [Garry and Paley, 2006]. Over the last couple of
years however, waiting lists have been increasing again: whereas 29% of primary care
trusts (PCTs)1 had waits of more than three months in 2009, this had increased to 41% in
2010 [magazine”, 2011].
Moreover, GPs might prefer to record depression symptoms rather than recording a
diagnosis of depression, which was also found in a THIN study assessing depression in
adults [Rait et al., 2009]. The decrease in contra-indicated SSRIs as opposed to fluoxetine
strengthens the possibility of a link with the CSM advice.
Although the Joinpoint program points to 2002 as the time point where SSRI rates
changed, the observed data shows that rates did not decrease until after 2003, the year
when the CSM advice was issued. However, prescription rates could have started de-
creasing prior to the CSM advice as information regarding the safety and effectiveness
of SSRIs was circulating in the specialist community before the advice was issued and
could have influenced changes in prescription recommendations. Similarly, the small dip
in fluoxetine rates around 2005 was not statistically significant. This dip might be related
to the requirement of the US Food and Drug Administration (FDA) to add a black box
warning to all antidepressants, including fluoxetine and TCAs, about an increased risk of
suicidal behaviour in 2004 [FDA, 2004].
The sharp decline in paroxetine prescription rates could be related to the advice by
the MHRA against the prescribing of paroxetine specifically. This advice was issued in
June 2003, preceding the overall SSRI advice in December of the same year. It followed
a review of randomised controlled trials that showed higher rates of suicidal thought
and behaviour (but not completed suicides) in patient who took paroxetine (25 out of
738; 3%), compared to those who took placebo (8 out of 647; 1%; p for difference =
0.01) [Waechter, 2003]. This might have led to patients and their parents being biased
against taking paroxetine as a first line of treatment. Therefore, it is difficult to determ-
1A primary care trust (PCT) is a type of NHS trust, part of the National Health Service in England.
PCTs commission primary, community and secondary care from providers.
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ine whether the sharp decline in paroxetine prescriptions in primary care was due to a
negative public opinion of the drug, or the advice issued by the CSM half a year later.
The increase in SSRI prescription rates after 2005 could indicate that concerns about
a possible suicide risk associated with SSRIs have waned. Several studies failed to show
an increased risk of suicide for SSRIs [Jick et al., 2004, Didham et al., 2005], or increases
in suicide rates that coincided with decreases in SSRI prescription rates [Gibbons et al.,
2007]. In the US, 2004 saw the largest single-year increase in suicide rates in adoles-
cents aged 10 - 19 years [Bridge et al., 2007]. From 1990 to 2003 suicide rates had
been decreased by 28%, but in 2004 they had increased with 15% from 6.78 to 7.32 per
100,000 people. This might have led GPs to revaluate prescribing SSRIs to children and
adolescents, although doubt continue to exist regarding the safety and effectiveness of
SSRIs [Hammad et al., 2006, Cepoiu et al., 2008].
4.5.2 Comparison to other studies
The antidepressant prescription rates I found are similar in size and trend to those found
by a General Practice Research Database study which studied prescription rates from
1992 to 2001 [Murray et al., 2004]. I also found similar age and gender effects. My
results also confirm findings by Murray et al. who found a decrease in SSRI prescribing
in between 2003 and 2004, while prescribing rates for fluoxetine remained stable [Murray
et al., 2005]. However, the study by Murray et al. did not assess data for individual drugs,
apart from fluoxetine, whereas my study did take different SSRIs into account.
A study based on Australian data also found a decrease in antidepressant use in chil-
dren, in particular of SSRIs [Dean et al., 2007]. They also saw a sharp rise of fluoxetine
over time, which I did not find in the UK. This might be explained by sertraline being
the most commonly prescribed antidepressant in Australia before the SSRI controversy
started, whereas fluoxetine was already the drug of first choice in the UK before the CSM
advice.
Previous research using THIN has shown that over time, GPs seemed to substitute
depression diagnoses for depression symptoms: rates for depression diagnoses decreased
while symptom recording increased. Meanwhile, the sum of depression diagnoses and
symptom rates remained stable [Rait et al., 2009]. For children, there did not appear to be
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a similar link between depression diagnosis and symptom recording. Rather, diagnoses
followed the prescribing trend.
4.5.3 Main Strengths and Limitations
The main strength of this study is its sample size that enables examination of outcomes
separately for girls and boys, and by drug. There is no clear reason to believe the results
would differ for the entire population of UK children.
However, since these findings relate to clinical general practices data, a few children
might have been missed if their depression was not severe enough to warrant a visit
to a GP, or if they were diagnosed and managed in other settings. I believe that these
data would have captured all adolescents in the NHS who are on antidepressant drug
therapy as prescribing in the UK is predominantly managed by general practitioners.
Moreover, a study on depression in adults found that although incidence rates in THIN are
lower than depression rates found in epidemiological studies, associations with covariates
such as gender and deprivation were similar [Rait et al., 2009]. Further, non-psychiatric
physicians recognition of depression has been found to have a limited sensitivity, but
a high specificity [Cepoiu et al., 2008, Kamphuis et al., 2011]. Childhood depression
rates might have been underestimated in this study, but trends and associations with other
variables are likely to be representative of the general population. Moreover, as I was
specifically interested in the effects of the CSM advice in primary care settings, this
limitation will have only a minimal effect on my results.
4.5.4 Conclusions
After 2002, general practitioners decreased their prescribing of contra-indicated SSRIs,
particularly paroxetine. Rates for fluoxetine, the only SSRI not to be contra-indicated,
remained stable. Both depression diagnoses and prescription rates decreased between
2002 and 2005, suggesting caution on the side of GPs. The timing and direction of these
trends imply that GPs followed the CSM advice, although it cannot be ruled out that these
trends resulted from the negative media attention SSRIs received around the same time.
After 2005, rates for all antidepressants, except paroxetine, started to rise. This is in line
with results from observational studies that found no increased risk of suicidal behaviour
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with SSRIs. Further evidence is required on the risk of suicide for each SSRI using real
time clinical data. Although not within the scope of this thesis, I have published an article
exploring this association (Appendix F on page 241).
4.6 How does this chapter inform my thesis?
Depression in adolescents is recognised and treated in primary care, which will make it
possible for me to use this as an outcome of my main analysis on the association between
parental and adolescent depression. In addition, some children seem to be prescribed an-
tidepressants in the absence of a depression diagnosis. I will consider these prescriptions
as a marker of a depression diagnosis in cases where children do not have a diagnosis for
any other potential antidepressant indication (e.g. eating disorders or anxiety).
For my main analysis (see chapter 7), I will include children born from 1994 on-
wards, and measure my main outcome, childhood depression as described in this chapter,
in children aged 13 years or over. This means I will include children with a depression
diagnosis or antidepressant prescription from 2007 onwards.
Figures 4.7 and 4.6 show the rates of depression diagnoses and antidepressant pre-
scriptions in children aged 13 - 18 years old between 2007 and 2011, the age group and
time period during which the outcome in my main analysis is measured.
Incidence rates for both depression diagnoses and antidepressant prescriptions were
stable for this age group in this period for both boys and girls (Figure 4.6). However,
rates were increasing with age and were, as expected, highest for girls aged 18 years
(Figure 4.7).
4.6. How does this chapter inform my thesis? 114
Figure 4.6: Rates of depression diagnoses and antidepressant prescriptions for children
aged 13 - 18 years
Figure 4.7: Rates of depression diagnoses and antidepressant prescriptions between 2007
- 2011
Part III
The association between parental and
adolescent depression
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In this part of my thesis, I will present my main analysis, a study involving a birth
cohort nested within THIN. Birth cohorts are often used in life course epidemiology.
This type of cohort study follows children from pregnancy or birth into childhood and
sometimes even to adolescence or adulthood. In most birth cohorts, some information on
the parents of the child is also available. Britain in particular has an impressive history
of birth cohorts. Studies such as the National Survey of Health & Development (NSHD)
have followed children from 1946 onwards. The NSHD has been called ”the granddaddy
of all cohort studies” because of its age and was set up by Dr James Douglas less than a
year after the end of the Second World War. Over 13,000 women who gave birth in March
1946 were interviewed for the study and the children have been followed ever since.
Several other birth cohorts followed, such as the National Child Development Study
(NCDS), set up in 1958, the 1970 British Cohort Study (BCS70) and the Millennium Co-
hort Study (MCS) that was established in 2000. Apart from national birth cohorts, there
have also been regional studies, most notably the Avon Longitudinal Study of Parents and
Children (ALSPAC).
Although these studies have proven invaluable for epidemiological research, they
have their limitations. Children and parents are followed up at set time points with pre-
defined questionnaires and/or examinations. At each assessment, only a limited amount
of information can be collected. When participants are assessed more frequently or as-
sessments are more invasive (e.g. more or longer questionnaires or a large range of med-
ical tests), they will be more likely to drop out of the study. Moreover, the assessments
themselves can influence the behaviour of study participants2. Therefore, cohort studies
always have to try to find the right balance between retaining participants and extracting
the desired information.
Another limitation of traditional birth cohorts is that they follow a specific generation
2This effect is known as the observer or Hawthorne effect, and is named after the Hawthorne Works
factory. Hawthorne Works had commissioned a study between 1924 and 1932 to assess whether workers
would become more productive in higher or lower levels of light. However, the workers’ productivity al-
legedly increased both when lighting was increased, and when it was decreased. The researchers eventually
found that knowing that their productivity was being assessed increased the workers’ output.
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of children. For instance, ALSPAC follows children born in 1991 or 1992. While the
cohort has been able to delve into many important research questions, it has become dated
already as children born in the early nineties will have had a very different exposure to
for instance the internet compared to children who are born today. Moreover, because
of the small time window of recruitment and different methods used in different cohorts,
it is difficult to compare children from various birth cohorts to account for changes in
children’s environment.
Electronic health records can provide an alternative to traditional birth cohorts that is
cheaper, collected continuously with minimal interference in participants’ lives, and that
is up-to-date. Although some detail might be lost in electronic health records compared
to questionnaire-based cohort studies, the two study designs can be combined to achieve
the best results. For instance, in THIN it is possible to go back to GPs with questionnaires
(either for the GP or for selected patients) and ALSPAC is in the process of linking its
data to the CPRD.
Chapter 5 will describe how I set up a family cohort in THIN and provide some
descriptive statistics of the cohort. Following that chapter, I will explore whether in-
ternalizing behaviours, as described in section 1.4.3 on page 43, can be used as an early
indicator in chapter 6. In this study, I will focus on sleep disorders. Finally, I will present
the main analysis where I used structural equation modelling to assess the association
between early comorbid parental and adolescent depression in chapter 7.
Chapter 5
The family cohort and study design
5.1 Objectives of the chapter
The main study for this part of my thesis consists of a family cohort nested within THIN.
This chapter will detail how individuals are linked together to create a family cohort, how
study variables are defined and will describe the characteristics of the family cohort.
The first family cohort in THIN was developed by Dr Irene Petersen and Dr Shreya
Dave´ for a study assessing the incidence of depression in parents [Dave´ et al., 2010]. The
cohort builds upon the pregnancy cohort developed by Dr Irene Petersen which was used
to determine trends in the prescription of antibiotics [Petersen et al., 2010], antidepress-
ants [Petersen et al., 2011] and antiepileptic drugs [Man et al., 2012] during pregnancy. It
is also being used in ongoing studies to assess pregnancy outcomes associated with drug
use in pregnancy.
5.2 Intermediate variables
As early parental depression and adolescent depression, the exposure and outcome for
my main analysis, are far apart in time, I will also assess intermediate variables that
could act as mediators. These variables, internalizing behaviour in children and recurrent
or chronic depresion in parents, will be measured throughout children’s lives and could
potentially inform prevention targets.
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5.2.1 Internalizing behaviour in children
As introduced in chapter 1, I plan to explore internalizing behaviour in children (see
section 1.4.3 on page 43). This could prove important as about three quarters of adult
mental disorders are extensions of juvenile disorders, approximately 50% of which could
be diagnosed before the age of 15 [Kim-Cohen et al., 2003]. For depression, the study
by Kim-Cohen and colleagues found that 84.5% of adults diagnosed with depression at
age 26 years had a history of juvenile mental illness, which was first measured at age 11
years. Among those with a depressive disorder at age 26 years, anxiety, depression and
conduct and/or oppositional defiant disorder have been the most common juvenile mental
illnesses.
Child and adolescent psychopathology are categorised into two broad classes: in-
ternalizing and externalizing behaviour. Externalizing problems are characterised by be-
haviours that are harmful and disruptive to others (e.g. aggression and hyperactivity),
whereas internalizing disorders signify a core disturbance in intropunitive emotions and
moods (e.g. sorrow, guilt, fear, and worry) [Zahn-Waxler et al., 2000]. Internalizing
behaviours in particular have been linked to later depressive disorders.
Anxiety, depression and sleep disorders have been classed as internalizing beha-
viours in children and adolescents and could be associated with later adolescent depres-
sion. Depression and anxiety are often comorbid in both children and adolescents [Brady
and Kendall, 1992, Pine et al., 1998], and adults [Sartorius et al., 1996] and share some
symptoms. Sleep disorders, insomnia in particular, are considered a symptom of depres-
sion, although they can also emerge as primary disorders. Therefore, I have selected these
three internalizing behaviours.
Other potential internalizing behaviours, that are more often present in younger chil-
dren, have been linked to early parental depression. A study in the ALSPAC cohort found
that anxiety in both mothers and fathers predated the occurrence of recurrent abdominal
pain (RAP) in children [Ramchandani et al., 2006]. The study had followed up almost
9,000 children up to age 6 3/4 years. RAP has been associated with depression and anxi-
ety in children, as well as depression in their parents [Walker and Greene, 1989, Campo
et al., 2001, 2004].
In addition, a population-based study in Finland found that both abdominal pain
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and headaches in childhood (measured at age eight years) were associated with severe
suicide attempts [Luntamo et al., 2013]. Headaches, particularly migraines, have been
found to be comorbid with depression: patients with migraines are more likely to develop
depression and patients with depression are more likely to develop migraines [Breslau
et al., 2003, Anttila et al., 2004].
Finally, fatigue could be associated with depression. Adolescents with unexplained
chronic fatigue score higher than controls for both anxiety and depression [Smith et al.,
2003]. Moreover, tiredness is recognised as a symptom of depression.
5.2.2 Recurrent parental depression
Another important intermediate variable is recurrent parental depression. Parents who
experience depression in the postnatal period are more likely to experience future epis-
odes of depression. For instance, a study in Sweden found that women with a history
of postpartum depressive symptoms were almost six times more likely to have recurrent
depressive symptoms (OR = 5.82, 95% CI: 3.79 - 8.93) compared to those without symp-
toms [Josefsson and Sydsjo¨, 2007]. The study, which assessed mothers and children four
years after childbirth, also found that both postpartum depression and current depres-
sion were associated with childrens’ behavioural problems, although the association was
stronger for current depression.
Other studies, not looking specifically at depression in the perinatal period, have also
noted depression chronicity is important in the association between parental and adoles-
cent depression. A study on a cohort of 816 women and their 15-year-old children in an
Australian community attempted to quantify the influence of maternal depression history
during the first ten years of life [Hammen and Brennan, 2003]. They found that adoles-
cent depression at 15 years was twice as likely among offspring of mothers who were
depressed at any time in their child’s life as compared to offspring of never-depressed
mothers. The association was stronger for mothers with more severe and/or longer de-
pression episodes.
Conversely, the Early Prediction of Adolescent Depression Study found that chil-
dren whose parents had experienced four or more episodes of depression were not more
likely to have a diagnosis for a psychiatric disorder when depression severity was also
5.3. THIN family cohort 121
taken into account [Mars et al., 2012]. The OR for child disorders predicted by parental
depression recurrence was 1.41 (95% CI: 0.80 - 2.47) compared to 1.81 (95% CI: 1.01 -
3.24) for depression severity. However, the confidence intervals for these estimates are
quite wide, indicating uncertainty about the true effect of depression recurrence. As the
sample only included 337 families, depression recurrence could still be associated with
child outcomes, though this needs to be assessed in a larger sample.
5.3 THIN family cohort
5.3.1 Linkage: Families in THIN
Mothers and children were linked on the basis of delivery/birth months and family identi-
fier codes in THIN. Linking each birth to the corresponding child involved matching the
mother’s delivery date to the child’s month of birth and family identifier. Mother-child
pairs were excluded from the cohort if the child could be linked to more than one mother
or if the child first registered at their GP practice after nine months of age. To enter the co-
hort for this study, children must be born between 1 January 1994 and 31 December 1997
and must be registered for at least 15 years. Parents must be registered for at least one
year, so that I could assess rates of early parental depression, but they could potentially
leave the cohort after this time point.
Potential fathers were linked to mother-child dyads using an algorithm that has been
explored in previous work on parental depression [Dave´ et al., 2010]. I selected males
older than 15 years who had the same family identifier as the mother and child at the time
of birth. The age difference between the mother and potential father was also restricted
to 15 years in order to decrease the risk of erroneously selecting older sons (or in rare
cases grandfathers) who live with the family as fathers of the child. Previous research
has shown that, in THIN, 40% and 10% of households contained either no or >1 resident
adult man, respectively, and these households were excluded as these were either single
parent families, or families where the father had (thus far) failed to register with a GP, or
registered with a different GP.
Because of my strict inclusion criteria, only traditional ’nuclear’ families consisting
of a mother and father with children were included in this cohort. Families with relat-
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ives living at the same address, same sex couples or single parents (though only if they
were single parents during the first year after childbirth) were not eligible for my cohort.
For families where multiple children were registered, I randomly chose one child to be
included in the THIN family cohort.
5.3.2 Variable definitions
The primary outcome variable of this study was adolescent depression in children aged
13 - 18 years (Table 5.1). This variable was based on different combinations of codes re-
flecting depression diagnoses, depression symptoms and prescribing of anti-depressants
at the appropriate therapeutic dose for treatment of depression, as explored in chapter 4.
Adolescents were considered to have depression if they had a diagnosis or antidepressant
code in their records, or at least two records of depression symptoms within a month. Fur-
thermore, for adolescents with a record of an antidepressant prescription, I excluded cases
where adolescents had a diagnosis of an eating disorder or anxiety as antidepressants can
also be prescribed for these indications.
Parental depression (both maternal and paternal) in the first postpartum year was
identified using the same code lists for diagnoses and prescriptions (but not depression
symptoms), with the addition of codes that specify postnatal depression. These code lists
were created and used in previous studies [Dave´ et al., 2010] and were developed in line
with methods described in chapter 2 and reviewed by a general practitioner (Prof Irwin
Nazareth). For both parental and adolescent depression, I considered one prescription
sufficient for a depression indication. For this study, I focussed on whether the patient was
depressed and not whether they were treated for their depression. As such, I considered
the decision of the GP to prescribe an antidepressant as indicative of depression (in the
absence of an eating disorder or anxiety diagnosis).
I explored childhood internalizing behaviour between the ages of 5 and 13 years
as a mediator. Internalizing behaviour is not measured directly in THIN. In order to
estimate this latent variable, I used the following indicator variables: sleep disorders,
anxiety disorders, recurrent abdominal pain or constipation, recurrent headaches or mi-
graine, chronic fatigue, and depressive symptoms (Figure 5.1). For these indications,
code lists were developed and reviewed by a general practitioner. For indicators relating
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to physical symptoms (abdominal pain, headaches, fatigue, dysphagia) I excluded cases
that were due to physical illness. Therefore, I excluded any cases where there was a dia-
gnosis for an organic disease (e.g. inflammatory bowel disease in the case of abdominal
pain) within a year of first presentation with symptoms.
Table 5.1: Timing of variable measurements
0 - 1 years 1 - 5 years 5 - 13 years 13 - 18 years
Early parental depression Parental depression
Covariates Childhood internalizing behaviour Adolescent depression
Information on Townsend scores, a measure for social deprivation as described in
chapter 2, was extracted as this might act as a confounder in the association between
parental and childhood depression. Negative life events (e.g. death of a parent or sib-
ling, parental divorce) were explored as confounders as these are known to be strongly
correlated to internalizing behaviour and depression.
I considered parental depression not within of the first year of life as an intermedi-
ate variable (or time-varying confounder) as parents with chronic or recurrent depression
could impose a greater risk on their children developing depression in later life, either
as an environmental influence or through direct genetic transmission. For each year of
follow-up (measured by child age), I assessed whether each parent has a record of de-
pression diagnosis or antidepressant prescription. The result is a cumulative depression
score ranging from 0 (no episodes of depression) to 12 (parental depression in each year
up to child age 12 years) for each parent.
Potential child abuse and neglect were considered as confounders, as it known that
there is a strong association between maltreatment and later depression. Moreover, chil-
dren of parents who were depressed in the antenatal period are four times more likely
to be exposed to child abuse [Kotch et al., 1999, Pawlby et al., 2011]. To identify child
maltreatment and neglect, I used a code list for suspected or potential child maltreatment
and neglect developed by Jenny Woodman [Woodman et al., 2012].
Finally, I included parent behaviour during pregnancy and the first year postpartum
that could influence both their risk of depression and the childs risk for later internalizing
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behaviour. This included alcohol [Khadjesari et al., 2013] and illicit drug use, severe men-
tal illness (e.g. schizophrenia and bipolar disorder), comorbidity, parental age and neg-
ative life events (divorce or death of parent/sibling). Other morbidities were assessed by
assessing the number of prescriptions from different British National Formulary (BNF)
chapters that a parent received during the first year after childbirth. Prescriptions for
vaccinations, anaesthesia and contraceptives were excluded from this index.
5.4 THIN family cohort characteristics
In total 4,942 families were followed up for at least 15 years. Of these, 2,353 (48%)
included families with a female child (Table 5.2). In general, a higher proportion of
families in this cohort were more affluent than the general population, thus families with
Townsend scores (score 1 or 2) made up 60% of the family cohort. However, a relatively
larger proportion of families with depressed adolescents came from more deprived areas.
Although there were few children with a record of the intermediate outcomes (recorded
when the children were between 5 and 13 years) the proportion was generally higher in
the group of children with adolescent depression.
The mean age at birth was 30.7 (sd: 4.7) years for mothers, and 33.1 (sd: 5.7) years
for fathers. On average, mothers had received prescriptions from two different BNF
chapters (median: 2, interquartile range: 1 - 3), while fathers received prescriptions from
one (median: 1, interquartile range: 0 - 2) BNF chapters.
Covariates, recorded in the first year postpartum, were more prevalent in families
where parents experienced depression, although prevalence was low overall (Table 5.3).
Records of (suspected) child maltreatment and neglect were more common among fam-
ilies where at least one parent experienced depression. While only 2.8% of families with
no record of early parental depression had a suspected child maltreatment record, 8.3%,
3.3% and 7.7% of families had a record if the mother, father or both parents experienced
early depression, respectively.
Illicit drug use was recorded for only 7 families included in the THIN family cohort.
Alcohol abuse, by either parent, was recorded most in families where the father had a
record of early depression (7.8%) compared to 2.1% and 1.4% in families with no early
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parental depression or maternal depression respectively.
Table 5.2: Child characteristics of the THIN family cohort
Baseline characteristics
Full cohort (4,942) Non-depressed
adolescents (4,492)
Depressed adoles-
cents (250)
Number (%) Number (%) Number (%)
Girls 2,353 (47.6) 2,182 (46.5) 171 (68.4)
Townsend score
1 (most aflluent ) 1,849 (37.4) 1,759 (37.5) 90 (36.0)
2 1,119 (22.6) 1,072 (22.9) 47 (18.8)
3 938 (19.0) 895 (19.1) 43 (17.2)
4 641 (13.0) 600 (12.8) 41 (16.4)
5 (most deprived) 368 (7.5) 339 (7.2) 29 (11.6)
Missing 27 (0.6) 27 (0.6) 0 (0)
Intermediate outcomes 5 - 10 years
Recurrent abdominal pain 71 (1.4) 64 (1.4) 7 (2.8)
Recurrent headaches/migraine 139 (2.8) 127 (2.7) 12 (4.8)
Tired all the time 58 (1.2) 54 (1.2) 4 (1.6)
Any psychosomatic symptoms 328 (6.6) 299 (6.4) 29 (11.6)
10 - 13 years
Sleep disorder 24 (0.5) 19 (0.4) 5 (2.0)
Anxiety 66 (1.3) 53 (1.1) 13 (5.2)
Depressive symptoms 41 (0.8) 29 (0.6) 12 (4.8)
Parental depression
Maternal early depression 447 (9.0) 422 (9.0) 25 (10.0)
Paternal early depression 116 (2.4) 111 (2.4) 5 (2.0)
Comorbid early depression 26 (0.5) 25 (0.5) 2 (0.8)
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Rates of parental depression (9.0% for mothers and 2.4% for fathers) recorded in the
1990s were lower than in families who had their children in the 2000s (13.9% for moth-
ers and 3.7% for fathers). As shown in Figure 5.2, rates for paternal early depression
have been increasing over time, which could explain the lower rates of paternal depres-
sion I found. A similar trend is found in maternal antidepressant rates (Figure 5.1): rates
were lower in the early 1990s, when SSRIs had just arrived on the market, and stead-
ily increased over time. Meanwhile, rates for maternal early depression rates declined,
favouring the recording of maternal depression symptoms.
Table 5.3: Prevalence of covariates in the first year after birth
Early depression: No Maternal Paternal Comorbid
Child maltreatment
& neglect
108 (2.5) 35 (8.3) 3 (3.3) 2 (7.7)
Illicit drug use 3 (0.1) 4 (1.0) 0 (0) 0 (0)
Alcohol abuse 93 (2.1) 6 (1.4) 7 (7.8) 0 (0)
Severe mental illness 30 (0.7) 11 (2.6) 5 (5.6) 1 (3.9)
Negative life events 742 (16.8) 126 (29.9) 18 (20.0) 10 (38.5)
Table 5.4: Prevalence of intermediate variables in children in the family cohort
Early depression: No Maternal Paternal Comorbid
Number (%) Number (%) Number (%) Number (%)
Recurrent abdominal pain 63 (1.4) 7 (1.7) 1 (1.1) 0
Recurrent headaches/migraine 120 (2.7) 16 (3.8) 3 (3.3) 0
Tired all the time 48 (1.1) 9 (2.1) 0 1 (3.9)
Any psychosomatic symptoms 279 (6.3) 43 (10.2) 5 (5.6) 1 (3.9)
Sleep disorders 19 (0.4) 5 (1.2) 0 0
Anxiety 52 (1.2) 13 (3.1) 1 (1.1) 0
Depressive symptoms 32 (0.7) 6 (1.4) 2 (2.2) 1 (3.9)
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Figure 5.1: Early maternal depression rates from 1994 to 2011. Total represents the
rates of diagnoses and/or prescriptions; line marks mothers potentially included in family
cohort
As shown in Table 5.5, parents who experienced early depression are more likely to
experience recurrence of depression compared to parents who were not depressed in the
first year postpartum. While 69.2% of parents without early depression did not have a
record of depression during follow-up, only 13.2% of mothers and 21.1% of fathers did
not have a recurrence.
Table 5.5: Recurrent parental depression in the THIN family birth cohort
Early parental depression No depression Maternal Paternal Comorbid
Number (%) Number (%) Number (%) Number (%)
No recurrence mother 3,033 (69.2) 55 (13.2) 50 (55.6) 5 (20.0)
No recurrence father 3,462 (78.6) 271 (64.4) 19 (21.1) 6 (23.1)
N of episodes mother (5-95% centiles) 0.61 (0 - 11) 6.30 (0 - 16) 1.19 (0 - 6) 6.24 (0 - 16)
N of episodes father (5-95% centiles) 0.66 (0 - 4) 1.26 (0 - 7) 6.06 (0 - 17) 5.38 (0 - 17)
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Figure 5.2: Early paternal depression rates from 1994 to 2011. Total represents the rates
of diagnoses and/or prescriptions; line marks fathers potentially included in family cohort
Internalizing behaviour in children is described in Table 5.6. Overall, few children
have a record of internalizing behaviour. Despite the small numbers, children of parents
with early depression seem to have a slightly higher prevalence of internalizing behaviour.
Table 5.6: Intermediate variable characteristics of the THIN family cohort
Early parental depression No depression Maternal Paternal Comorbid
Intermediate child outcome Number (%) Number (%) Number (%) Number (%)
Recurrent abdominal pain or constipation 63 (1.4) 7 (1.7) 1 (1.1) 0
Recurrent headaches/migraine 120 (2.7) 16 (3.8) 3 (3.3) 0
Tired all the time 48 (1.1) 9 (2.1) 0 1 (3.9)
Any psychosomatic symptoms 279 (6.3) 43 (10.2) 5 (5.6) 1 (3.9)
Sleep disorders 19 (0.4) 5 (1.2) 0 0
Anxiety 52 (1.2) 13 (3.1) 1 (1.1) 0
Depressive symptoms 32 (0.7) 6 (1.4) 2 (2.2) 1 (3.9)
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5.5 Sensitivity analyses
As I only included families with at least 15 years of follow-up in the main cohort, only a
few families had information available before pregnancy. In addition, many parents move
around the time they start a family, leading them to switch GP as well. For these reasons,
I did not assess covariates or depression rates in families before birth. However, since
many more families that have less than 15 years of follow-up are available, I could assess
recording of these variables before birth in other families.
As a sensitivity analysis, I have explored depression rates and covariate prevalence
in all families that have at least three years of follow-up available before the birth of the
child included in the THIN family cohort (Table 5.7).
Early parental depression No depression Maternal Paternal Comorbid
(71,090) (10,732) (2,935) (1,151)
Depression history of mother 7,142 (10.1) 4,540 (42.3) 232 (7.9) 249 (21.6)
Depression history of father 2,358 (3.3) 307 (2.9) 1,315 (44.8) 190 (16.5)
Comorbid depression history 657 (0.9) 457 (4.3) 349 (11.9) 481 (41.7)
Child maltreatment & neglect 7,589 (10.7) 1,413 (13.2) 396 (13.5) 195 (16.9)
Illicit drug use 427 (0.6) 193 (1.8) 99 (3.4) 87 (7.5)
Alcohol abuse 467 (0.7) 158 (1.5) 99 (3.4) 87 (7.5)
Severe mental illness 140 (0.2) 111 (1.0) 75 (2.6) 43 (3.7)
Negative life events 1,589 (2.2) 503 (4.7) 168 (5.7) 101 (8.7)
Table 5.7: Prevalence of covariates in the three years before birth
Covariates are more prevalent in families who experience early depression, and
are more prevalent compared to the analysis including only the first year postpartum
(Table 5.3).
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Townsend score
Follow-up 1 (least deprived) 2 3 4 5 (most deprived) missing
1-4 years 17,135 14,099 14,818 13,537 9,042 5,152
(23.2%) (19.1%) (20.1%) (18.3%) (12.3%) (7.0%)
5-9 years 13,611 9,672 8,437 6,855 4,110 1,452
(30.8%) (21.9%) (19.1%) (15.5%) (9.3%) (3.3%)
10-14 years 6,812 4,444 3,578 2,722 1,553 502
(34.7%) (22.7%) (18.2%) (13.9%) (7.9%) (2.6%)
15-19 years 2,372 1,492 1,253 916 570 101
(35.4%) (22.3%) (18.7%) (13.7%) (8.5%) (1.5%)
Table 5.8: Townsend scores by birth cohort follow-up
Finally, I examined cohort attrition. It is possible that certain families are more
likely to move and deregister from a GP register practice, and thus be lost to follow-
up. Table 5.8 show the distribution of Townsend scores in families followed up for 1-4
years, 5-9 years, 10-14 years and, the group included in my family cohort, 15-19 years.
Families with higher Townsend scores (indicating low deprivation levels) are more likely
to be follow-up for longer. Whereas 23% of the group with 1-4 years of follow-up had
a Townsend score of 1, more than 1 in 3 families (35%) in the group with 15-19 years
of follow-up was in the least deprived group. It is possible that part of this difference is
explained by a lower proportion of missing values for Townsend scores, as this decreases
with follow-up.
People who are more ill might be less likely to move, hence, I also examined co-
morbidity scores in the groups with different lengths of follow-up. As shown in Table 5.9
comorbidity scores do not vary between groups of different follow-up.
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Maternal comorbidity Mean Median 5-95% percentiles
1-4 years follow-up 2.79 2 1-6
5-9 years follow-up 2.78 2 1-6
10-14 years follow-up 2.74 2 1-6
15-19 years follow-up 2.84 3 1-6
Paternal comorbidity
1-4 years follow-up 1.96 2 1-4
5-9 years follow-up 1.90 2 1-4
10-14 years follow-up 1.83 1 1-4
15-19 years follow-up 1.88 2 1-4
Table 5.9: Parental comorbidity scores by birth cohort follow-up
5.6 Discussion
With the methods used in previous studies, I was able to construct a family birth cohort
within THIN following almost 5,000 families from birth to at least 15 years later. Mothers
and children were linked using birth/delivery records and family identifier codes. Poten-
tial fathers were linked to mothers and children using the same family identifier code, and
by restricting the potential age difference between fathers and mothers to 15 years.
Parents in the family cohort were older than the national average. In the 1991 census,
the average age of all fathers in England and Wales at the birth of a child was 30.8 years,
compared to 33.1 years in THIN [for National Statistics, 2013]. Similarly, the average age
for mothers was 27.7 years in 1991 according to the Office for National Statistics (ONS)
data, while the average age in the family cohort was 30.7 years. This could be explained
by the relatively high proportion of more affluent families (60.0%) in the family cohort,
as the average age was lower for more deprived families. In addition, it is likely that I
have missed some of the first children in families, as families tend to move house around
the time they start their families. As a result, the apparent age of new parents might be
slightly higher than average.
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Families who were less deprived were overrepresented in the family cohort, with
35% being in the least deprived Townsend score quintile, compared to 23% in a cohort
of families followed-up for 1-4 years. As it is known that deprivation is associated with
a higher depression risk, the missing data on more deprived families could have affected
my findings, although it is difficult to predict in what direction they might have been
altered. Ideally, I would have investigated the possible impact of missing data by per-
forming a simulation study or multiple imputation, but that was beyond the scope of my
work. Another consequence could be a lower number of patients with depression, which
would lead to a loss of power to detect an association in the first place. There did not
appear to be any difference between families with different follow-up times with regards
to comorbidity scores.
Depression in parents might be underreported in the family cohort as these families
had their children in the mid-nineties. Since then, it appears the theshold for depression
recording by GPs, and/or the reporting by patients has changed. As shown in Figure 5.2,
rates for paternal depression were lower for fathers between 1994 and 1997 compared to
the later time period. Similarly, rates for antidepressant prescriptions for SSRIs, which
I used to identify early parental depression, were lower in the mid-1990s. As described
in appendix B, SSRIs had just come onto the market in this time and, understandably,
new drugs are not readily prescribed to pregnant or lactating women. This might have
led to some parents who did experience depression to be classified as non-early parental
depression in my cohort. This could result in a underestimation of the effects of early
parental depression on adolescent depression.
The cohort is likely to be representative of children in the UK. However, I may have
introduced bias as families are lost to follow-up. This happens if they deregister from their
GP practice (though not if one parent deregisters), which might happen when moving
house. There are no reasons to assume this will make our cohort less representative of
the UK population.
I made the assumption that patients received anti-depressant prescriptions solely for
depression. Because prescriptions are not always directly linked to medical diagnoses in
THIN, it is possible that patients in the cohort receive antidepressants for reasons other
than depression. However, I only included antidepressants when they were prescribed
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at the appropriate dose for depression treatment and excluded patients when they had
a diagnosis for eating disorders or anxiety, therefore minimising the risk of including
prescription for indications other than depression.
5.7 How will this chapter inform my thesis?
The family cohort I described in this chapter will be the cohort I use for my main analysis
in Chapter 7. The cohort, consisting of 4,942 families, was constructed within THIN
to create a representative cohort of UK families. However, families included in the co-
hort were more likely to be more affluent compared to general population. In a cohort
including 1,224,100 children aged 5 - 18 years (which I used in Chapter 6), 14.0% and
19.1% of children had a Townsend score of 5 or 4 (scores representing the more deprived
quintiles), respectively. In comparison, only 7.5% and 13.0% of families included in the
family cohort had a score of 5 or 4.
The proportion of missing Townsend scores was slightly lower in the family cohort
compared to the 5 - 18 years child cohort (0.6% versus 2.0%). This could be the result
of the longer follow-up in the family cohort of at least 13 years, compared to 5 years on
average for the 5 - 18 year child cohort. This longer follow-up period would provide a GP
with more opportunities to record the postcode on which the Townsend score is based.
The proportion of girls and boys was similar with 48.0% girls in 5 - 18 years child
cohort, and 47.6% girls in the family cohort.
A possible explanation for the lower proportion of more deprived families could be
that these families are more likely to move and change GP practice and thus be lost to
follow-up. As depression is positively associated with deprivation, this could mean that
I will lose the part of the population who is most likely to experience my exposure and
outcome of interest.
Chapter 6
Paediatric sleep disorders and
adolescent depression
6.1 Objectives of the chapter
In this chapter I will present a study to assess the viability of my objective to assess
whether internalizing behaviours in childhood can be used to identify children at risk
of adolescent depression. Sleep disorders, insomnia in particular, have been linked to
depression in adults. Moreover, it is a specific symptom used in both DSM-IV and ICD-
10 to identify depressive disorders. As such, the feasibility study focusses on paediatric
sleep disorders and their association with adolescent depression.
6.2 Sleep disorders in children
Sleep problems are common, affecting 25% to 40% of children and adolescents [Owens
et al., 2005]. Disrupted or inadequate sleep has been shown to affect neurobehavioural
functioning in school-age children [Sadeh et al., 2002] and is correlated with concurrent
anxiety and depression [Gregory and O’Connor, 2002]. However, little is known about
the incidence of sleep disorders (as opposed to sleep disruption) in school-age children
(age 5-18 years) and their recognition and treatment in primary care [Ford and Kamerow,
1989, Ohayon, 2002]. The few studies that have attempted to assess sleep disorders
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in children have been cross-sectional studies [Ipsiroglu et al., 2001, Meltzer et al., 2010,
Mindell, 1993, Simonds and Parraga, 1982]; or have focussed on groups with particularly
high rates of sleep disorders, such as children with epilepsy, autism spectrum disorders
(ASD), and attention-deficit/hyperactivity disorders (ADHD) [Cortese et al., 2009, Jan
et al., 2006].
There is also a lack of data on prescriptions of hypnotics issued to children with
sleeping disorders in primary care. A US study looking at hospitalised children found
that antihistamines were most commonly prescribed to children with sleeping problems
(37% of prescriptions), followed by benzodiazepines (9%) and other hypnotic agents
(3%) [Meltzer et al., 2007]. No medications have a UK market authorisation for treatment
of paediatric sleeping disorders, and there are no guidelines regarding the use of these or
other drugs for treatment of sleep disorders in children.
In adults, an association between sleep disorders, insomnia in particular, and depres-
sion has been found [Baglioni et al., 2011]. Adults with primary insomnia were two to
three times as likely as people with no sleep difficulties to develop depression later in life.
Insomnia and hypersomnia are recognised as symptoms for major depression disorder by
the DSM. Whether this association also exists for children remains unclear.
This study aimed assess the association between paediatric sleep disorders and ad-
olescent depression. I also briefly explore the incidence of sleep disorders and hypnotic
prescriptions in children in UK primary care.
6.3 Methods
6.3.1 Study population
I used data from The Health Improvement Network (THIN) primary care database, as
described in chapter 2. Children who were registered for at least one year with their
GP between 1 January 1995 and 31 December 2011 were included in the cohort. They
entered the cohort from the age of five, and left the cohort 30 June in the year they turned
19, deregistered from the practice, or died. I studied children from the age of five, as
sleeping patterns are established by this age, and a similar sleep rhythm is imposed on all
children as they enter primary school. Furthermore, most children will be able to sleep
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through the night and will not need daytime naps unlike their younger counterparts (i.e.
those under 5 years of age [Thiedke, 2001]).
6.3.2 Exposures and outcome
First, I examined trends in sleep disorders and hypnotic prescriptions by sex, depriva-
tion, age and calendar year. Second, I examined indications that could be associated
with recording of sleep disorders in young children. Finally, I examined the associations
between sleep disorder and risk of depression.
The exposure of interest was sleep disorders. This variable is based on different
combinations of codes reflecting insomnia (problems falling and staying asleep); hyper-
somnia (problems staying awake); sleep rhythm problems (problems sticking to a regular
sleep schedule); and sleep-disruptive behaviours (unusual behaviours during sleep), fol-
lowing ICD-10 classification. Sleep disorders due to physical illness such as narcolepsy
and sleep apnoea were excluded. A Read code list was created using the method previ-
ously described in section 2.4.1 on page 59, and evaluated by a GP (Irwin Nazareth).
To assess drug treatment, I created a drug code list based on the BNF for children,
chapter 4.1 Hypnotics [Paediatric Formulary Committee, 2010]. I also included sedating
antihistamines (BNF chapter 3.4.1) if they were prescribed within one month of a sleep
disorder diagnosis.
I explore the association between sleep disorders and depression. Depression was
identified by using Read code lists for depression diagnoses, symptoms and antidepress-
ant prescriptions. These code lists have been developed for chapter 4.
6.3.3 Analysis
Incidence rates and 95% confidence intervals for each class of sleep disorders and hyp-
notics were calculated by calendar year, age, sex, and deprivation quintile using person-
years-at-risk (PYAR) as the denominator. To assess temporal trends in the change in
incidence per calendar year, incidence rate ratios (IRR) were calculated for each in-
dicator using Poisson regression models, with adjustment for clustering at the practice
level. I used fractional polynomial models to take account of non-linear time and age
trends [Royston and Altman, 1994]. Each model contained a continuous variable for
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time (by calendar year) and age, a binary variable for sex, and a categorical variable for
deprivation quintile.
I examined statistical interactions between age, sex and deprivation and the analysis
was accordingly stratified by those variables where there was an interaction. Comor-
bidity in young children (age <12 year) was assessed by calculating incidence rates for
diagnosis of neurodevelopmental disorders such as autism spectrum disorder, ADHD,
and epilepsy in children with and all children without a hypnotic prescription. I chose
these neurodevelopmental disorders as children with these disorders have been found to
have high rates of sleep disorders [Cortese et al., 2009, Jan et al., 2006]. I calculated
incidence rate ratios adjusting for age, calendar year, sex, and deprivation quintile.
I longitudinally assessed the association between the different classes of sleep dis-
orders and depression by comparing children with sleep disorders and a group of ran-
domly selected children with no sleep disorders, but with similar distribution in terms of
sex, deprivation quintile, year of birth and follow-up time. This comparison was done by
using a multivariable time-to-event model (Cox proportional hazards model). The start of
the follow-up was from the first diagnosis of a sleep disorder and a matched date for the
children without sleep disorder. The analyses were adjusted for clustering using robust
standard errors.
All data management and analyses were performed using Stata SE version 12.1
(StataCorp, College Station, TX).
6.4 Results
In total, 1,224,100 children aged 5-18 years were registered with a practice for at least
one year between 1995 and 2011. Of these children, 19,518 (1.6%) had at least one
record of a sleep disorder, and 9,816 (0.8%) had been prescribed hypnotics. Children with
sleep disorders had a slightly longer follow-up period than children without (median: 7.4
years vs 5.0 years) and were more likely to be in the more deprived Townsend quintiles
(Table 6.1).
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Characteristic Sleep disorders All children
(19,518) (1,224,100)
Girls (%) 10,409 (53.3) 588,049 (48.0)
Median age at entry (5th-95th centiles) 7.9 (5.0 - 16.5) 7.5 (5.0 - 16.8)
Median age at exit (5th-95th centiles) 18.5 (8.8 - 19.0) 15.5 (7.0 - 19.0)
Median time in study (5th-95th centiles) 7.4 (1.7 - 13.5) 5.0 (1.3 - 12.3)
Deprivation (Townsend score) (%)
1 (least deprived) 4,116 (21.1) 300,290 (24.5)
2 3,445 (17.7) 247,677 (20.2)
3 3,991 (20.6) 246,245 (20.1)
4 4,315 (22.1) 234,191 (19.1)
5 (most deprived) 3,337 (17.1) 170,990 (14.0)
0 (missing) 314 (1.6) 24,707 (2.0)
Table 6.1: Study population characteristics. Values are numbers (column percentages)
unless otherwise indicated
6.4.1 Trends in sleep disorders and hypnotic prescriptions
Of the children with sleep disorders, 12,745 (65%) had a record for insomnia, followed
by children with a record of sleep disorder, not otherwise specified (2,504, 13%), sleep
rhythm disorder (2,496, 13%), sleep disruptive behaviour (2,488, 13%), and hypersomnia
(319, 2%). As numbers for hypersomnia were very low, these were excluded from further
analyses.
Of the children with a diagnosed sleeping disorder, 4,267 (28.0%) were prescribed
hypnotics. However, not all children prescribed a hypnotic had a record of sleeping dis-
order. Thus, of the 11,410 children with a prescription for a hypnotic, only 59.7% had a
record of a sleeping disorder. Melatonin was the most prescribed hypnotic, with 49,633
(67%) of all prescriptions, followed by zopiclone and temazepam (7,481 and 4,056 pre-
scriptions, respectively).
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Insomnia is the most commonly diagnosed sleep disorder increasing from 10.6 (95%
CI: 9.7 - 11.6) per 10,000 PYAR for children aged 5-12 years to 48.3 (95% CI: 46.2 - 50.4)
per 10,000 PYAR for children age 18 years (Figure 6.1). Over time, rates for insomnia
have increased from 10.7 (95% CI: 8.5 - 13.2) per 10,000 PYAR in 1995 to 24.6 (95%
CI: 23.3 - 26.0) per 1,000 PYAR in 2011 (Figure 6.1).
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Figure 6.1: Incidence rates of insomnia, sleep disruptive behaviour, sleep rhythm dis-
order, and Not Otherwise Specified (NOS) sleep disorder by A) age and B) by calendar
year. Dots represent data, line are fitted fractional polynomial models.
6.4. Results 141
Sedating antihistamines are most commonly prescribed to children aged 5-14 years
(rate: 9.2 (95% CI: 9.0 - 9.5) per 10,000 PYAR); while other hypnotics (chloral hydrate,
triclofos sodium, chloral betaine, and clomethiazole) are most commonly prescribed to
older adolescents (age 15-18 years, Figure 6.2). Melatonin was first prescribed to children
in 2001. However, it became the most prescribed hypnotic for boys in 2006 (Figure 6.2)
with 16.0 (95% CI: 14.5 - 17.5) incident prescriptions per 10,000 PYAR.
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(a)
(b)
Figure 6.2: Incidence rates of prescriptions for hypnotics by A) age and B) by calendar
year Non-benzodiazepine hypnotics are zaleplon, zolpidem and zopiclone, other hypnot-
ics are chloral hydrate, triclofos sodium, chloral betaine, and clomethiazole Dots repres-
ent data, line are fitted fractional polynomial models.
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Children under the age of 12 years with prescriptions for hypnotics were more likely
to have epilepsy (16% versus 7%, respectively), autism spectrum disorder (32% versus
4%), or attention-deficit/hyperactivity disorder (52% versus 6%, Table 6.2).
Children with hypnotic pre-
scription
General population
Epilepsy 1,571 (16%) 85,687 (7%)
ASD 3,141 (32%) 48,964 (4%)
ADHD 5,104 (52%) 73,446 (6%)
Table 6.2: Prevalence of epilepsy, autism spectrum disorder (ASD), and attention-
deficit/hyperactivity disorder (ADHD) in children aged <12 years with and without a
record of a hypnotic prescription.
6.4.2 Sleep disorders and depression
Of the children with records of both sleep disorder and depression, 24% had a preceding
diagnosis for depression, while 8% had a concurrent (within a month before or after
prescription) depression diagnosis. I excluded these children from the rest of my analyses.
For children aged 5-12 years when they were first diagnosed with a sleep disorder,
the hazard ratio for later adolescent depression (between 12-18 years) was 3.69 (95%
CI: 2.90-4.70) for boys and 5.01 (3.84-6.54) for girls. For 13-18 year olds, the hazard
ratio for developing adolescent depression at least a month later was 2.51 (2.36-2.67) for
boys and 2.00 (1.93-2.09) for girls (Table 6.3). Young people (13-18 years) with sleeping
disorder from the most deprived areas (Townsend quintile 5) were more likely to become
depressed than those from the least deprived areas (Townsend quintile 1; HR: 1.62, 95%
CI: 1.43-1.83 for boys, and 1.40, 95% CI: 1.05-1.60 for girls).
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5-12 year olds 13-18 year olds
Boys Girls Boys Girls
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Sleep disorder 3.69 (2.90 - 4.70) 5.01 (3.84 - 6.54) 2.51 (2.36 - 2.67) 2.00 (1.93 - 2.09)
Townsend score
1 (most affluent) Reference Reference Reference Reference
2 1.21 (0.82 - 1.79) 1.03 (0.67 - 1.58) 1.35 (1.21 - 1.51) 1.06 (0.99 - 1.13)
3 1.15 (0.75 - 1.76) 1.34 (0.88 - 2.04) 1.35 (1.20 - 1.50) 1.16 (1.08 - 1.24)
4 1.56 (1.02 - 2.40) 0.96 (0.60 - 1.54) 1.50 (1.34 - 1.67) 1.25 (1.17 - 1.34)
5 (most deprived) 1.48 (0.88 - 2.47) 1.10 (0.64 - 1.90) 1.62 (1.43 - 1.83) 1.40 (1.05 - 1.60)
Table 6.3: Hazard ratios for adolescent depression, by age group and sex
In line with the hazard ratios shown in Table 6.3, absolute rates for adolescent de-
pression differed between children with and without a preceding sleep disorder. For
younger children, aged 5-12 years, the absolute risk difference was small: 0.3% of chil-
dren without a sleep disorder developed adolescent depression, compared to 1.2-1.3% of
boys and girls with a sleep disorder (Table 6.4). For adolescent boys, a preceding sleep
disorder increases the risk of adolescent depression from 4.6% to 12.1%, while the risk
increases from 11.9% to 24.1% for girls.
Children without a sleep disorder Children with sleep disorder
Boys, 5-12 year old 2.96 (2.50 - 3.51) 11.66 (9.93 - 13.69)
Girls, 5-12 year old 2.56 (2.10 - 3.12) 13.33 (11.31 - 15.70)
Boys, 13-18 year old 45.99 (44.24 - 47.81) 121.07 (115.66 - 126.74)
Girls, 13-18 year old 119.12 (116.45 - 121.85) 241.00 (233.57 - 248.66)
Table 6.4: Rates of adolescent depression per 1,000 person-years in children with and
without a preceding sleep disorder
6.5. Discussion 145
6.5 Discussion
6.5.1 Key findings
Insomnia was the most commonly recorded paediatric sleep disorder in UK primary care,
and was associated with adolescent depression. Children with a record of insomnia were
at least twice as likely to develop adolescent depression compared to children without
sleep disorders. Sedating antihistamines and melatonin were the most commonly pre-
scribed hypnotics in primary care. Insomnia was the most commonly diagnosed sleep
disorder in primary care across the entire 5 - 18 year age range, affecting 10.6 per 10,000
PYAR children from age 5 to age 12 years, and up to 48.3 per 10,000 PYAR for 18-year
old children.
Some cross-sectional studies have found sleep problems in 25% to 40% of children
and adolescents [Owens et al., 2005], which is much higher than my findings. This
discrepancy indicates that while many children and adolescents may experience sleep
problems, only few will have such severe sleep disorders that they will consult their GP.
Although there are no NICE guidelines on the treatment of paediatric sleep dis-
orders, the British Association for Psychopharmacology (BAP) have reviewed the avail-
able treatment evidence and recommend behavioural therapy [Wilson et al., 2010]. The
BAP made an exception for the prescription of melatonin for children who were not tak-
ing stimulants but were diagnosed with ADHD, for which there is some evidence of effic-
acy [Bendz and Scates, 2010], although a recent RCT found little benefit [Gringras et al.,
2012]. However, melatonin has only been licensed for treatment of insomnia in adults
over 55 years. There is still little information on its long-term effects and uncertainty
regarding the effects on other circadian rhythms including endocrine or reproductive hor-
mone secretion [Paediatric Formulary Committee, 2010].
Benzodiazepines and non-benzodiazepine hypnotics (’Z-drugs’) were prescribed
mainly to older adolescents and only in small quantities (median: 1 two-week prescrip-
tion). As both benzodiazepines [Owen and Tyrer, 1983] and (to a lesser extend) non-
benzodiazepine hypnotics [Hajak et al., 2003] can lead to dependence and withdrawal
symptoms, these drugs should be prescribed with care.
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6.5.2 Comparison to other studies
Studies in the US have found that antihistamines are the most commonly prescribed drugs
to treat sleep disorders in children [Meltzer et al., 2007, Schnoes et al., 2006]. Similarly,
I found that antihistamines were the most prescribed hypnotic between 1995 and 2011.
However, in boys melatonin surpassed antihistamines as the most commonly prescribed
hypnotic in 2006. A study of hospitalised children found that 6% had been prescribed
medications for sleep [Meltzer et al., 2007]. Antihistamines were the most commonly
prescribed drugs (36.6%), followed by benzodiazepines (19.4%).
Community child and adolescent psychiatrists from the East Midlands in the UK
have been found to be increasing their prescribing of psychotropic medications in gen-
eral, with two-thirds of consultants stating that they were using melatonin to treat sleep
disturbance in children with ASD and ADHD [Doerry and Kent, 2003]. This is in line
with my findings, as I find that younger children treated with hypnotics are more likely
to have been diagnosed with neurodevelopmental disorders such as ASD, ADHD, and
epilepsy.
A cross-sectional study on 823 US children found that children with sleep problems
were almost 7 times as likely to show concurrent symptoms of anxiety and/or depression
(OR=6.9, 95% CI: 4.1 11.4) [Johnson et al., 2000]. However, the association was not sig-
nificant when assessing whether sleep problems at age 6 years affected depression/anxiety
at age 11, although that might be due to small sample size. Another cross-sectional study
on 4,494 US adolescents (age 12-18) found that insomnia symptoms were a risk factor
for depression symptoms in young adulthood (OR=2.2, 95% CI: 1.34-3.58) [Roane and
Taylor, 2008]. I demonstrated this effect longitudinally in this study.
A prospective longitudinal study in New Zealand found that persistent sleep prob-
lems between ages 5 and 9 years were not associated with depression at ages 21 or 26
(OR=0.99, 95% CI: 0.63-1.56), but were associated with anxiety (OR=1.60, 95% CI:
1.05-2.45) [Gregory et al., 2005]. However, despite focussing on more common sleep
problems rather than sleep disorders, numbers of exposed children were still low. The
lack of an association between paediatric sleep problems and later depression in this
study could also indicate that sleep problems in prepubescent children are not related
to depression. Although I found a strong association between more severe sleep dis-
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orders and depression in my younger age group, this association could be confounded
by the presence of neurodevelopmental disorders such as ADHD or other unmeasured
confounders.
6.5.3 Strengths & limitations
In THIN, I had limited information on whether GPs referred children to behavioural or
psychotherapy, or gave advice on sleep hygiene as this is poorly recorded in primary care.
As such, I cannot assess whether GPs use non-pharmacological options as a first line of
treatment. However, as I was primarily interested in the identification of paediatric sleep
disorders in primary care and its association with depression, this should not affect the
validity of my findings.
Second, I only have information on drug prescriptions, not whether they were dis-
pensed by a pharmacy, or used by a patient. However, a validation study found that
rates of prescriptions and dispensing in THIN were very closely associated [The NHS
Information Centre and Services, 2011] (see also Chapter 2).
Finally, it is unclear whether the trends I observe in sleep disorders and hypnotic pre-
scriptions over time indicate whether paediatric sleep disorders are increasing or whether
the detection of the problem is on the rise. Diagnoses of sleep disorders in children and
the issue of hypnotic prescriptions can occur in secondary care, and there is recent evid-
ence of an increase in hypnotic prescribing by child and adolescent psychiatrists [Doerry
and Kent, 2003].
6.6 How does this chapter inform my thesis?
My results suggest that there is a slight rise in paediatric sleep disorders diagnosed in
primary care between 1995 - 2011, particularly insomnia. In addition, hypnotics are
prescribed more commonly, with a distinct rise in the prescription of melatonin. Hence,
I should be able to detect sleep disorder in the family cohort, although rates appear to be
low.
Importantly, paediatric sleep disorders seem to be related to later adolescent depres-
sion, indicating that I can use them as an indicator for internalizing behaviour in my main
analysis. As such, I have included sleep disorders, based on diagnoses and/or prescrip-
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tions between as a type of internalizing behaviour in my main analysis, which will be
detailed in the next chapter.
Chapter 7
Parental depression and adolescent
depression
7.1 Objectives of the chapter
In this chapter of my thesis, I will explore the association between early comorbid par-
ental depression and adolescent depression and assess to what extend this association is
mediated by recurrent parental depression and childhood internalizing behaviour.
The classic approach to mediation analysis in epidemiologic research involves first
regressing the outcome (Y) on the exposure (X) and any confounding factors (C) (Fig-
ure 7.1). Then, the potential mediator (M) will be added to the regression model and
the estimates for the coefficients associated with the exposure (X) in the first and second
regression model will be compared. If the coefficients for the first and second regression
model differ, then some of the effect is thought to be influenced by the mediator.
This classic approach to mediation analysis of just including the mediator in the
regression is subject to two important limitations: mediator-outcome confounding and
exposure-mediator interactions (see appendix D.1).
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Indirect effect
Direct effect
Figure 7.1: General mediation model
7.2 Introduction to structural equation modelling
Structural equation modelling (SEM) is a statistical technique that can be used to estimate
and test causal relationships and adjust for mediator-outcome confounding as well as
exposure-mediator interaction. SEM can estimate multiple outcomes and intermediate
variables simultaneously, and construct latent variables, correcting for any correlations
between them.
The term ’structural equation modelling’ relays two important aspects of the method:
a) that the causal processes under study are represented by a series of structural (i.e.
regression) equations, and b) that these structural relations can be modelled pictorially to
enable a clearer conceptualisation of the theory under study [Byrne, 2011].
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Figure 7.2: Theoretical associations (a-j) between early parental depression, recurrent
parent depression between the ages of 1-13 years, internalizing behaviour between ages
5-10 years manifested by diagnoses for recurrent abdominal pain, migraine and fatigue,
internalizing behaviour between ages 10-13 years manifested by diagnoses for anxiety,
depressive symptoms and sleep disorders and adolescent depression between the ages of
13-18 years
The theoretical model for my study, as shown in Figure 7.2, explores the association
between early comorbid parental depression and adolescent depression. I will use Cox
regression to provide a raw estimate of this association. Then, I will estimate how much
of this association (if there is one) is mediated by recurrent parental depression. I will
assess this by comparing the direct and indirect effects, which is possible by using SEM
as the simultaneous estimation of the regression equations allows for them to be adjusted
for one another. Finally, I will assess whether internalizing behaviour is on the causal
pathway, again by comparing direct and indirect effects of early parental depression on
adolescent depression.
As mentioned in chapter 5, internalizing behaviour is not measured directly in THIN.
However, individual aspects that could indicate internalizing behaviour are recorded in
THIN. As there are many different types of behaviours and disorders that could poten-
7.2. Introduction to structural equation modelling 152
Figure 7.3: A theoretical measurement model for internalizing behaviour
tially be indicative of internalizing behaviour, I explore a measurement model to try to
reduce the number of variables into one or more latent variables by using exploratory
factor analysis (EFA) [Fabrigar et al., 1999, Gorsuch, 1983]. In Figure 7.3, the latent
variable is represented by an oval, indicating that this is the variable that is to be estim-
ated in the measurement model. The variables that are measured, the factors, are indicated
by rectangles.
EFA is used to select indicators that measure the latent variable of interest and its
goal is to explain a set of data in less than the total number of observations [Rabe-Hesketh
and Skrondal, 2008]. Before using EFA, I will inspect the correlation matrix. EFA as-
sumes that the selected factors are measuring the same concept, so there should be some
correlation between the factors. If the majority of correlation are lower than 0.20, this
could indicate that my selected factors are measuring different things and that EFA is not
appropriate.
With EFA, each potential factor is assigned a factor loading. This loading indicates
how strongly each factor is associated with the latent variable, and is used to determ-
ine which factors can be used to estimate the latent variable. Factors with a loading of
>0.40 are considered acceptable, and ideally each factor would only load onto one latent
variable.
To determine on the number of factors to include for each latent variable, I will
assess the eigenvalues of the factors. The eigenvalue represents the total variance of each
factor. I will use the Kaiser criterion to select the number of factors to include, which
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means I will use factors with an eigenvalue >1 [Kaiser, 1958].
I will model the EFA using oblique factor rotation, as this type of factor rotation
allows for the individual factors to be associated to one another.
After selecting the factors for the latent variable(s), I will use Exploratory Structural
Equation Modelling (ESEM)1 [Wall and Li, 2003, McArdle, 2009]. ESEM is a method
that combines features of unrestrictive measurement models (EFA) with restrictive meas-
urement models (confirmatory factor analysis CFA). ESEM allows part of the structural
model to be exploratory, in the sense that no constraints are imposed on whether factor
loadings should be fixed at 0, akin to CFA, while these latent factors are allowed to influ-
ence all manifest indicators according to a pre-defined structure. By using a multivariate
structural model, I will be able to estimate direct and indirect effects simultaneously.
It is likely that not all factors I have identified as potential indicators of internaliz-
ing behaviour will be selected by EFA. If factors are shown not to load onto the latent
variable(s), I will model them individually. If no latent variable constructs are appro-
priate, I will construct two binary variables indicating whether children experienced any
indicators between ages 5-10 years (recurrent abdominal pain, migraine, and fatigue) or
ages 10-13 years (anxiety, sleep disorders, depressive symptoms). Furthermore, instead
of ESEM, I will use ’regular’ SEM as latent variable constructs will not need to be con-
firmed. I will correct analysis for covariates mentioned in the previous chapter (Townsend
deprivation quintile, maternal and paternal age at birth, birth year, child gender, potential
child maltreatment or neglect, parental illicit drug use, alcohol abuse and comorbidity). I
will not list the covariates in the diagrams for simplicity. However, their association with
the outcome is shown in Appendix D.1.
All data management and exploratory analyses will be performed using Stata SE ver-
sion 12.1 (StataCorp, College Station, TX). EFA and (E)SEM analyses will be performed
1ESEM is a combination between path analysis and confirmatory factor analysis, and as such provides
a method for describing the assumed causal relationships between observed variables that are related them-
selves. Traditional multiple regression can run into problems with interpretation and multicollinearity when
multiple predictor variables are considered, but this can be avoided with SEM. This method is particularly
useful for analysing longitudinal repeated measures data.
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using MPlus version 7.0 (Muthe´n & Muthe´n, 2012).
7.3 Model description
I will test and compare three different models. However, I will start by estimating the
main effects of maternal, paternal and comorbid early depression using logistic regres-
sion with robust standard errors to adjust for clustering effect by practice. I hypothesise
that children exposed to early parental depression will be at an increased risk of adoles-
cent depression, and that children exposed to comorbid early depression will be at the
highest risk. I will further explore the association between early parental and adolescent
depression by comparing three risk models using structural equation modelling:
• Model 1 (parental depression model), in which the effect of parental early depres-
sion on adolescent depression is hypothesised to be mediated by recurrent parental
depression during childhood.
• Model 2 (internalizing behaviour model), in which the effect of parental early de-
pression on adolescent depression was hypothesised to be mediated by internalizing
behaviour in children between the ages of 5 to 10 years and 10 to 13 years.
• Model 3 (integrated model), including direct effects of early parental depression on
adolescent depression and mediating effects of both recurrent parental depression
and internalizing behaviour.
The results will be depicted by path coefficients which are partial standardised regression
coefficients that measure the effect of one variable on another, while controlling for all
other variables prior in the model. Parameters are estimated using Full Maximum Likeli-
hood methods, which allow a complete case analysis and provide unbiased and efficient
parameter estimates if data (Townsend scores in this instance) are missing at random [Al-
lison, 2001].
The exposure, outcome, mediators and covariates entered in the analysis are de-
scribed in detail in previous chapters and summarised for one family in Figure 7.4).
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7.4 Results
I used the birth cohort consisting of 4,942 families and variable definitions as described
in chapter 5 for this analysis. The overall results for the association between early par-
ental depression and adolescent depression are described in Table 7.1. Early maternal
depression increased the risk of adolescent depression twofold (fully adjusted OR: 2.04,
95% CI: 1.22 - 3.41), while paternal early depression does not appear to have an effect
(OR: 0.38, 95% CI: 0.11 - 1.35). The effect of comorbid early parental depression does
not reach statistical significance, although the effect estimate is similar to that of maternal
early depression (OR: 2.02, 95% CI: 0.42 - 9.67).
Table 7.1: Odds Ratios for offspring depression in families with and without parental
depression in 4,880 complete cases
Model 1 Model 2 Model 3
Early depression n cases (%) OR (95% CI) OR (95% CI) OR (95% CI)
Maternal only 447 (9.0%) 1.10 (0.71 - 1.71) 1.80 (1.09 - 2.970 2.04 (1.22 - 3.41)
Paternal only 116 (2.4%) 0.65 (0.20 - 2.08) 0.50 (0.15 - 1.68) 0.38 (0.11 - 1.35)
Comorbid 26 (0.5%) 1.64 (0.38 - 7.01) 1.99 (0.45 - 8.86) 2.02 (0.42 - 9.67)
Model 1: Univariate associations between early parental depression and adolescent depres-
sion
Model 2: Model 1 with adjustments for covariates (Townsend quintile, child birth year, pos-
sible maltreatment and neglect, illicit drug use, alcohol abuse, maternal and paternal age,
comorbidity, and severe mental illness, child sex and negative life events as measured during
the first year after birth)
Model 3: Model 2 with additional adjustment for recurrent parental depression
Each additional year during which a parent experiences a depression episode in-
creases the risk of adolescent depression by 14% for mothers (OR: 1.14, 95% CI: 1.05 -
1.25), while the effect for fathers is not statistically significant (OR: 1.03, 95% CI: 0.98 -
1.08).
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Table 7.2: Absolute number of adolescents with depression by parental depression
Maternal early depression Paternal early depression
Child depression n % n %
No 229 5.1% 249 5.2%
Yes 25 5.6% 5 4.4%
As shown in Tables 7.2 and 7.3, the effect of early parental depression on adolescent
depression appears small. Maternal early depression increases the outcome by 0.5%,
while paternal early depression appears to results in slightly lower numbers (although
numbers are small in this group).
Importantly, recurrent parental depression appears to have a stronger effect on ad-
olescent outcome, more than doubling the number of the adolescents with depression in
mother who have 5+ years with recurrences of depression compared to non-depressed
mothers. The effect of early parental depression appears small, though the analysis is
again limited by small numbers (figures for fathers’ depression are not presented for the
same reason).
Table 7.3: Absolute number of adolescents with depression by maternal early and recur-
rent depression
No early maternal depression Early maternal depression
n % n %
No recurrence 99 4.0% 11 4.0%
1-4 recurrences 96 5.9% 12 9.7%
5+ recurrences 28 10.5% 2 7.4%
7.4. Results 158
7.4.1 Exploratory Factor Analysis: measuring internalizing beha-
viour
First, I produced the correlation matrix shown in Table 7.4. As the majority of factors
have a correlation of <0.20, factor analysis is not appropriate in this instance.
Table 7.4: Correlation matrix showing factor correlations
Correlation 1 2 3 4 5 6
1 1.00
2 0.08 1.00
3 0.04 0.06 1.00
4 0.02 0.00 0.00 1.00
5 0.02 0.02 0.00 0.03 1.00
6 0.01 0.03 0.03 0.00 0.42 1.00
1) Recurrent abdominal pain
2) Recurrent headaches / migraine
3) Tired all the time
4) Sleep disorders
5) Anxiety
6) Depressive symptoms
Depressive symptoms and anxiety are moderately correlated (Pearson’s ρ: 0.42,
p<0.01). However, as this correlation is only just above the threshold of 0.40, I chose
not to use latent variable modelling as a data reduction step, but rather construct two
composite scores indicating internalizing behaviour between ages 5-10 years and 10-13
years. The prevalence of internalizing behaviour is similar for children of parents with
no early parental depression compared to comorbidly-depressed parents (7.2% and 7.7%,
respectively, Table 7.5). However, in families where only the mother experienced early
depression, 51 (12.1%) children experienced internalizing behaviour. For internalizing
behaviour between 10-13 years, prevalence rates were higher for all children with at least
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one depressed parent, although the sample size was small.
Table 7.5: Prevalence of childhood internalizing behaviour (IB) by parental depression
Early parental depression No depression Maternal Paternal Comorbid
(4,405) (421) (90) (26)
IB 5 - 10 years (%) 316 (7.2) 51 (12.1) 5 (5.6) 2 (7.7)
IB 10 - 13 years (%) 83 (1.9) 18 (4.3) 3 (3.3) 1 (3.9)
7.4.2 Structural equation modelling
I fitted the hypothesised model as suggested in Figure 7.2 using SEM (see Appendix E
for the Mplus code). The results of these analyses are shown in Figures 7.5, 7.6, and 7.7;
pathways that have been set to 0 (in Figures 7.5 and 7.6) are not shown in order to make
the figures more easily interpretable. Similarly, the models were adjusted for the covari-
ates mentioned in Chapter 5 (Townsend quintile, child birth year, possible maltreatment
and neglect, illicit drug use, alcohol abuse, maternal and paternal age, comorbidity, and
severe mental illness, child sex and negative life events as measured during the first year
after birth), but the related coefficients are not shown.
Figure 7.5: Model 1 (parental depression model). *p<0.01. Single-headed arrows reflect
hypothesised relationships between variables. Regression coefficients are shown next to
each path.
When focussing on the association between early parental depression and adolescent
depression, mediated by recurrent parental depression (Figure 7.5) most of the association
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appears due to the indirect pathway. Both the association between early parental depres-
sion and recurrent parental depression, and between recurrent depression and adolescent
depression are statistically significant. Meanwhile, the association between early parental
depression and adolescent depression is not statistically significant (p = 0.78).
Figure 7.6: Model 2 (internalizing behaviour). *p<0.001, **p<0.01, ***p<0.05. Single-
headed arrows reflect hypothesised relationships between variables. Regression coeffi-
cients are shown next to each path.
The association between early parental depression, internalizing behaviour and ad-
olescent depression is explored in Figure 7.6. Internalizing behaviour between the ages
of 10 to 13 is strongly associated with adolescent depression independent from parental
effects, with a weaker but still statistically significant association for IB at 5 - 10 years.
Internalizing behaviour between the ages of 5 to 10 years is not associated with
internalizing behaviour between the ages of 10 to 13 years. These results are in line with
the results from the EFA (section 7.4.1, page 158), that suggested that the selected factors
could not be reduced to one latent variable.
The regression coefficients from the integrated analysis are shown in Figure 7.7 and
Table 7.6. Again, early parental depression does not seem to be associated directly with
adolescent depression (OR: 1.06, 95% CI: 0.69 - 1.63). However, the indirect pathways
via recurrent parental depression and internalizing behaviour are both statistically signi-
ficant. It is interesting that early parental depression has a stronger effect on internalizing
behaviour in early adolescence. This might be due to better ”specificity” of the symptoms
at that developmental age.
Internalizing behaviour between the ages of 10-13 years (sleep disorders, anxiety
and depressive symptoms) has the largest effect on adolescent depression (OR: 6.59, 95%
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Figure 7.7: Model 3 (integrated model). *p<0.001, **p<0.01, ***p<0.05. Single-
headed arrows reflect hypothesised relationships between variables. Regression coeffi-
cients are shown next to each path
CI: 3.91 - 11.09). To a lesser extent, internalizing behaviour between the ages of 5 to 10
years (recurrent abdominal pain, migraines and fatigue) also appears to increase the risk
of adolescent depression (OR: 1.63, 95% CI: 1.08 - 2.45). However, the two variables are
not associated with one another (OR: 1.17, 95% CI: 0.60 - 2.31). This might suggest they
measure something slightly different, for instance somatisation and emotional disorders.
7.5 Sensitivity analysis
The risk associated with internalizing behaviour (IB) between the ages of 10-13 years
was very large (OR: 6.59, 95% CI: 3.91 - 11.09). As this variable was a composite
score comprising diagnoses and/or symptoms for sleep disorders, anxiety, and depressive
symptoms, it is possible that this association is driven by only one of these disorders.
In Table 7.7, the associations between the individual components and adolescent
depression are shown. While depressive symptoms seem to contribute much of the overall
effect of internalizing behaviour (OR: 7.19, 95% CI: 2.91 - 17.79), the association of sleep
disorders with adolescent depression is also large (OR: 6.09, 95% CI: 2.05 - 18.12). The
effect of anxiety is smaller in comparison and not statistically significant (OR: 2.02, 95%
CI: 0.85 - 4.62).
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Table 7.6: Integrated model results; estimates, 95% CIs and P values
Parameter (letter in Figure 7.2) Odds Ratios (95% CI) P value n (%)
Outcome: adolescent depression
Internalizing behaviour at ages 10-13 years (a) 6.59 (3.91 - 11.09) <0.001 105 (2.1%)
Recurrent parental depression (b) 1.54 (1.26 - 1.87) <0.001 2,176 (44.3%)
Internalizing behaviour at ages 5-10 years (c) 1.63 (1.08 - 2.45) 0.02 372 (7.6%)
Early parental depression (d) 1.06 (0.69 - 1.63) 0.78 533 (10.9%)
Outcome: Internalizing behaviour at ages 10-13 years
Recurrent parental depression (e) 1.22 (0.90 - 1.65) 0.20 55 (1.1%)
Internalizing behaviour at ages 5-10 years (f) 1.17 (0.60 - 2.31) 0.63 10 (0.2%)
Early parental depression (g) 1.72 (1.05 - 2.81) 0.03 22 (0.4%)
Recurrent parental depression
Internalizing behaviour at ages 5-10 years (h) 1.07 (1.00 - 1.14) 0.06 188 (3.8%)
Early parental depression (i) 1.74 (1.65 - 1.84) <0.001 244 (5.0%)
Internalizing behaviour at ages 5-10 years
Early parental depression (j) 1.20 (0.89 - 1.62) 0.24 57 (1.2%)
Table 7.7: Sensitivity analysis: adolescent depression risk by type of internalizing beha-
viour
Internalizing behaviour type OR (95% CI)
Sleep disorders 6.09 (2.05 - 18.12)
Anxiety 2.02 (0.82 - 4.62)
Depressive symptoms 7.19 (2.91 - 17.79)
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Table 7.8: Sensitivity analysis: Integrated model results; estimates, 95% CIs and P values
Parameter (letter in Figure 7.2) Whole population Girls
OR (95% CI) OR (95% CI)
Outcome: adolescent depression
Internalizing behaviour at ages 10-13 years (a) 6.51 (3.87 - 10.97) 2.96 (1.28 - 6.84)
Recurrent parental depression (b) 1.54 (1.26 - 1.88) 1.42 (1.11 - 1.81)
Internalizing behaviour at ages 5-10 years (c) 1.62 (1.07 - 2.43) 1.46 (0.89 - 2.40)
Early maternal depression (d) 1.11 (0.94 - 1.31) 0.99 (0.78 - 1.25)
Early paternal depression (d) 0.81 (0.59 - 1.12) -
Outcome: Internalizing behaviour at ages 10-13 years
Recurrent parental depression (e) 1.22 (0.90 - 1.65) 1.09 (0.67 - 1.79)
Internalizing behaviour at ages 5-10 years (f) 1.17 (0.60 - 2.28) 1.04 (0.36 - 3.02)
Early maternal depression (g) 1.25 (1.04 - 1.52) 1.24 (0.88 - 1.75)
Early paternal depression (g) 1.05 (0.74 - 1.51) 0.84 (0.21 - 3.29)
Recurrent parental depression
Internalizing behaviour at ages 5-10 years (h) 1.07 (1.00 - 1.14) 1.04 (0.95 - 1.14)
Early maternal depression (i) 1.21 (1.18 - 1.23) 1.21 (1.17 - 1.25)
Early paternal depression (i) 1.19 (1.14 - 1.23) 1.18 (1.11 - 1.25)
Internalizing behaviour at ages 5-10 years
Early maternal depression (j) 1.12 (1.00 - 1.26) 1.13 (0.96 - 1.32)
Early paternal depression (j) 0.86 (0.66 - 1.12) 0.95 (0.68 - 1.31)
Finally, I repeated the analysis using the integrated SEM model to separate out the
effects of maternal and paternal depression individually, and to examine the outcome in
boys and girls separately (Table 7.8). Similar to the results of the logistic regression, early
maternal depression appears to have a stronger effect compared to paternal depression,
although with smaller numbers, the effect does not reach statistical significance.
When the analysis is restricted to include only girls, the results are similar, although,
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due to smaller numbers, confidence intervals are wider. I was not able to estimate the
effect of paternal early depression on adolescent depression in girls due to low numbers.
Similarly, I could not repeat the analysis for boys.
In order to assess potential sources of bias that could have influenced the classical
mediation method, I performed counterfactual mediation analsysis. An explanation of
this method, and the results, can be found in appendix D.3.
7.6 Discussion
Early parental depression increases the risk of adolescent depression, although the effect
is mainly indirect through recurrent parental depression. Early internalizing behaviour
at ages 5 to 13 years old could indicate that children are at risk of developing depres-
sion in adolescence. Comorbid parental depression, though rare in this cohort, did not
significantly increase the risk of adolescent depression.
Initially, I aimed to use factor analysis as a data reduction step, using several indic-
ators to measure one underlying structure I called ’childhood internalizing behaviour’.
Several previous cohort studies assessing the effects of parental depression have used
questionnaires assessing internalizing behaviour. However, there did not appear to an
underlying structure to the factors I identified. Only anxiety and depression in children
aged 10 to 13 years appeared to be moderately correlated.
It is possible that GPs only register one type of psychosomatic complaint in chil-
dren’s medical records. If children come back with different psychosomatic symptoms,
they could be referred to mental health services rather than the GP treating the symptoms
him or herself. Alternatively, it is possible that it is rare for children to have multiple
psychosomatic symptoms that are above the threshold that would urge them, or their par-
ents, to seek help for them. In this second case, it would be possible for questionnaires
to pick internalizing behaviour up that does not interfere with daily life, but it would be
hard to impossible to measure it in a primary care database.
The results from the SEM analysis suggested that internalizing behaviour between
the ages of 10 and 13 years was more strongly associated with adolescent depression
than internalizing behaviour between the ages of 5 and 10 years, and that the two were
7.6. Discussion 165
not associated to one another. This latter finding is in agreement with the results from
the exploratory factor analysis, which suggested the behaviours could not be reduced to
one underlying structure. As the later internalizing behaviour was measured more closely
in time to adolescent depression, it is not surprising that this measure was more closely
associated with depression than the earlier measured internalizing behaviours. Moreover,
the behaviours measured at ages 5 to 10 years could be partly due to physical rather than
psychological causes, though I attempted to exclude those. It also is possible that the two
groups of internalizing behavour measure something slightly different (somatisation and
emotional disorders) and are part of different phenotypes leading to adolescent depres-
sion.
The sensitivity analysis on individual internalizing behaviours showed that the effect
was not only due to the continuity of depressive symptoms in early adolescence to ad-
olescent depression. Sleep disorders, as discussed in chapter 6, appear to be an important
indicator of future emotional problems as well. The effect of anxiety at ages 10 to 13
was smaller and not statistically significant. However, anxiety could still be an important
indicator for psychological disorders other than depression, such as generalised anxiety
disorder. Moreover, depression and anxiety have high comorbidity and, especially in a
younger population, are often indistinguishable.
It is likely that I have underestimated the prevalence of internalizing behaviour in
children and adolescents. As these behaviours could present psychological problems,
rather than disorders, and as such children might not have consulted their GP for them,
or GPs could have chosen to not code them in patients’ records. As I am likely to pick
up only the most severe cases of internalizing behaviour, this underascertainment could
have influenced the assocations reported, however, it is difficult to assess the direction of
bias.
The final sensitivity analysis showed that the effects of early parental depression
were strongest for maternal depression and for girls. Although other studies have found
similar results, the lack of an effect for paternal depression and in boys could be due to a
lack of men acknowledging their depressive symptoms and/or seeing their GP for them.
Rates of early depression in fathers have been slowly rising over the years (chapter 5), as
have the rates for adolescent depression in boys (chapter 4).
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My effect estimates for early parental depression are similar to those found in the
ALSPAC study [Pearson et al., 2013]. This British birth cohort, which includes 4,566
children born in the early nineties, found that antenatal (OR: 1.28, 95% CI: 1.08 - 1.51)
and postnatal maternal depression symptoms (OR: 1.26, 95% CI: 1.06 - 1.50, though
only for mothers with low education) were both risk factors for adolescent depression
at age 18 years. These estimates were corrected for parental depression recurrence and
similar to what I estimated the direct effect for maternal early depression to be (OR:
1.11). Moreover, the study by Pearson and colleagues did not find an effect of paternal
early depression (OR: 0.9, 95%CI: 0.7 - 1.1), which I also did not find (OR: 0.81, 95%
CI: 0.59 - 1.13).
Other, notably smaller, studies have found higher effect estimates. A study on a
cohort of 93 dyads from Cambridge found that children of postnatally depressed mothers
were 5 times (OR: 4.99, 95% CI: 1.68 - 14.70) as likely to experience depression by age
16 than children of non-depressed mothers [Murray et al., 2011]. This study also found
very high absolute rates of adolescent depression, with 41.5% of children of depressed
mothers experiencing depression themselves (in the control group, only 12.5% of children
had experienced depression). As shown in chapters 4 and 5, adolescent depression rates
are lower in THIN, potentially as depression is not always recognised in primary care and
adolescents might not see their GP very often. Moreover, the confidence interval from
the study by Murray and colleagues is very wide, though not overlapping with either my
or ALSPACs estimate.
Other studies using the ALSPAC study found that paternal depression was independ-
ently associated with child development at age 3.5 years [Ramchandani et al., 2005a],
recurrent abdominal pain at age 6 3/4 years [Ramchandani et al., 2006] and behavi-
oural/emotional and psychiatric problems at age 7 [Ramchandani et al., 2008b,a]. How-
ever, in my analyses, paternal depression did not appear to be associated with internaliz-
ing behaviours in children, or adolescent depression. This difference could be due to ways
these behaviours and problems were ascertained. Whereas I used primary care records,
ALSPAC uses questionnaires which are more sensitive to subclinical symptoms. How-
ever, as mentioned earlier, a recent ALSPAC study did not find an association between
early paternal depression and adolescent depression [Pearson et al., 2013], in line with
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my results. This could indicate that early paternal depression has time-limited effects on
child outcomes, although, as research into the effect of fathers mental health is only fairly
recent, more research is needed.
I could not replicate the adverse effects of comorbid parental depression found by
other studies in the THIN family cohort [Mezulis et al., 2004, Paulson et al., 2006]. This
is likely due to the very small number of families with comorbid parental depression (26)
in THIN, which caused the confidence intervals to be very wide. Combined with the
previous research on these families, and the results from chapter 5 showing that problems
related to adversity tend to cluster in these families, there is a hint that children in these
families could be at a higher risk of psychiatric problems.
7.7 How does this chapter inform my thesis?
In part III of my thesis, I updated and extended a birth cohort within THIN, assessed
whether sleep disorders could be used as an early indicator of adolescent depression, and
assessed the association between early parental depression and adolescent depression
using this cohort.
Updating the THIN family cohort to 2011 and including families based on family
ID codes increased the cohort to 4,942 families with at least 15 years of follow-up. This
cohort had slightly lower rates of early parental depression, possibly due to lower recog-
nition and treatment of depression in the 1990s and families with depression being more
likely to move house and drop out of the THIN cohort. Families with lower deprivation
scores were also underrepresented.
Few children had a record of the internalizing behaviours I had previously selec-
ted. Rates for recurrent abdominal pain, headaches or migraine, fatigue, sleep disorder,
anxiety and depressive symptoms ranged from 0.5% to 2.8% in the cohort. Rates were
slightly higher for the 250 (5.1%) children who developed adolescent depression, but
only marginally so.
Sleep disorders are associated with adolescent depression in THIN, and appear to
double the risk of later adolescent depression. They could form an epiphenomenon of
depression in early teenage years, or could be easier to report than depressive symptoms.
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However, in younger children (aged 5 to 12 years) sleep disorders are almost exclus-
ively recorded in children with neurodevelopmental disorders such as autism spectrum
disorders, attention-deficit hyperactivity disorders or epilepsy. Therefore, sleep disorders
might be an indicator for more general health problems in this group of children, rather
than a specific indicator for adolescent depression.
Finally, early parental depression is associated with adolescent depression, though
the association is mainly indirect via recurrent parental depression. Early internalizing
behaviour at ages 5 to 13 years old could indicate that children are at risk of developing
depression in adolescence. Comorbid parental depression, though rare in this cohort, did
not significantly increase the risk of adolescent depression.
Part IV
Synthesis
169
Chapter 8
Summary, implications and conclusions
8.1 Summary
In this thesis, I examined the question whether children of parents who both had depres-
sion in the first year after childbirth (early comorbid parental depression) were more likely
to develop depression in adolescence compared to children of non-depressed parents or
families in whom only one parent was depressed.
In part I, I reviewed the literature on the intergenerational transmission of depression
and introduced THIN, the UK primary care database I have used for the main analysis. In
part II, I focussed on the exposure and outcome I used in my main analysis. I performed a
systematic review on the prevalence of early comorbid parental depression and its effects
on child outcomes. I also examined adolescent depression. Finally, in part III, I used
THIN data to explore the association between early (comorbid) parental depression and
adolescent depression in a family cohort.
As described in the introduction to my thesis, I aimed to answer my main research
question by examining three subquestions:
• What is the prevalence of early comorbid parental depression?
• How has adolescent depression been recorded in UK primary care over time?
• What is the association between early comorbid parental depression and adolescent
depression?
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The next sections will summarise the results for each of these questions.
8.1.1 Prevalence of comorbid early parental depression
I found prevalence rates for comorbid early parental depression ranging from 0% to
20% in my systematic review (Chapter 3). The 20 studies that contributed to the re-
view differed in their assessments depression using a range of questionnaires or different
cut-off scores for the same questionnaire. Moreover, parental depression was assessed
at different time points. Lastly, several studies potentially were affected by serious is-
sues around selection bias. It was, hence, inappropriate to perform a meta-analysis to
determine an overall estimate of the prevalence of comorbid early parental depression.
In the second part of my systematic review, I identified only two studies that had
explored the effects of comorbid early parental depression on child outcomes. The first
study [Paulson et al., 2006] found that parental health behaviour was worse when both
parents were depressed compared to families with one depressed parent, or families where
neither parent experienced depression.
The second study [Mezulis et al., 2004], found that internalizing behaviour by the
age of 5 years was higher in children exposed to comorbid early parental depression. The
effect was strongest for girls. They found no effect of parental depression, comorbid or
single parent, on externalizing behaviour.
No studies looked beyond the age of five years, though several studies have tried
to assess the effects of maternal early depression, and to a lesser extent, paternal early
depression on mental health outcomes in adolescence. Several studies have found associ-
ations between early parental depression and adolescent depression, however it is unclear
whether this is a causal association. As detailed in Chapter 1, several explanations have
been offered for the apparent association between early parental depression and adoles-
cent depression. Possible explanations include exposure to maternal stress hormones or
antidepressants during pregnancy, lack of stimulation and impaired parenting during the
first year of life, chronic exposure to depression, or inheritance of genetic susceptibility
for depression.
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8.1.2 Trends in childhood depression
Next, I assessed trends in the recording of childhood depression diagnoses, symptoms,
and antidepressant prescriptions in primary care in the UK (Chapter 4). While rates of
symptom recording steadily increased from the 1990s throughout the 2000s, diagnoses
and antidepressant prescriptions showed a different pattern. Both were increasing from
1995 up to 2002 - 2003, after which they decreased suddenly. Depression diagnoses rates
were stable after 2005, while antidepressant prescriptions increased again from 2005 to
2010, back to 2002 levels.
The decrease in both depression diagnoses rates and antidepressant prescription rates
coincided with the MHRA warning against the prescription of SSRI antidepressants (ac-
cept for fluoxetine) in young people. Rates for paroxetine decreased most dramatically,
leading to the drug being prescribed only sporadically after 2004. All other SSRIs were
also affected by the warning, although to a lesser extent.
8.1.3 Early comorbid parental depression and adolescent depression
In this part of my thesis I attempted to address my main research question to examine
whether children exposed to comorbid early parental depression are more likely to de-
velop adolescent depression than children exposed to early parental depression in one
parent, or no parental depression (Chapter 7). I used a cohort of almost 5,000 children
(Chapter 5), their mothers and fathers who have been prospectively followed for at least
15 years in The Health Improvement (THIN) primary care database.
I found that children exposed to early comorbid parental depression are twice as
likely to develop adolescent depression compared to children not exposed to parental de-
pression. However, the effect was not statistically significant. Maternal early depression
independently doubled the risk of adolescent depression, whereas paternal depression did
not appear to have an effect on child depression, contrary to results from previous stud-
ies. However, other studies have not taken mediation by recurrent parental depression
into account, or adjusted for it inappropriately.
The effect of early parental depression on adolescent depression was strongly me-
diated by recurrent parental depression. Parents who experienced early depression were
much more likely to have subsequent depression episodes. It is appears that it is this
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group, families with both early and subsequent parental depressive episodes, where chil-
dren are at the highest risk of developing adolescent depression.
Moreover, parents who had experienced early depression were more likely than non-
depressed parents to have a record of subsequent depression episodes. Of the parents who
did not experience early depression, 31% of mothers and 22% of fathers remained had
an episode of depression during the study period. Of the parents who did have records
for early depression, 87% of mothers and 79% of fathers had a depression recurrence.
Mothers with early depression had records of recurrence in six years on average (5-95%
centiles: 0 - 16 years). Similarly, fathers with early depression had recurrence in six years
on average (5-95% centiles: 0 - 17 years). This represents a large burden of exposure to
depression for children in the group with parents experiencing both early and recurrent
depression. Importantly, this burden has been mostly ignored by other studies focussing
on the effects of early parental depression on later child outcomes.
These findings indicate that, opposed to previous research, early parental depression
does not appear to have as definitive an effect on child outcomes as previously thought.
Rather, it is the group of children exposed to continuous or recurrent depression (as op-
posed to just early parental depression) who are at high risk of developing adolescent
depression. Whether this increase in risk is due to chronic exposure or genetic susceptib-
ility remains a question to be answered.
I also examined symptoms that could indicate that children are at risk of developing
adolescent depression. I started with a study in which I assessed sleep disorders in chil-
dren and their association with adolescent depression (Chapter 6). There was a strong
association between sleep disorders and depression, in both younger children (age 5 - 12
years) and adolescents (age 13 - 18 years). In the younger age group, sleep disorders were
almost always accompanied by neurodevelopmental disorders such as autism, ADHD or
epilepsy. Therefore, sleep disorders are probably not an appropriate indicator of internal-
izing behaviour in children aged 5 to 12 years. However, sleep disorders double the risk
of subsequent adolescent depression for children aged 13 years and over. This suggests
that sleep disorders can be used as an early indicator of depression. Also, it demon-
strates there is potential to use other internalizing behaviours to find early indicators of
depression, as I planned in my main analysis.
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Next, I examined other internalizing behaviour symptoms between the ages of 5 -
10 years (recurrent abdominal pain, fatigue and recurrent headaches of migraine) and
10 - 13 years (sleep disorders, anxiety, depression symptoms). Internalizing behaviour
between the ages of 10 - 13 years appeared to be strongly associated with adolescent
depression (OR: 6.61, 95% CI: 3.92 - 11.12). Internalizing behaviour in children aged 5 -
10 years had a weaker, though still statistically significant effect (OR: 1.64, 95% CI: 1.09
- 2.25). Moreover, exposure to early parental depression doubled the risk of internalizing
behaviour between the ages of 10 - 13 years (OR: 2.00, 95% CI: 1.30 - 3.08), suggesting
that these behaviours (sleep disorders, depressive symptoms and anxiety) could be used
to identify high-risk individuals.
8.2 Limitations
Despite the relatively large size and long and unobtrusive follow-up, my study has some
important limitations.
In deciding on inclusion criteria and designing the algorithm to identify families
within THIN, I was only able to include traditional families made of a mother, father
and at least one child. Therefore, the results of my thesis might not be representative
of modern or extended family types, such as single parents, families with grandparents
living in or families with same-sex parents. However, the traditional family is the most
common family type at birth and as a result, my cohort is largely representative of UK
births.
Second, in using a primary care database, I could have missed some adolescents
with depression. Adolescent are generally not very forthcoming with any mental health
problems or depressive symptoms, and thus might have not contacted their family doctor
themselves with their problems. This study would have hence only captured the more
severe forms of depression.
Moreover, it is possible that parents who experienced mental illness themselves were
more likely to recognise depression in their children compared to non-depressed parents.
If this is the case, it could have lead me to overestimate the association between parental
and offspring depression.
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I could only estimate the prevalence of some important known confounders in my
study. Child maltreatment and neglect [Woodman et al., 2012], alcohol abuse [Khadjesari
et al., 2013] and illicit drug use are known to be underrecorded in primary care. GPs
might have only recorded suspicions of these behaviours in the records of those children
with more advanced manifestations of these behaviours.
8.3 Strengths
The strengths of my study lie in its large sample size and long follow-up. As more
practices join UK primary care databases, and follow-up continues on existing practices,
numbers will continue to grow in coming years, making the family cohort an extremely
valuable resource for research into children’s health. Compared to other birth cohorts,
such as the ALSPAC study, which are used for similar studies, THIN provides excellent
value for money. As it uses data that is routinely collected by GPs, this imposes a minimal
intrusion on participants’ lives.
Moreover, as opposed to cohort studies, the records present real-life data: health
events are recorded when they happen in real time, rather than at set time points, risking
recall bias. In addition, the information represents clinically relevant information, based
on individuals decisions to consult their GP, rather than a response to a questionnaire.
Although GPs are known to miss some depression diagnoses (sensitivity), the specificity
of GP depression diagnoses is high, as described in Chapter 4.
Finally, I used appropriate methods to assess mediation by recurrent parental de-
pression, a factor that has been ignored by many previous studies. Moreover, studies
that did attempt to correct for the influence of recurrent parental depression did not take
the limitations of classic mediation analysis into account and could therefore suffer from
bias.
In analysing my data both using the classic methods, and SEM, I have found that
results markedly differ. Whereas the classic mediation method did not identify recurrent
parental depression as a mediator, SEM found it to be a very strong mediator. The indir-
ect effect of early parental depression via recurrent depression on adolescent depression
dominated the direct effect that was found using the classic analysis method. This finding
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provides evidence that other studies could have been biased. Most notably this could have
affected studies on the effects of early parental depression, although mediation analysis
is performed in many other areas of epidemiological and psychological research as well.
8.4 Implications
Early parental depression doubles the risk of adolescent depression in offspring [Manning
and Gregoire, 2009]. The effect is strongly mediated through chronic or recurrent parental
depression rather than the postnatal period being a sensitive period for child development.
This implies that parental mental health, especially over the long term, should be taken
into account when assessing mental health problems in children and adolescents. This
finding emphasises the importance the role of family doctors who, rather than just treat
the patient, are involved and aware of the entire family and any problems that may arise.
Primary care is key resource for children and young people with emotional difficulties
and their families [Sayal et al., 2010].
However, few parents of children with mental health problems have expressed con-
cerns about consulting GPs for these problems, including short appointments, continuity
of care and trusting relationships with GPs [Sayal et al., 2010]. Concerns about embar-
rassment, stigma of mental health problems and being labelled or receiving a diagnosis
further threw up barriers to primary care access. These barriers might be even more im-
portant in families where parents have experienced mental health problems themselves,
as their contact and relationship with their GP could influence help-seeking behaviour for
their children.
A large number of children are exposed to parental depression during their child-
hood: a study using THIN data estimated that up to the age of 12 years, 40% and 20%
of children are exposed to at least one episode of maternal or paternal depression, re-
spectively [Dave´ et al., 2010]. Because many parents who recover from an episode of
depression continue to experience subclinical levels of depressive symptoms, children
are often to exposed to depression and associated disruption in parenting for prolonged
periods of time [Brennan et al., 2002]. In addition, depression can often become a chronic
or recurrent illness [Mueller et al., 1999], leading children to become exposed multiple
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times over.
It is possible that the postnatal period, as a sensitive period for child development,
does not have a definitive effect as previous studies have suggested. Rather, the first year
after child birth is a sensitive period for emotional disorders in parents. Parents who ex-
perience early depression in this stressful and life-changing period are much more likely
to experience subsequent depressive episodes, as discussed in Chapter 5. The period after
birth could serve as a depression ’stress test’ for parents: parents who are susceptible to
emotional disorders could be more likely to develop symptoms in this period in particular.
If the postnatal period is a sensitive period for parents, this would also put less emphasis
on possible long-lasting adverse effects for children originating in this period. This hy-
pothesis would not replace the theory on a sensitive period for emotional development
in children, rather it complement it and put more emphasis on development throughout a
child’s life.
Parental depression has been identified as one of the most potent risk factors for
the development of adolescent depression: children of depressed parents have a two-
to fourfold increased risk of developing depressive disorders [England et al., 2009]. In
my thesis, I found a similar increase in risk. As adolescence is a period of formative
biological and social transition [Blakemore and Mills, 2013], it is important to develop
interventions for high-risk children, such as those exposed to a depressed parent (Fig-
ure 8.1).
Several papers have reported on such interventions, although a systematic review
found that they have little overall effect [Calear and Christensen, 2010]. Beardslee and
colleagues reported that parental depression was an important modifier of the effect of
their Cognitive Behavioural Prevention (CBP) program [Beardslee et al., 2013]. Their
large trial, which followed 316 participants for 33 months, included adolescents at high
risk of depression. Youths were recruited if their parents had a history of depression or
if they themselves had a history of depressive disorder or current depressive symptoms.
While the CBP program significantly reduced the number of depressive episodes over
the almost three years of follow-up for the group not exposed to parental depression,
depression rates were similar for CBP and usual care for the youths whose parents were
depressed at baseline.
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Figure 8.1: An integrative model of transmission of risk from depressed parents to off-
spring. Based on original Figure by Goodman and Gotlib [Goodman and Gotlib, 2002]
Attention should also be paid to adverse childhood experiences in a more general
sense. As demonstrated in Chapter 5, parents who experience early depression are also
more likely to engage in harmful drinking behaviour, illicit drug use, have records of
potential child maltreatment or neglect and severe mental illness. These experiences are
also known to have adverse effects on children’s outcomes [Bellis et al., 2013] and should
be considered in planning family or child treatment. The risk of developing a mental
health problem is strongly increased by social disadvantage and adversity, both of which
seem to cluster in families who also experience early depression.
These implications tie in with the recently published report by the Chief Medical
Officer [Davies, 2013]. In this report, Dame Sally Davies recommends that children with
long-term conditions, such as those with mental health disorders, should have a named
GP who co-ordinates their disease management and stresses the importance of school
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nurses, who could also play an important part in the prevention and recognition of mental
health problems.
Finally, researchers should be aware of the limitations of classic mediation analysis
(Appendix D.1). As shown in my study, results can be severely biased when mediation is
not appropriately accounted for in statistical analysis. Methods such as structural equa-
tion modelling account for mediator-outcome confounding and exposure-mediator effect
modification and give unbiased results. In addition, methods that are currently in develop-
ment, such as counterfactual mediation analysis (Appendix D.3), can assess the presence
of confounding and effect modification and will help identify cases where classic medi-
ation analysis is inappropriate.
8.5 Future Research
Although I have attempted to address mediation by using structural equation model-
ling and counterfactual mediation analysis, some aspects of confounding may have been
missed. There might be an important interplay between psychological problems in chil-
dren and parental mental health which cannot be quantified by either of the methods and
data used in this thesis. While parental depression could have an adverse influence on
children’s outcomes, the problems children are experiencing can also affect parental out-
comes. This could lead to a feedback loop in which psychological problems reinforce
themselves.
A potential way to deal with variables that are associated with each other in this
way is the use of Marginal Structural Models (MSMs). MSMs were developed and are
often used in HIV/AIDS treatment research. Treatment for HIV is dependent on disease
severity as measured by a patient’s CD4 1 count. When a person’s CD4 count drops
below a specified threshold, an aggressive treatment is initiated. However, CD4 count
can recover and increase to above the treatment threshold level. When this happens the
aggressive treatment will be halted again. In this scenario, the exposure (HIV drugs)
1CD4 count measures the number of healthy CD4 T-cells, which are white blood cells that can be
infected by HIV. When more CD4 T-cells are infected by HIV, the CD4 count decreases and the patient is
at risk of developing AIDS.
8.5. Future Research 180
and mediator (CD4 count) are involved in a feedback loop which traditional statistical
methods struggle to adjust for.
MSMs are able to adjust effect estimates for these time-dependent confounders. This
is achieved by using inverse probability weighting (IPW) to balance out the confounding
at baseline [Sterne et al., 2005]. The weights are based on the inverse of each patient’s
probability of the treatment history they actually had, given their covariate history. If a
majority of patients never reaches the threshold, this group will be given a low weight
in the analysis, while rare patients - in terms of treatment regime and covariates - will
receive higher weights. The weighted analysis creates a statistical pseudo-population in
which the probability of being treated at each time point is unrelated to the measured
prognostic factors, solving the problem of time-dependent confounding.
This method could be applied to my research, however, rather than weighting fam-
ilies for treatment probability, families would be weighted for parental depression prob-
ability. This means that THIN would have to contain enough information to construct a
regression model to predict parental depression. As many of the factors that are associ-
ated with depression are available in THIN (e.g. history of depression, deprivation, alco-
hol/drug use), MSMs could be an interesting option for exploring the interplay between
parental depression and child outcomes. However, in using only primary care data, in-
formation on important factors might still be missing. Therefore, linking primary care
data to other data sources will important for making more complicated analyses work
(see below for more on linking data).
Second, the effects of parental depression were most pronounced in girls in my study,
who were more than twice as likely to develop depression compared to boys. Other stud-
ies have found similar results, although results did often not reach statistical significance
due to small sample sizes. The lack of or reduction of an effect in boys could be due to
boys expressing depression or mental illness differently. Studies that have assessed ex-
ternalizing behaviour rather than internalizing behaviour (e.g. irritability or aggression)
have found stronger effects in boys.
A recent study using data from the US National Comorbidity Survey Replica-
tion [Martin et al., 2013] found similar differences in between men and women. Rather
than only looking at the traditional symptoms associated with depression, this study ex-
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plored symptoms included in two new scales on alternative depression symptoms that
were administered to a national sample of 5,692 individuals representative of the Eng-
lish speaking US population. The authors found that men reported higher levels of anger
attacks/aggression, substance abuse and risk taking compared with women. When us-
ing the new scales, a higher proportion of men (26.3%) met the criteria for depression
compared to women (21.9%). When both traditional and alternative scales were used,
similar proportions of men and women met the criteria for depression (30.6% and 33.3%,
respectively.
It would be interesting to try to assess externalizing behaviour in boys in primary
care. The effects of parental depression on boys could lead to different symptoms com-
pared to girls, such as higher rates of conduct problems, attention-deficit hyperactivity
disorder, aggressive behaviour in children, and substance abuse in adolescents. In addi-
tion, it would be interesting to extend this study to hospital data in the Hospital Episodes
Statistics (HES) database. The CPRD database is linked to HES and THIN is in the pro-
cess of being linked. HES data contains information on emergency admissions, which
could be used to assess suicide attempts in more detail than possible in THIN. Moreover,
some data on psychiatric treatment is available in HES that could be used to look at
mental illness in more detail.
In addition to exploring behaviours and symptoms that could indicate mental illness
in boys, primary care and hospital data could also be further explored for behaviours that
are indicative of future depressive illness. Although some of the internalizing behaviours
in this study appear to be associated with adolescent depression (particularly anxiety and
depressive symptoms), other indicators might exist. For instance, consulting behaviour
or covariates associated with school or education could be associated with depression.
With the recent approval of an Administrative Data Research Centre for England, based
at UCL, and the Farr Institute, data linkage will receive a much needed boost and it might
possible to link to other data sources such as educational data as well.
As mentioned in the limitations section, THIN has limited information on some of
the more important confounders such as child maltreatment and neglect that are known to
be associated with both parental depression and child outcomes. However, estimates of
community prevalence of these, and other confounders are available, as are estimates of
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their potential influence on child outcomes. These can be used in a sensitivity analysis to
estimate the potential effect of these confounders on the overall effect estimate. As these
methods are novel and I only heard about them at a conference in August 2013, I was not
able to apply them in my thesis.
An example of this method for sensitivity analyses is given in a paper by Palmsten
and colleagues [Palmsten et al., 2013]. In their paper, they assessed the risk of postpartum
haemorrhage associated with SSRI and non-SSRI antidepressants using US claims data.
Although their dataset is one of the largest databases containing information on preg-
nancies and detailed information on antidepressant prescriptions, it lacks important con-
founders such as obesity. Therefore, the researchers used information from the Na-
tional Health and Nutrition Examination Survey (NHANES) to estimate the prevalence of
obesity in women using SSRI, non-SSRI or no antidepressants. Relative risks for the as-
sociation between obesity and postpartum haemorrhage were estimated between 1.5 and
2.0, based on existing literature. In using this external information, the authors were able
to perform robustness checks on their effect estimates and found that estimates moved
slightly towards the null, though remained statistically significant.
8.6 Conclusion
In conclusion, children whose parents experience early depression are twice as likely to
develop depression as adolescents compared to children of non-depressed parents, al-
though parental depression over childrens life course has an important mediating effect.
The effect appears similar for families where one or two parents experience early depres-
sion, although the numbers of families with comorbid early depression were too small to
draw firm conclusions.
In addition, internalizing behaviours in childhood seem to be intermediate variables
on the causal pathway from early parental depression to adolescent depression and could
potentially be used to identify children at high risk of developing depression. However,
as this thesis only focussed on internalizing behaviour, which was recorded in only a few
instances, further research is needed to explore other potential indicators. Externalizing
behaviour and education records could provide more insight in the aetiology of adolescent
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depression from a population health perspective.
These results suggest a family-based approach, involving both parents and children,
to prevent adolescent depression. Further research is needed to identify appropriate inter-
ventions.
Appendix A
Research profile
A.1 Funding
I received a PhD training fellowship from the National Institute for Health Research
(NIHR) School for Primary Care Research (SPCR) to cover research and training costs
for this PhD project. I received additional scholarship funds to attend the International So-
ciety of Pharmacoepidemiology (ISPE) annual conference in Barcelona, Spain, in August
2012, and in Montreal, Canada, in August 2013. Finally, I was a co-applicant for pub-
lic engagment grant from the UCL Volunteering Services Unit to set up London Science
Buskers, a group of postgraduate students at UCL who are trying to take their science to
the street.
A.2 Collaboration and data sharing
All analyses included in this thesis were performed by me. However, my supervisors
helped in refining the research questions, analysis plans and interpretation of the data.
For Chapter 3 I had the help of Ruth Muscat, a librarian at the Royal Free Medical School
Library, who helped me operationalise the search question for my systematic review and
identify additional databases to search. I also had the help of Shuk-Li Man, Jenny Wood-
man, Jesca Brouwer, Hilary Davies and Ruth Blackburn in selecting studies to include in
my review and data extraction.
In order to identify some of the covariates for my main analysis, I used code-lists
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and algorithms developed by other THIN team members at UCL. The Read code list for
identifying (suspected) child maltreatment and neglect was developed by Jenny Wood-
man. Hilary Davies developed the Read and drug code lists to identify illicit drug use in
THIN. Algorithms for defining alcohol abuse and comorbidity scores were developed by
Dr Louise Marston. Read codes for identifying severe mental illness were developed by
Dr Sarah Hardoon. Finally, Laura Horsfall developed the algorithm for determining dates
for Acceptable Computer Usage (ACU) in individual GP practices.
The birth cohort nested in THIN was developed by my supervisor, Dr Irene Petersen,
and was extended to include fathers by Dr Shreya Dave´. I used this cohort as the basis
for the family cohort included in my thesis, but updated it to the most recent data and
extended the matching algorithm to be able to include more families.
Finally, Dr Nadia Micali from the UCL Department of Neurosciences & Mental
Health advised on the analysis plan for the structural equation modelling analysis.
A.3 Software
As described in the relevant chapters, I used Stata (versions 11.2-12.1) and MPlus (ver-
sion 7.1) for statistical analysis in my thesis. All graphs included in my thesis were
produced using Stata and, where necessary, adapted using GIMP 2.0 image editing soft-
ware.
Figures 1.2, 1.3, 2.2, 3.1, 4.1, 7.2, 7.3, 7.5, 7.6, 7.7, and 8.1 were drawn using Mi-
crosoft Word, and Figures 2.1, 2.3, and 7.4 were produced using easel.ly, a free website
providing basic data visualisation tools.
This thesis was compiled using LATEX.
A.4 Conference posters and presentations
I have presented parts of my thesis at local, national and international conferences. Parts
of Chapter 4 were presented as poster presentations at the Society for Academic Primary
Care (SAPC) annual conference in Bristol, 2011; the European Drug Utilization Research
Group (EuroDURG) conference in Antwerp, Belgium, 2011; and the ISPE annual con-
ference in Barcelona, 2012.
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I presented analyses based on Chapter 6 at the NIHR SPCR conference in London
in 2012; at the European Epidemiology Congress (EuroEpi) in Aarhus, Denmark, 2013;
and at the ISPE annual conference in Montreal, Canada, 2013.
A.5 Courses
Thanks to the generous fellowship I received from the NIHR SPCR, I was able to at-
tend several short courses that proved essential to finishing my PhD project. Particularly
helpful were courses run by the London School of Hygiene and Tropical Medicine (Sys-
tematic Reviews and Meta-analyses of Health Research - ran by Katherine Ker and Pablo
Perel; Causal Inference in Epidemiology: Recent Methodological Developments - ran
by Prof Bianca de Stavola, Prof Simon Cousens, and Rhian Daniel; Factor Analysis and
Structural Equation Modelling: and Introduction Using Stata and MPlus - ran by Prof
Bianca de Stavola and Dr George Ploubidis).
I attended a course on Missing Data in Mental Health Research at the University
of Cambridge, ran by Prof Ian White and Prof Sabine Landau. I also attended pre-
conference courses in pharmacoepidemiology and methodology at both the ISPE annual
conferences I attended, and at EuroEpi. The UCL grad school have also provided me
with a lot of useful courses ranging from inproving my presentation skills, via thesis
formatting to writing about science for the general public.
Finally, I have been involved in the Introduction to Primary Care Databases course
run by my department, Primary Care and Population Health. I have given lectures on
creating codelists, and an introduction to Stata Programming. I have also taught on the
Use of Evidence module for medical students at UCL. This teaching consists of leading
five working groups of second year medical students on systematic reviews and basic
statistics.
Appendix B
A short history of safety concerns
regarding antidepressants
Since the development of SSRIs there have been concerns about the safety of these drugs.
In 1984, the West-German Regulatory Agency, the Bundesgesundheidsamt (BGA), rejec-
ted fluoxetine, one of the first SSRIs to go to market, as being “totally unsuitable for treat-
ing depression” (Figure B.1). Six years later, in 1990, the BGA would approve fluoxetine
for depression, but not after a further two rejections due to concerns about the possibility
of fluoxetine increasing the risk of suicide. It was approved for the US market by the
Food and Drug Authority (FDA) in December 1987, and in November 1988 for the UK
market for treatment of depression disorder.
Soon after its introduction, case reports about patients developing suicidal tendencies
started to emerge [Teicher et al., 1993, Papp and Gorman, 1990]. In 1991, the FDA
organised an advisory meeting to review the evidence available at the time for a link
between fluoxetine and suicidal behaviour in adult patients [Mann et al., 2005]. Although
data on other SSRIs was available at the time, they were not yet licensed and thus not
included in this meeting. Concerns were raised following case reports of few patients who
had exhibited suicidal behaviour upon initiation of treatment with the SSRI fluoxetine,
as well as some cases involving TCAs. However, the FDA did not find evidence of
an increased risk of suicidal behaviour in individuals taking these drugs. Rather, they
found the apparent association was due to confounding by indicating: the few individual
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Figure B.1: Summarising opinion of the German Bundesgesundheidsamt (West-German
Drug Regulatory Agency) concerning Fluctin (fluoxetine) in a fax dated 25 May 1984 to
Eli Lilly
patients who worsened on taking antidepressants were severely depressed and would have
progressed to suicidal behaviour with or without the drugs. Or put in other words: it was
the disease rather than the drug. The FDA did advise Lilly, the pharmaceutical company
that produced fluoxetine, to run a challenge-dechallenge-rechallenge trial1 to rule out any
drug effect, but although protocols were drawn up, the trial was never executed.
Despite the FDA’s ruling, doubts about the effectiveness and adverse events related
to SSRIs remained. During the 1990s, several law suits were filed against Lilly for hold-
ing back vital information about a possible link between their drug Prozac (fluoxetine)
and suicidal behaviour. Lilly argued that fluoxetine, the most researched drug in history,
was not to blame. Fourteen of these were settled, and the one law suit that did go to trial
was won by Lilly.
In 2002, the BBC investigative programme Panorama revealed that pharmaceut-
ical companies had been withholding negative trial results on multiple SSRIs [Cowen,
2002]. In a programme called ‘The Secrets of Seroxat’, aired in October 2002, they high-
1Challenge-dechallenge-rechallenge (CDR) is a medical testing protocol in which a medicine or drug
is administered, withdrawn, and then re-administered, while being monitored for adverse effects at each
stage. During the withdraw phase, the medication is allowed to wash out of the system in order to determine
what effect the medication is having on an individual.
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lighted the case of paroxetine (brand name: Seroxat), which according to the programme
caused severe withdrawal symptoms, as well as the suicides of several patients. Follow-
ing the programme and resulting negative media attention, the Medicines and Healthcare
products Regulatory Agency (MHRA) decided to review the efficacy and adverse advents
associated with paroxetine. The review was extended to include all antidepressants a few
months later.
During its investigation, the MHRA demanded that pharmaceutical companies
provide all available data. It reanalysed published and unpublished data on paroxetine,
and found that the drug failed to demonstrate significant beneficial effects, and was asso-
ciated with a small increase in suicidal behaviour and ideation [Committee on Safety of
Medicines, 2003]. As a result, it released an advice against the prescription of paroxetine
to children and young people under the age of 18 in June 2003 [Waechter, 2003]. This
was followed by a broader advice in December of the same year, advising against the
initiation of treatment with SSRIs for childhood depression [Healy, 2003, Gunnell et al.,
2005]. Fluoxetine, the only drug which is licensed to treat depression in children in the
UK, was exempted from this advice following a favourable balance of benefits and risk.
While the UK was first to issue an advice against prescription of SSRIs, Europe
and the US followed suit over the next years with similar cautions. The FDA issued a
black box warning2 in October 2004 for all antidepressants (including TCAs and other
antidepressants as well), warning about an increase in the risk of suicidality in paediatric
patients taking these drugs [FDA, 2004]. In 2007 the black box warning was extended to
18-24 year olds (Figure B.2). The European Medicines Evaluation Agency (EMEA) is-
sued a warning in April 2005. After an extensive review by the Committee for Medicinal
Products for Human use (CMPH), they warned against the prescription of SSRIs and
2In the United States, a black box warning is a type of warning that appears on the package insert for
prescription drugs that may cause serious adverse effects. It is so named for the black border that usually
surrounds the text of the warning. A black box warning indicates that the drug carries a significant risk of
serious or even life-threatening adverse effects. The FDA can require a pharmaceutical company to place
a black box warning on the labelling of a prescription drug, or in literature describing it. It is the strongest
warning by the FDA that a medication can carry whilst remaining on the market.
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serotonin-norepinephrine reuptake inhibitors (SNRIs) in children. While both the FDA
and the EMEA included fluoxetine in their warnings, the MHRA did not as it deemed
the benefits greater than the risk for this particular drug [National Institute for Health and
Clinical Excellence, 2005, Whittington et al., 2004].
Figure B.2: Text of the updated black box warning issued by the FDA in August 2007
The evidence suggesting an increased rate of suicidal behaviour and intentional self
harm associated with SSRIs is limited and inconsistent. In adolescents and young adults,
RCTs indicate an increase in the risk of suicidal behaviour [Hammad et al., 2006]. How-
ever, the results from trial data should be interpreted with caution. Randomised controlled
trials were not primarily designed to measure suicidal behaviour, rather these data were
collected as a part of adverse event monitoring. It would be unethical to power an RCT
on suicide rates [Rothman and Michels, 1994]. None of the clinical trials on SSRIs in a
paediatric setting have recorded a completed suicide, and the setting of the trials might
not be comparable to the general population [Hammad et al., 2006, Stone et al., 2009].
The results from observational studies are also divided: some indicate that SSRIs
protect from suicidal behaviour [Gibbons et al., 2007], others find no effect [Schneeweiss
et al., 2010, Jick et al., 2004], or an increase [Olfson et al., 2006]. However, these studies
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suffer from methodological flaws: small samples, high attrition rates and, most import-
antly, confounding by severity. Given their toxicity in overdose, a prescriber would be
unlikely to prescribe a TCA in preference to a SSRI to a patient who was considered to
be at risk of suicidal behaviour [Didham et al., 2005]. The evidence from clinical trials
and observational studies is summarised in Appendix B on page 191.
Following the CSM advice, fewer children and adolescents in the UK were pre-
scribed antidepressants in primary care [Murray et al., 2005, Bergen et al., 2009]. There
was a 48% reduction in the initiation of CSM-contraindicated antidepressants in children
between 2002 and 2004. However, the use of fluoxetine and non-SSRI antidepressants in
children had not significantly risen during the same period. A similar pattern was found in
a study in Australia, where antidepressant use, and SSRI use in particular, in children and
adolescents decreased between 2002 and 2005. In stark contrast, the use of SSRIs and all
antidepressants increased significantly in adults during the same period. Safety concerns
regarding antidepressants, selective serotonin reuptake inhibitors (SSRIs) in particular,
have been around since these drugs were initially developed3. Suicidal behaviour is com-
mon in adolescents: 8% report intentional self-harm [Moran et al., 2012]. Moreover, a
third of young people who experience a depressive episode will make a suicide attempt
at some stage, and 3-4% of those who experience depression will die from suicide [Har-
rington et al., 1994]. It remains unclear whether it is the underlying disease or the drugs
which cause the apparent link.
B.1 Evidence from randomised clinical trials
Few randomized controlled trials testing SSRIs in children and adolescents have been per-
formed. Their interpretation with regards to suicide-related behaviour has been fraught
with problems. As mentioned in the last chapter (reference to page number), the FDA
have analysed clinical trial data using a surrogate representing suicide-related behaviour.
The term they use for this behaviour, suicidality, was coined by the FDA for this purpose.
However, it is unclear what this term exactly entails [Klein, 2005].
3Although some argue that concerns arose as early as 1963, when the poet Sylvia Plath committed
suicide a few days after starting an antidepressant (a mono-amine oxidase inhibitor). [Cooper, 2003]
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The term was originally conceived to cover the suicidal thinking and behaviour that
was observed in paediatric clinical trials, as no completed suicides were observed. How-
ever, it was unclear whether suicide itself (whether attempted or completed) was included
in the term, and how the general public, who would read the term in the black box warn-
ing, would interpret the term. As shown in Table B.1, although the FDA themselves
needed to clarify the meaning of the word to not include suicide4, they left it with the
press to convey the meaning of the word suicidality to the general public [fda, 2004].
Table B.1: Transcript (pages 213 - 216) from the Joint Meeting of the CDER Psycho-
pharmacologic Drugs Advisory Committee and the FDA Pediatric Advisory Committee
held on 14 September 2004. Emphasis added
Dr. Irwin (committee member): Is there a word suicidality?
Dr. Goodman (committee chairman): Every time I write it in Word, it gets red
underlined.
Dr. Irwin: It seems to me, I mean to me, I am not certain anyone really knows what
it is that we are saying and what you are voting on, or, to me, I would like to know
what suicidality is.
Dr. Goodman: I don’t think it is in an Oxford Dictionary either.
Ms. Griffith (patient representative): It is not in Webster’s.
Dr. Irwin: In a sense, it confounds things by, you know, the front page of the paper
today, I think may lead to kind of a misrepresentation.
Dr. Pollock (committee member): Can’t we just use the explicit language?
continued on next page
4As referenced by Dr Irwin in the transcript, newspapers had misinterpreted the term as meaning that
clinical trials had found children who committed suicide while on antidepressants. The confusion surround-
ing the term suicidality still exists, as exemplified by the Wikipedia page for Suicidality which redirects to
the page for Suicide.
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Dr. Goodman: That is, in part, what I would favor, is that if we use it, I think we
need to at least parenthetically define what we mean when we are answering the
question.
Dr. Temple (FDA associate director for medical policy): Yes, that is what we do. I
think that is what we actually did in labeling. Whether we should coin a new word
is debatable, obviously, but it means suicidal behaviour plus suicidal ideation. That
is what we use it to mean as those items.
Dr. Goodman: Would it be fair for us to slightly modify the question, or do we
have to take it as it is, because what I would say, if we could use the definition that
corresponds to Outcome 3, I would feel most comfortable, because that corresponds
to the reclassification and the way you approach the dataset. So, suicidality, suicide
attempt, preparatory action/or suicidal ideation.
Dr. Katz (FDA Supv. Medical Officer and Director of Division of Neuropharma-
cological Drug Products): Yes, you can certain amend the question. We called it
suicidal behavior and ideation, but it is clearly what is embodied in Codes 1, 2, and
6.
Dr Goodman: I think we have a clarification on that and hopefully, the public will
understand what we mean, too, and that, I think we will leave it to the press to
do their job in trying to best define what we mean and dont mean by that
term, specifically, that we are not talking about actual completed suicide if we are
restricting our deliberations to the clinical trials, because there werent any instances.
More controversy surrounding clinical trials for antidepressants in children arose
after a trial comparing GlaxoSmithKline’s (GSK) paroxetine with imipramine [Keller
et al., 2001], also known as study 329, was published in 2001. The study followed 275
adolescents with major depression for 8 weeks while they took paroxetine, imipramine
or a placebo. The main outcomes of the study were the endpoint response and change
from baseline on the Hamilton Rating Scale for Depression (HAM-D). The study con-
cluded that paroxetine was effective for treating major depression in adolescents and was
generally well tolerated.
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However, soon after its publication, letters to the editor appeared in the Journal of
the American Academy of Child & Adolescent Psychiatry expressing concerns regarding
the conclusions of the study. The authors of these letters were particularly concerned with
the article’s representation of the serious adverse effects that occurred with paroxetine:
although 11 adolescents reported serious adverse effects (compared to five for imipramine
and two for placebo), only one case (severe headache) was considered to be related to
paroxetine [Correll and Pleak, 2002, Parsons, 2002, Weintrob, 2002]. The criteria for
determining causation of serious events were not stated. The other 10 reported serious
adverse effects, which included five reports of agitated/suicidal behaviour, were attributed
to the underlying depression.
When the FDA later reanalysed the data from study 329 in their review of SSRIs
in children, they found ten children (out of a total of 93) on paroxetine had experience a
potentially suicidal reaction. Although not reported in the original study, the difference in
number of adverse events (though small) was statistically significant (p=0.01) [Jureidini
et al., 2004]. Nevertheless, Keller et al. concluded that ”paroxetine was generally well
tolerated in this adolescent population, and most adverse effects were not serious,” al-
though seven patients were admitted to hospital during treatment with paroxetine.
Moreover, the study showed evidence of distorted and unbalanced report-
ing [Jureidini and Tonkin, 2003]. The authors defined what they would classify as a
treatment response (a fall in HAM-D below 8 or by 50%) in the methods section of the
paper, but this has changed in the results section leading to a p-value of 0.02, rather
than 0.11 with the original definition of response. Secondly, while the authors state
two primary outcomes in their methods section (a ’response’ on the HAM-D, and total
score), they only report on one outcome in the results section (the distorted ’response’
variable) and mention there was no difference between paroxetine and placebo in the
second primary outcome in the discussion section. Drs Jureidini and Tonkin, authors of
this letter to the editor, even go as far as to suggest that as the research was funded by
GSK, this might have influenced the reporting of this drug ”in the most favourable light”.
It has since transpired that the study was ghost-written by medical contractor Sci-
entific Therapeutics Information, Inc. for GSK, and that many of the co-authors on the
original paper were not involved in the actual study. GSK used Study 329 as an evid-
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ence base to market its antidepressant paroxetine as an effective treatment for in children.
However, in 2012 it settled a lawsuit for consumer fraud for a record $3 billion (1.9 bil-
lion) [Outterson, 2012]. In the case of paroxetine, prosecutors claimed GSK employed
several tactics aimed at promoting the use of the drug in children, including helping to
publish a medical journal article that misreported data from a clinical trial Thomas and
Schmidt [2012], West and Ortiz [2011]. During the trial, documents relating to study 329
revealed that the published article differed significantly from the original study protocol:
the primary outcomes were changed, and eight ”efficacy measures” that had not been
pre-specified were introduced. When analysed using the original protocol, there were no
differences between paroxetine and placebo on either of the primary outcomes. The US
attorney general handling the case concluded that GSK caused the article to misrepresent
and minimise paroxetine’s risk to children and adolescents [West and Ortiz, 2011]. To
date, the article has not been retracted.
In addition to study 329, GSK conducted two other double-blind placebo-controlled
studies of paroxetine for paediatric and adolescent depression: study 377, which ran from
April 1995 to May 1998, and study 701, which ran from March 2000 to January 2001.
Both studies are unpublished and failed to show a difference in efficacy between par-
oxetine and placebo on any pre-specified primary or secondary endpoint [West and Ortiz,
2011]. Despite the failure of its three clinical trials and the absence of FDA approval,
GSK actively promoted paroxetine to treat adolescent and childhood depression from
1999 to at least 2003.
Clinical trials on other SSRIs suffered from similar bias. A study by Drs Jureidini
and Tonkin [Jureidini et al., 2004], who expressed their concern about GSK’s study 329,
examined the methodology of paediatric SSRI trials in more detail. Out of the seven
published trials they identified, six used a placebo control and were included in their
review. Funding was disclosed to be from pharmaceutical companies in three of these
studies (GSK, Eli Lilly and Pfizer) [Emslie et al., 2002, Keller et al., 2001, Wagner et al.,
2003], one study was attributed to the National Institute of mental Health (though FDA
data showed it to be sponsored by Eli Lilly) [Emslie et al., 1997], and two older trials did
not disclose funding [Mandoki et al., 1997, Simeon et al., 1990].
The studies reported 42 different outcome measures, but only 14 showed a statistical
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advantage for an antidepressant over placebo. None of the 10 measures relying on patient
or parent reported outcomes showed a statistically significant advantage for an antide-
pressant. None of the studies presented data on rates of (attempted) self-harm, presenta-
tions to emergency or mental health services. Of the six placebo-controlled studies, only
two found statistically significant advantages in antidepressants over placebo on primary
outcomes. However, in one of these studies, the reported primary outcome differed from
the pre-specified outcome in the study protocol[Emslie et al., 1997] (for study 329, the
authors used the non-significant protocol-specified primary outcomes; they were not able
to calculate these for the study [Emslie et al., 1997]).
As in study 329, the trial by Wagner and colleagues [Wagner et al., 2003] failed to re-
port a statistically significant increase in serious adverse events in patients on an SSRI. In
their study on sertraline, 17/189 patients treated with sertraline withdrew because of ad-
verse events, compared to 5/184 in the placebo group (p=0.01). Despite these results they
concluded that ”sertraline is an effective, safe, and well tolerated short-term treatment for
children and adolescents”. The rates for serious adverse events (9% in the Wagner study,
12% in the Keller study [Keller et al., 2001]) are likely to be underestimates of the true
rates [Herxheimer and Mintzes, 2004, Ioannidis and Lau, 2001].
All trials suffered from high withdrawal rates, ranging from 17% to 32% for patients
treated with SSRIs, and from 17% to 46% for patients treated with placebo. These rates
are particularly high when the short study periods (6-10 weeks) are taken into account.
Moreover, as most studies used an intention to treat, last observation carried forward
approach in their analysis, these high withdrawal rates could have introduced bias5.
In addition, most trials used categorical outcomes (yes/no depression, or response
vs. non-response), which are likely to inflate small differences between groups [Kirsch,
2003]. Moreover, unblinding due to the high prevalence of side effects in SSRI users
5The last observation carried forward approach is based on the assumption that the condition of patients
who have dropped out would have remained unchanged for the remainder of the study, had they continued in
it. If patients in one arm, for instance the placebo arm, were more likely to drop out, their last observations
(that are likely to still show increased scores on depression questionnaires) will be used in the final analysis,
and could skew the results towards showing an advantage in the other group, in our case the SSRI group.
B.1. Evidence from randomised clinical trials 197
may have also inflated the effects of the antidepressants studied6. Finally, the study by
Wagner and colleagues [Wagner et al., 2003] is described as two clinical trials, although
both use identical methods and are treated as a single trial in the analysis in order to
have adequate statistical power to detect small differences between treatments. Neither
trial individually showed a statistically significant advantage for sertraline over placebo
in terms of the primary endpoint, although combined the effect (2.7 points on a 113 point
scale) is statistically significant.
Despite important flaws in the methodology and reporting of these randomized con-
trolled trials, an increased risk of suicidal behaviour for adolescents and young adults
is found consistently [Hammad et al., 2006]. A recent Cochrane review found evid-
ence of an increased risk (RR: 1.58; 95% CI 1.02-2.45) of suicide-related outcomes for
children and adolescents on antidepressants compared with placebo (based on 17 trials;
N=3229) [Hetrick et al., 2012]. However, the reviewers deemed the evidence for this
association to be of low quality.
Overall, the results from these trials should be interpreted with caution as they were
not primarily designed to measure suicidal behaviour and it would be unethical to do so.
Moreover, none of these trials on SSRIs recruited from general population setting: com-
pared to those included in clinical trials, clinical patients tend to have more co-morbidities
and be more severely ill. Also, patients with (a history of) suicidal behaviour are often
excluded from entering trials. As a possible result from this, no trials have reported a
completed suicide [Hammad et al., 2006]. Furthermore, most trials had methodological
flaws such as high attrition rates, issues regarding measurement instruments and clinical
6A Cochrane review that compared antidepressant trials that used active placebos (placebos that cause
side effects) versus inert placebos, found that the latter reported higher efficacy of antidepressants [Mon-
crieff et al., 2004]. Trial patients who experience side effects will be strengthened in their belief that they
are assigned to the treatment group, and will thus experience a stronger placebo effect. The placebo effect
in paediatric antidepressant trials is important, as the differences between patients on treatment compared
to those on placebo tend to small (statistically, but not clinically significant). For instance, Emslie and
colleagues found that fluoxetine led to a 22-point decrease on the CDRS-R, while placebo led to a 15-point
decrease [Emslie et al., 2002].
B.2. Evidence from observational studies 198
usefulness of outcomes, often variously defined across trials. Finally, the usual length for
clinical trials is 8 to 12 weeks, while clinical treatment is recommended for at least six
months by the National Institute for Health and Clinical Excellence (NICE) guidelines.
B.2 Evidence from observational studies
Large scale post-licensure medical product safety surveillance is important for detecting
adverse events potentially not identified in pre-licensure studies, which often lack power
for rare outcomes, enrol relatively restricted populations, and provide little information
about longer-term adverse effects [Nelson et al., 2011].
Observational studies in young people have found mixed results. An ecological
study examining US and Dutch data found that while SSRI prescriptions decreased in
both countries following the warnings regarding paediatric SSRI use, suicide rates for
children and adolescents increased [Gibbons et al., 2007]. However, the trends in SSRI
prescriptions and suicide rates started changing at different time points, making an asso-
ciation less probable [Jureidini, 2007].
Although different regulators have warned against the use of different antidepress-
ants and antidepressant groups, observational research has found no significant variations
in event rates of suicidal behaviour in children taking various antidepressants [Schnee-
weiss et al., 2010]. The study by Schneeweiss et al. used propensity scores [Rubin, 1997]
to be able to compare similar patients and partially taking confounding by indication
into account. Their finding of no meaningful differences between fluoxetine, citalopram,
fluvoxamine, paroxetine, sertraline or TCAs supports the FDA’s decision that all antide-
pressants should be treated equally in a warning. However, as they did have a control
group, they were unable to examine whether rates for suicidal behaviour were increased
by antidepressants.
A matched case-control study using GPRD UK primary care data on 159,810 anti-
depressant users also found that the risk of suicidal behaviour was similar among users
of amitriptyline, fluoxetine, and paroxetine compared with the risk of dosulepin, which
was used as a reference antidepressant [Jick et al., 2004]. However, the study did find
that the risk of suicidal behaviour was increased in the first month after prescriptions star-
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ted, especially in the first nine days. The data for this study stems from 1993 to 1999.
Although antidepressants were prescribed regularly to adults during this time period, pre-
scriptions for children were still relatively rare (ref to results from chapter 4). Moreover,
dosulepin is no longer used as an antidepressant today, resulting in the comparison being
less informative.
Another matched case-control study, using US Medicaid7 data, tried to assess risk
of suicidal behaviour for both children and adults [Olfson et al., 2006]. Although suicide
attempts and suicide deaths were not associated with antidepressants in adults (ORs 1.10
and 0.90, respectively), there was a significant association for suicide attempts (OR 1.52;
95% CI: 1.12-2.07) and completed suicides (OR 15.62 95% CI: 1.65 - ) for children aged
6 18 years. This estimate might be biased by confounding by severity. Given the risk
of death in overdose, the lack of efficacy in children, and the side effects associated with
them, a prescriber would be less likely to prescribe TCAs in preference to SSRIs for a
person at risk of suicidal behaviour [Didham et al., 2005].
The finding of age-dependent effects of antidepressants is supported by animal stud-
ies, which have shown that both fluoxetine and paroxetine exert age-dependent effects
in rats. In adolescent, as opposed to adult rats, exposure to these drugs resulted in an
increase in depression-like behaviour [Homberg et al., 2011, West et al., 2010].
B.3 Evidence for the efficacy of antidepressants
A Cochrane review assessed the available evidence for the efficacy of second generation
antidepressants in children and adolescents [Hetrick et al., 2012]. The review included
19 trials, 14 of which provided useable data on efficacy. The results from these trials are
summarised in Figure B.3. The trials included in this meta-analysis reported the mean
difference in depression scores from baseline as measured on the Children’s Depression
Rating Scale, Revised (CDRS-R), ranging from a minimum score of 17 (not depressed)
to 113 (severely depressed). Although the pooled effect favours antidepressants over
placebo, the mean difference is very small at -3.51 points (95% CI: -4.55 to -2.47).
In addition to a small effect size, none of the included studies were judged to be at
7Medicaid is the US health program for certain people and families with low incomes and resources.
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low risk of bias. Selective reporting was a particular problem in the included trials, with
18 of the included trials at high risk of this type of bias. As such, the review concluded
that the evidence that antidepressants can decrease depressive symptom scores is of low
quality.
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Figure B.3: Forest plot comparing second generation antidepressants versus placebo.
Outcome: depression symptoms severity (CDRS-R).
Appendix C
Stata do-files and resulting code lists
C.1 Stata do-file for creating depression code list
***************************************
****DEPRESSION code list update****
***************************************
*AUTHOR: LINDA WIJLAARS
*CREATED: JANUARY 2011
*THIN-VERSION: 1005
*UPDATED OLD CODELIST (THIN 0806?)
*VERSION 2.0
*UPDATED FOR THIN1011 (DECEMBER 2011) / STATA12.0
set more off
local path "C:\data\THIN10_1005\Codes/"
local path2 "C:\data\THIN1011\"
/*SEARCH FOR WORDS RELATING TO DEPRESSION
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IN FULL READCODE LIST*/
use "‘path2’Readcodes1101", clear
duplicates drop medcode, force
gen lcase=lower(description)
gen depress=0
foreach word in "depression" "depressed" "depressive" ///
"affective disorder" "affective illness" "dysthymia" {
replace depress=depress|strpos(lcase, "‘word’")
}
drop lcase
/*EYEBALL THE RESULTS FOR COMMON STEMS IN THE READCODE*/
sort depress medcode
foreach word in "1B17.12" /// C/O - feeling unhappy
"1BP..00" /// Loss of interest
"1BP0.00" /// Loss of interest in previously
enjoyable activity
"1BT..11" /// Low mood
"1BT..12" /// Sad mood
"1BU..00" /// Loss of hope for the future
"1BQ..00" /// Loss of capacity for enjoyment
"Eu33200" /// [X]Recurr depress disorder
cur epi severe without psyc sympt
"Eu32211" /// [X]Endogenous depression
without psychotic symptoms
"Eu3y011" /// [X]Mixed affective episode
{
replace depress=depress|strpos(medcode, "‘word’")
C.1. Stata do-file for creating depression code list 204
}
/*DROP CODES THAT ARE NOT RELATED TO DEPRESSION*/
keep if depress
/*CREATE NEW INDICATOR VARIALBE FOR CODES THAT
SHOULD BE EXCLUDED (EG THOSE RELATING TO FAMILY HISTORY
OR QUESTIONNAIRES)*/
gen lcase=lower(description)
gen out=0
foreach word in ///
"scale" "fh" "member" "h/o" "resolved" "score" ///
"screen" "question" "management" "advice" "review" ///
"letter" "monitoring" "except" "administration" ///
"senile" "remission" "beck" "history" "bipolar" ///
"manic-depressive" "manic-depression" "psychosis"{
replace out=out|strpos(lcase, "‘word’")
}
drop lcase
/*CHECK CODES PICKED UP IN LAST STEP
AND DELETE THEM FROM LIST*/
sort out depress medcode
replace out=0 if medcode=="E112300" | medcode=="E113300"
keep if out!=1
/*REMOVE CODES NOT RELATING TO DEPRESSION
(EG ECG DEPRESSION/SKULL DEPRESSION)*/
foreach word in "32E4.00" /// ECG: S-T depression
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"6G00.00" /// Postnatal depression counselling
"7J02200" /// Elevation of depressed fracture of cranium
"8HHq.00" /// Referall for guided self-help for depression
"9HA1.00" /// Removed from depression register
"D41y300" /// Bone marrow depression
"E004300" /// Arteriosclerotic dementia with depression
"E02y300" /// Drug-induced depressive state
"E11..12" /// Depressive psychoses
"Eu20400" /// [X]Post-schizophrenic depression
"Eu25.00" /// [X]Schizoaffective disorders
"Eu25000" /// [X]Schizoaffective disorder, manic type
"Eu25100" /// [X]Schizoaffective disorder, depressive type
"Eu25200" /// [X]Schizoaffective disorder, mixed type
"Eu25y00" /// [X]Other schizoaffective disorders
"Eu25z00" /// [X]Schizoaffective disorder, unspecified
"PE03.00" /// Depressions in skull
"Q018.00" /// Fetus or neonate affected by
maternal postnatal depression
"Q482000" /// Newborn cerebral depression
"R007z13" /// [D]Postoperative depression
"S03z.11" /// Depressed skull fracture NOS
"ZRrI.00" /// Wakefield self-assessment depression inventory
{
replace depress=depress & !strpos(medcode, "‘word’")
}
/*REMOVE OBSELETE CODES*/
keep if depress
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drop depress out
label define depcat 1 "Diagnosis" 2 "Symptom" 3 "Antidepressant"
label values depcat depcat
replace DepCat=4 if medcode=="1BT..12" | medcode=="1JJ..00"
drop if DepCat==.
drop DepCat
save "’path‘Depression_THIN1011.dta", replace
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C.2 Depression code list
Read code Description Category
1B17.00 Depressed Diagnosis
1BT..00 Depressed mood Diagnosis
2257.00 O/E - depressed Diagnosis
62T1.00 Puerperal depression Diagnosis
8BK0.00 Depression management programme Diagnosis
9HA0.00 On depression register Diagnosis
9k40.00 Depression - enhanced service completed Diagnosis
9kQ..00 On full dose long term treatment depression - enh serv admin Diagnosis
9kQ..11 On full dose long term treatment for depression Diagnosis
E112.00 Single major depressive episode Diagnosis
E112.11 Agitated depression Diagnosis
E112.12 Endogenous depression first episode Diagnosis
E112.13 Endogenous depression first episode Diagnosis
E112.14 Endogenous depression Diagnosis
E112000 Single major depressive episode, unspecified Diagnosis
E112100 Single major depressive episode, mild Diagnosis
E112200 Single major depressive episode, moderate Diagnosis
E112300 Single major depressive episode, severe, without psychosis Diagnosis
E112500 Single major depressive episode, partial or unspec remission Diagnosis
E112z00 Single major depressive episode NOS Diagnosis
E113.00 Recurrent major depressive episode Diagnosis
E113.11 Endogenous depression - recurrent Diagnosis
E113000 Recurrent major depressive episodes, unspecified Diagnosis
E113100 Recurrent major depressive episodes, mild Diagnosis
E113200 Recurrent major depressive episodes, moderate Diagnosis
continued on next page
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Read code Description Category
E113300 Recurrent major depressive episodes, severe, no psychosis Diagnosis
E113500 Recurrent major depressive episodes,partial/unspec remission Diagnosis
E113700 Recurrent depression Diagnosis
E113z00 Recurrent major depressive episode NOS Diagnosis
E118.00 Seasonal affective disorder Diagnosis
E11y200 Atypical depressive disorder Diagnosis
E11z200 Masked depression Diagnosis
E135.00 Agitated depression Diagnosis
E200300 Anxiety with depression Diagnosis
E204.00 Neurotic depression reactive type Diagnosis
E204.11 Postnatal depression Diagnosis
E290.00 Brief depressive reaction Diagnosis
E290z00 Brief depressive reaction NOS Diagnosis
E291.00 Prolonged depressive reaction Diagnosis
E2B..00 Depressive disorder NEC Diagnosis
E2B0.00 Postviral depression Diagnosis
E2B1.00 Chronic depression Diagnosis
Eu32.00 [X]Depressive episode Diagnosis
Eu32.11 [X]Single episode of depressive reaction Diagnosis
Eu32.12 [X]Single episode of psychogenic depression Diagnosis
Eu32.13 [X]Single episode of reactive depression Diagnosis
Eu32000 [X]Mild depressive episode Diagnosis
Eu32100 [X]Moderate depressive episode Diagnosis
Eu32200 [X]Severe depressive episode without psychotic symptoms Diagnosis
Eu32211 [X]Single episode agitated depressn w’out psychotic symptoms Diagnosis
Eu32212 [X]Single episode major depression w’out psychotic symptoms Diagnosis
continued on next page
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Read code Description Category
Eu32213 [X]Single episode vital depression w’out psychotic symptoms Diagnosis
Eu32400 [X]Mild depression Diagnosis
Eu32500 [X]Major depression, mild Diagnosis
Eu32600 [X]Major depression, moderately severe Diagnosis
Eu32700 [X]Major depression, severe without psychotic symptoms Diagnosis
Eu32y00 [X]Other depressive episodes Diagnosis
Eu32y11 [X]Atypical depression Diagnosis
Eu32y12 [X]Single episode of masked depression NOS Diagnosis
Eu32z00 [X]Depressive episode, unspecified Diagnosis
Eu32z11 [X]Depression NOS Diagnosis
Eu32z12 [X]Depressive disorder NOS Diagnosis
Eu32z13 [X]Prolonged single episode of reactive depression Diagnosis
Eu32z14 [X] Reactive depression NOS Diagnosis
Eu33.00 [X]Recurrent depressive disorder Diagnosis
Eu33.11 [X]Recurrent episodes of depressive reaction Diagnosis
Eu33.12 [X]Recurrent episodes of psychogenic depression Diagnosis
Eu33.13 [X]Recurrent episodes of reactive depression Diagnosis
Eu33.14 [X]Seasonal depressive disorder Diagnosis
Eu33.15 [X]SAD - Seasonal affective disorder Diagnosis
Eu33000 [X]Recurrent depressive disorder, current episode mild Diagnosis
Eu33100 [X]Recurrent depressive disorder, current episode moderate Diagnosis
Eu33200 [X]Recurr depress disorder cur epi severe without psyc sympt Diagnosis
Eu33211 [X]Endogenous depression without psychotic symptoms Diagnosis
Eu33212 [X]Major depression, recurrent without psychotic symptoms Diagnosis
Eu33214 [X]Vital depression, recurrent without psychotic symptoms Diagnosis
Eu33y00 [X]Other recurrent depressive disorders Diagnosis
continued on next page
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Read code Description Category
Eu33z00 [X]Recurrent depressive disorder, unspecified Diagnosis
Eu33z11 [X]Monopolar depression NOS Diagnosis
Eu34.00 [X]Persistent mood affective disorders Diagnosis
Eu34100 [X]Dysthymia Diagnosis
Eu34111 [X]Depressive neurosis Diagnosis
Eu34113 [X]Neurotic depression Diagnosis
Eu34114 [X]Persistant anxiety depression Diagnosis
Eu34y00 [X]Other persistent mood affective disorders Diagnosis
Eu34z00 [X]Persistent mood affective disorder, unspecified Diagnosis
Eu3y111 [X]Recurrent brief depressive episodes Diagnosis
Eu41200 [X]Mixed anxiety and depressive disorder Diagnosis
Eu41211 [X]Mild anxiety depression Diagnosis
Eu53011 [X]Postnatal depression NOS Diagnosis
Eu53012 [X]Postpartum depression NOS Diagnosis
R007z13 [D]Postoperative depression Diagnosis
13JK.00 Business worries Symptom
13JK.14 Work worries Symptom
13JM.14 Work worries Symptom
1B1..00 General nervous symptoms Symptom
1B12.00 ’Nerves’ - nervousness Symptom
1B12.11 ’Nerves’ Symptom
1B12.12 Tension - nervous Symptom
1B13.00 Anxiousness Symptom
1B13.11 Anxiousness - symptom Symptom
1B17.11 C/O - feeling depressed Symptom
1B17.12 C/O - feeling unhappy Symptom
continued on next page
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Read code Description Category
1B1U.00 Symptoms of depression Symptom
1B1U.11 Depressive symptoms Symptom
1BK..00 Worried Symptom
1BP..00 Loss of interest Symptom
1BP0.00 Loss of interest in previously enjoyable activity Symptom
1BQ..00 Loss of capacity for enjoyment Symptom
1BT..11 Low mood Symptom
1BU..00 Loss of hope for the future Symptom
E201.00 Hysteria Symptom
E201000 Hysteria unspecified Symptom
E201z00 Hysteria NOS Symptom
Eu41112 [X]Anxiety reaction Symptom
R2y2.00 [D]Nervousness Symptom
R2y2.11 [D]Nerves Symptom
R2y2.12 [D]Nervous tension Symptom
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C.3 Stata do-file for creating antidepressant code list
***************************************
****ANTIDEPRESSANT code list update****
***************************************
*AUTHOR: LINDA WIJLAARS
*CREATED: FEBRUARY 2011
*THIN-VERSION: 1005
*UPDATED OLD CODELIST (THIN 0806?)
*VERSION 2.0
*UPDATED FOR THIN1011 (DECEMBER 2011) / STATA12.0
set more off
local path "C:\data\THIN1011\"
local path2 "C:\data\THIN10_1005\Codes\"
/*SELECT DRUGCODES THAT APPEAR IN BNF CHAPTER 4.3 (ANTIDEPRESSANTS)*/
use "‘path’Drugcodes1101", clear
keep if substr(bnfcode1,1,5)=="04.03" |substr(bnfcode2,1,5)=="04.03" ///
| substr(bnfcode3,1,5)=="04.03"
/*HOUSEKEEPING */
duplicates drop
rename multilexeid drugcode
tostring drugcode, replace
/*MAKE ’STRENGTH’ INTO A NUMERICAL VARIABLE*/
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destring strength, replace
/*MERGE ’NEW’ CODELIST WITH ’OLD’ CODELIST*/
merge m:1 drugcode using "‘path2’all_antidepressants_2010_string"
replace merge=4 if merge==.
label define _merge 4 "Code added December 2011", modify
/*GENERATE INDICATOR VARIABLE FOR TYPE AND LABEL*/
*gen type=0
replace type=1 if bnfcode1=="04.03.01.00" | bnfcode2=="04.03.01.00" ///
| bnfcode3=="04.03.01.00"
replace type=2 if bnfcode1=="04.03.02.00" | bnfcode2=="04.03.02.00" ///
| bnfcode3=="04.03.02.00"
replace type=3 if bnfcode1=="04.03.03.00" | bnfcode2=="04.03.03.00" ///
| bnfcode3=="04.03.03.00"
replace type=4 if bnfcode1=="04.03.04.00" | bnfcode2=="04.03.04.00" ///
| bnfcode3=="04.03.04.00"
*label define typemap 1 "Tricyclic antidepressant" ///
2 "Monoamine-oxidase inhibitor" 3 "SSRI" 4 "Other"
*label values type typemap
/*CHECK WHETHER ALL CODES CORRESPOND TO A DRUG TYPE*/
tab type, missing
*no missings
sort _merge genericname
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drop _merge
*GENERATE DRUGNAME VARIABLE FOR ’NEW’ DRUGS*
generate b=strpos(genericname, " ")
generate drug_name2=substr(genericname,1,b-1)
replace drug_name2=genericname if b==0
drop b
*drug_name is a numeric variable with labels attached for each drug
*the added drugs also need to be assigned a value corresponding
to the earlier created labels + 2 new labels for new drugs*
drop drug_name2
*save new file*
compress
save "C:\data\THIN10_1005\Codes\all_antidepressants_2011.dta", replace
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C.4 Antidepressant code list
This is a sample of antidepressant codes, the full contains 800 drug codes. Here, I have
included only one code for each drug. Each drug has multiple codes in the full list,
representing different manufacturers, doses, and formulations.
multilexid BNF chapter 1 BNF chapter 2 ATC code Type Drug name
99861989 04.03.01.00 00.00.00.00 N06A A09 TCA AMITRIPTYLINE
97814988 04.03.01.00 00.00.00.00 N06A A04 TCA CLOMIPRAMINE
94145992 04.03.01.00 00.00.00.00 N06A A16 TCA DOSULEPIN
84904998 04.03.01.00 00.00.00.00 TCA DOXEPIN
95695997 04.03.01.00 00.00.00.00 N06A A10 TCA NORTRIPTYLINE
98077990 04.03.01.00 00.00.00.00 N06A A07 TCA LOFEPRAMINE
95927998 04.03.01.00 00.00.00.00 N06A A21 TCA MAPROTILINE
99492989 04.03.01.00 00.00.00.00 N06A X03 TCA MIANSERIN
92271990 04.03.01.00 00.00.00.00 N06A X05 TCA TRAZODONE
98136996 04.03.01.00 00.00.00.00 N06A A06 TCA TRIMIPRAMINE
94683990 04.03.01.00 00.00.00.00 N06A A02 TCA IMIPRAMINE
94008998 04.03.01.00 00.00.00.00 N06A A17 TCA AMOXAPINE
98134998 04.03.01.00 00.00.00.00 N06A A15 TCA BUTRIPTYLINE
98146998 04.03.01.00 00.00.00.00 N06A A01 TCA DESIPRAMINE
96637992 04.03.01.00 00.00.00.00 TCA DIBENZEPIN
96109997 04.03.01.00 00.00.00.00 N06A A13 TCA IPRINDOLE
97807992 04.03.01.00 00.00.00.00 TCA NOMIFENSINE
97827992 04.03.01.00 00.00.00.00 TCA OPIPRAMOL
TCA = tricyclic antidepressant
MAOI = mono-amine oxidase inhibitor
SSRI = selective serotonin reuptake inhibitor
continued on next page
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multilexid BNF chapter 1 BNF chapter 2 ATC code Type Drug name
95372998 04.03.01.00 00.00.00.00 N06A A11 TCA PROTRIPTYLINE
95624998 04.03.01.00 00.00.00.00 N06A X09 TCA VILOXAZINE
98327992 04.03.01.00 00.00.00.00 TCA ZIMELDINE
83620998 04.03.01.00 00.00.00.00 N06C A01 TCA PERPHENAZINE
93759998 04.03.02.00 00.00.00.00 N06A G02 MAOI MOCLOBEMIDE
99377998 04.03.02.00 00.00.00.00 N06A F03 MAOI PHENELZINE
96107998 04.03.02.00 00.00.00.00 N06A F05 MAOI IPRONIAZID
97169990 04.03.02.00 00.00.00.00 N06A F01 MAOI ISOCARBOXAZID
95143998 04.03.02.00 00.00.00.00 N06C MAOI TRANYLCYPROMINE
87662998 04.03.03.00 00.00.00.00 N06A B10 SSRI ESCITALOPRAM
94895990 04.03.03.00 00.00.00.00 N06A B04 SSRI CITALOPRAM
96281990 04.03.03.00 00.00.00.00 N06A B03 SSRI FLUOXETINE
96493998 04.03.03.00 00.00.00.00 N06A B08 SSRI FLUVOXAMINE
92734990 04.03.03.00 00.00.00.00 N06A B05 SSRI PAROXETINE
93747990 04.03.03.00 00.00.00.00 N06A B06 SSRI SERTRALINE
82038998 04.03.03.00 00.00.00.00 SSRI DAPOXETINE
99634998 04.03.04.00 04.02.01.00 N05A F01 Other FLUPENTIXOL
86982998 04.03.04.00 00.00.00.00 N06A X11 Other MIRTAZAPINE
91362996 04.03.04.00 00.00.00.00 N06A X06 Other NEFAZODONE
88836998 04.03.04.00 00.00.00.00 N06A X18 Other REBOXETINE
98257998 04.03.04.00 00.00.00.00 N06A X02 Other TRYPTOPHAN
82540998 04.03.04.00 00.00.00.00 N06A X16 Other VENLAFAXINE
86998998 04.03.04.00 00.00.00.00 N06A X21 Other DULOXETINE
TCA = tricyclic antidepressant
MAOI = mono-amine oxidase inhibitor
SSRI = selective serotonin reuptake inhibitor
continued on next page
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multilexid BNF chapter 1 BNF chapter 2 ATC code Type Drug name
94663992 04.03.04.00 00.00.00.00 Other TRYPTOPHARYPTOPHA
82861998 04.03.04.00 00.00.00.00 N06A X22 Other AGOMELATINE
TCA = tricyclic antidepressant
MAOI = mono-amine oxidase inhibitor
SSRI = selective serotonin reuptake inhibitor
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C.5 Sleep disorder code list
Read code Description Category
1B1B.00 Cannot sleep - insomnia Insomnia
1B1B.11 C/O - insomnia Insomnia
1B1B000 Initial insomnia Insomnia
1B1B100 Middle insomnia Insomnia
1B1B200 Late insomnia Insomnia
1BX0.00 Delayed onset of sleep Insomnia
E274.12 Insomnia due to nonorganic sleep disorder Insomnia
E274100 Transient insomnia Insomnia
E274111 Insomnia NOS Insomnia
E274200 Persistent insomnia Insomnia
E274B00 Repeated rapid eye movement sleep interruptions Insomnia
E274C00 Other sleep stage or arousal dysfunction Insomnia
E274D00 Repetitive intrusions of sleep Insomnia
E274D11 Restless sleep Insomnia
Eu51000 [X]Nonorganic insomnia Insomnia
Fy00.00 Disorders of initiating and maintaining sleep Insomnia
R005.00 [D]Sleep disturbances Insomnia
R005.11 [D]Insomnia - symptom Insomnia
R005100 [D]Insomnia with sleep apnoea Insomnia
R005200 [D]Insomnia NOS Insomnia
R005800 [D]Sleep dysfunction with sleep stage disturbance Insomnia
R005900 [D]Sleep dysfunction with arousal disturbance Insomnia
R005z00 [D]Sleep dysfunction NOS Insomnia
Z1M1.00 Disturbing sleep Insomnia
1B1B.12 C/O - somnolence Exessive daytime sleepiness
continued on next page
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Read code Description Category
1BX1.00 Excessive sleep Exessive daytime sleepiness
E274.11 Hypersomnia of non-organic origin Exessive daytime sleepiness
E274300 Transient hypersomnia Exessive daytime sleepiness
E274311 Hypersomnia NOS Exessive daytime sleepiness
E274400 Persistent hypersomnia Exessive daytime sleepiness
E274A00 Sleep drunkenness Exessive daytime sleepiness
Eu51100 [X]Nonorganic hypersomnia Exessive daytime sleepiness
F27..00 Cataplexy and narcolepsy Exessive daytime sleepiness
F271.00 Narcolepsy Exessive daytime sleepiness
F27z.00 Cataplexy or narcolepsy NOS Exessive daytime sleepiness
Fy01.00 Disorders of excessive somnolence Exessive daytime sleepiness
R000000 [D]Drowsiness Exessive daytime sleepiness
R000100 [D]Somnolence Exessive daytime sleepiness
R005300 [D]Hypersomnia with sleep apnoea Exessive daytime sleepiness
R005400 [D]Hypersomnia NOS Exessive daytime sleepiness
E274600 Shifting sleep-work schedule Sleep rhythm problem
E274F00 Inversion of sleep rhythm Sleep rhythm problem
Eu51200 [X]Nonorganic disorder of the sleep-wake schedule Sleep rhythm problem
Eu51211 [X]Psychogenic inversion of circadian rhythm Sleep rhythm problem
Eu51212 [X]Psychogenic inversion of nyctohemeral rhythm Sleep rhythm problem
Eu51213 [X]Psychogenic inversion of sleep rhythm Sleep rhythm problem
Fy02.00 Disorders of the sleep-wake schedule Sleep rhythm problem
R005.12 [D]Sleep rhythm problems Sleep rhythm problem
R005500 [D]Sleep rhythm inversion Sleep rhythm problem
R005600 [D]Sleep rhythm irregular Sleep rhythm problem
R005700 [D]Sleep-wake rhythm non-24-hour cycle Sleep rhythm problem
continued on next page
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Read code Description Category
1B1D.00 C/O nightmares Sleep-disruptive behaviors
1B1D.11 Nightmares - symptom Sleep-disruptive behaviors
1BN1.00 Wanders at night Sleep-disruptive behaviors
1BN2.00 Wanders during the day and at night Sleep-disruptive behaviors
E26y000 Bruxism (teeth grinding) Sleep-disruptive behaviors
E274700 Somnambulism - sleep walking Sleep-disruptive behaviors
E274800 Night terrors Sleep-disruptive behaviors
E274900 Nightmares Sleep-disruptive behaviors
Eu51300 [X]Sleepwalking Sleep-disruptive behaviors
Eu51400 [X]Sleep terrors Sleep-disruptive behaviors
Eu51500 [X]Nightmares Sleep-disruptive behaviors
Eu51511 [X]Dream anxiety disorder Sleep-disruptive behaviors
F13z200 Restless legs syndrome Sleep-disruptive behaviors
8G99.00 Sleep restriction therapy Other / NOS
8G9B.00 Sleep hygiene behaviour education Other / NOS
8HTn.00 Referral to sleep clinic Other / NOS
8Q0..00 Sleep management Other / NOS
9Nk0.00 Seen in sleep clinic Other / NOS
E274.00 Non-organic sleep disorders Other / NOS
E274000 Unspecified non-organic sleep disorder Other / NOS
E274y00 Other non-organic sleep disorder Other / NOS
E274z00 Non-organic sleep disorder NOS Other / NOS
Eu51.00 [X]Nonorganic sleep disorders Other / NOS
Eu51y00 [X]Other nonorganic sleep disorders Other / NOS
Eu51z00 [X]Nonorganic sleep disorder, unspecified Other / NOS
Eu51z11 [X]Emotional sleep disorder NOS Other / NOS
continued on next page
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Read code Description Category
Fy0..00 Sleep disorders Other / NOS
Fyu5800 [X]Other sleep disorders Other / NOS
R005000 [D]Sleep disturbance, unspecified Other / NOS
Appendix D
Mediation analysis
D.1 Classic mediation analysis
In most epidemiological studies, confounders for the exposure-outcome association are
measured and adjusted for. However, for mediation analysis it is also important to con-
sider mediator-outcome confounders. If these confounders are not controlled for then
results from the classic approach can be highly biased [Herna´ndez-Dı´az et al., 2006,
Pearl, 2001].
An example of when classic mediation analysis leads to biased results is the so
called ’birth weight paradox’ [Herna´ndez-Dı´az et al., 2006]. Smoking during pregnancy
is associated with an increased risk of low birth weight (LBW) infants, and low birth
weight in turn, is associated with increased infant mortality. Smoking during pregnancy
is also associated with an increase in the risk of infant mortality. However, when birth
weight is included in the analysis as a mediator, the effect of smoking on infant mortality
is reversed. Studies have found that among groups of LBW infants, maternal smoking
during pregnancy is actually a protective factor: the relative rate of mortality if reduced
by 20% for LBW infants of smoking mothers.
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Low birth weightSmoking Infant mortality
Birth defects
Figure D.1: The birth weight paradox
However, this apparent risk reduction is due to mediator-outcome confounding by
covariates such as birth defects (Figure D.1). LBW infants born to smokers may have a
lower risk of mortality than other LBW infants whose LBW is due to causes associated
with high mortality such as birth defects. Only when mediator-outcome confounding by
birth defects is taking into account (or when birth weight is not included as a mediator) a
correct estimate can be provided.
The importance of controlling for mediator-outcome confounding when examining
direct and indirect effects was also pointed out early on in the psychology literature on
mediation in a paper by Judd and Kenny from 1981 [Judd and Kenny, 1981]. How-
ever, a paper on the same subject published five years later by Baron and Kenny [Baron
and Kenny, 1986] became the go-to paper for researchers interested in mediation ana-
lysis. The second paper has been cited almost 40,000 times according to Google Scholar
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(compared to just over 1,000 for the first paper) and unfortunately does not mention that
mediator-outcome confounding is a limitation to the classic mediation approach. As a
result, many papers using this approach do not consider this type of confounding and are
thus at risk of bias [VanderWeele and Vansteelandt, 2010].
The second limitation to the classic approach is that it doesn’t allow for exposure-
mediator interaction. Usually, exposure-mediator interaction terms are not considered
for the regression models in mediation analysis. If interaction is present, it could severely
bias the results.
Moreover, even if the interaction term is included in the regression analysis, part
of the problem remains. As the exposure is linked to two coefficients in a regression
model including an interaction term (both the coefficient linked to the exposure, and
the coefficient for the exposure-mediator interaction) it is not possible to quantify the
mediation. Thus, in the case of exposure-mediator interaction, the classic approach will
give biased results.
D.2 Results: classic mediation analysis
In order to explore whether the limitations of the classic method for mediation analysis
would affect the outcome of my proposed analysis, I’ve have performed this analysis as
well (Table D.1). The coefficient estimates for the exposure (presented in their exponen-
tiated form as Incidence Rate Ratios (IRRs) to make them more readily interpretable) are
very similar between the two models. The IRR for children in families where one parent
experiences depression is 1.39 (95% CI: 0.90-2.14) in the model without the potential
mediator, and 1.40 (95% CI: 0.89-2.19) in the model with the potential mediator. Simil-
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arly, the IRRs for children in families where both parents experience early depression are
comparable (IRR = 1.93, 95% CI: 0.49-7.62 and IRR = 1.78, 95% CI: 0.56-6.96) in the
models with and without the potential mediator.
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Variable
Model 1 Model 2
IRR (95% CI) P value IRR (95% CI) P value
Early parental depression
No EPD Reference Reference
One parent EPD 1.39 (0.90 - 2.14) 0.13 1.40 (0.89 - 2.19) 0.15
Comorbid EPD 1.93 (0.49 - 7.62) 0.35 1.78 (0.56 - 6.96) 0.41
Recurrent parental depression
No recurrent depression - - Reference
1-4 episodes - - 1.44 (1.11 - 1.87) 0.006
5-9 episodes - - 2.01 (1.36 - 2.97) <0.001
10+ episoded - - 0.88 (0.38 - 2.05) 0.77
Townsend score
1 (most affluent) Reference Reference
2 0.82 (0.58 - 1.15) 0.25 0.83 (0.59 - 1.17) 0.30
3 0.87 (0.60 - 1.24) 0.46 0.87 (0.61 - 1.23) 0.43
4 1.13 (0.79 - 1.61) 0.51 1.10 (0.77 - 1.57) 0.59
5 (most deprived) 1.39 (0.93 - 2.09) 0.11 1.32 (0.88 - 2.00) 0.18
Maternal age at birth 0.99 (0.95 - 1.02) 0.50 0.99 (0.96 - 1.03) 0.72
Paternal age at birth 1.02 (0.99 - 1.05) 0.14 1.02 (0.99 - 1.05) 0.14
Birth year 0.71 (0.66 - 0.76) <0.001 0.71 (0.66 - 0.76) <0.001
Child maltreatment 2.75 (1.77 - 4.27) <0.001 2.63 (1.70 - 4.06) <0.001
Illicit drug use 3.86 (0.34 - 44.32) 0.28 3.93 (0.40 - 38.15) 0.24
Alcohol abuse 1.22 (0.61 - 2.46) 0.57 1.17 (0.58 - 2.39) 0.66
Maternal comorbidity 1.00 (0.94 - 1.07) 0.92 0.99 (0.93 - 1.06) 0.86
Paternal comorbidity 1.12 (1.03 - 1.22) 0.01 1.11 (1.02 - 1.21) 0.02
Female child 2.50 (1.94 - 3.23) <0.001 2.54 (1.97 - 3.28) <0.001
Model 1: without recurrent parental depression; Model 2: with recurrent parental depression
Table D.1: Negative binomial regression analysis showing risk ratios for adolescent de-
pression in models with and without recurrent parental depression
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Following the classic approach’s reasoning, these results would indicate that recur-
rent parental depression is not a mediator in the association between early parental depres-
sion and adolescent depression as the estimates of the coefficients have not substantially
changed.
D.3 Counterfactual mediation analysis
I performed a counterfactual mediation analysis in Stata that allows for exposure-
mediator interaction to explore why the results from the classic approach differed from
those of the SEM modelling. This counterfactual approach has been developed by
VanderWeele and Vansteelandt [VanderWeele and Vansteelandt, 2009] and has been im-
plemented in SAS and SPSS [Valeri and VanderWeele, 2013], as well as in Stata [Emsley
and Liu, 2013].
Counterfactuals can be used in statistics to model outcomes that we are interested
in, but did not observe. For instance, imagine a simple clinical trial where participants
are randomised to either receive an active treatment, or a placebo. For each patient,
we can only observe one outcome: either associated with receiving the treatment or the
placebo. The first patient in the trial might have received the active treatment, and was
cured. What we want to know though, is what the outcome would have been if this
patient had not received the treatment: the counterfactual outcome. Is the outcome due to
patient-related factors, or due to the treatment? While it is impossible to directly observe
a counterfactual outcome, it is possible to estimate it on a population level. Using the
information of many patients with different characteristics, exposure and outcome levels,
counterfactual outcomes can be estimated.
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In counterfactual mediation analysis, counterfactuals are estimated for both the ex-
posure and the mediator. Two models are fitted to the data, one to model the outcome, and
another to separately model the mediator. This approach allows for mediator-outcome
confounding and can quantify exposure-mediator interaction, the two important limita-
tions of the classic mediation approach.
The results of this approach are shown in Table D.2. Interaction between early par-
ental depression and recurrent parental depression is modelled in the exposure-outcome
model and is non-significant (coefficient estimate: 0.26, 95% CI: -0.37 - 0.88; P value:
0.42). This appears to indicate that the differences between the results from the classic ap-
proach and SEM are not due to exposure-mediator interaction, but that mediator-outcome
confounding has biased the classic approach’s results.
Using counterfactual mediation analysis, it is also possible to estimate direct and
indirect effects. Two types of direct effect are estimated: the controlled and natural direct
effect. The controlled direct effect is the direct effect when the level of the mediator is
set to the same predetermined level for each individual, independent of the level of the
exposure. For instance, in my analysis, I have the mediator level to no parental recurrent
depression for all individuals. The model then estimates what the outcome for each in-
dividual would be for each level of early parental depression, if their parents would not
have experienced any episodes of depression during their childhood.
The natural direct effect is slightly different. Rather than setting the level of the
mediator at the same level for each individual, it models the mediator at the level it
would have naturally been (hence the name) for each counterfactual level of exposure.
The estimates for the controlled and natural direct effects are similar (0.55 and 0.64, re-
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1 depressed parent Comorbid depression
Estimate (95% CI) P value Estimate (95% CI) P value
Exposure-outcome model
Early parental depression (EPD) -0.60 (-1.60 - 0.40) 0.24 -0.60 (-1.60 - 0.40) 0.24
Recurrent depression 0.41 (0.22 - 0.60) <0.001 0.41 (0.22 - 0.60) <0.001
EPD × recurrent depression 0.26 (-0.37 - 0.88) 0.42 0.26 (-0.37 - 0.88) 0.42
Exposure-mediator model
EPD 2.38 (2.09 - 2.66) <0.001 0.41 (0.22 - 0.60) <0.001
Overall effect estimates
Controlled direct effect 0.55 (0.20 - 1.49) 0.24 0.30 (0.11 - 0.82) 0.02
Natural direct effect 0.64 (0.33 - 1.24) 0.18 0.41 (0.12 - 1.47) 0.17
Natural indirect effect 1.30 (1.06 - 1.60) 0.01 1.50 (1.01 - 2.23) 0.047
Marginal total effect 0.83 (0.50 - 1.38) 0.47 0.62 (0.23 - 1.63) 0.33
Table D.2: Counterfactual mediation analysis results for early parental depression
spectively) and neither reaches statistical significance. However, the natural indirect is
statistically significant (estimate: 1.30, 95% CI: 1.06 - 1.60; P value: 0.01), similar to
the SEM results. When assessing the total effect, the indirect and direct effects appear to
cancel each other out, resulting in a non-significant total effect.
Appendix E
MPlus SEM code
Title:
Stata2Mplus conversion for full_file.dta
Data:
File is full_file2.dat ;
Variable:
Names are
pnd c_dep_count c_sex c_townsend
outcome m_age f_age year maltreatment drug_abuse
drinker smi neg_life_evnt f_comorbidity m_comorbidity
abdopain headache tatt psychosomatic sleep anxiety dep_pre
id time ib10 ib13 par_dep;
usevariables are
pnd c_sex c_townsend
outcome m_age f_age year maltreatment
drug_abuse drinker f_comorbidity
m_comorbidity ib10 ib13;
Missing are all (-9999) ;
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categorical are ib10 ib13;
Model: outcome ON ib13 c_dep ib10 pnd c_sex c_townsend
m_age f_age year maltreatment drug_abuse
drinker f_comorbidity m_comorbidity;
ib13 ON c_dep ib10 pnd c_sex c_townsend m_age f_age
year maltreatment drug_abuse drinker
f_comorbidity m_comorbidity;
c_dep ON ib10 pnd c_sex c_townsend m_age f_age
year maltreatment drug_abuse drinker
f_comorbidity m_comorbidity;
ib10 ON pnd c_sex c_townsend m_age f_age year
maltreatment drug_abuse drinker
f_comorbidity m_comorbidity;
Analysis:
Type=general;
estimator=ML;
OUTPUT:
standardized sampstat ;
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Abstract
Background: In 2003, the Committee on Safety of Medicines (CSM) advised against treatment with selective serotonin
reuptake inhibitors (SSRIs) other than fluoxetine in children, due to a possible increased risk of suicidal behaviour. This study
examined the effects of this safety warning on general practitioners’ depression diagnosing and prescription behaviour in
children.
Methods and Findings: We identified a cohort of 1,502,753 children (,18 y; registered with GP for .6 m) in The Health
Improvement Network (THIN) UK primary care database. Trends in incidence of depression diagnoses, symptoms and
antidepressant prescribing were examined 1995–2009, accounting for deprivation, age and gender. We used segmented
regression analysis to assess changes in prescription rates. Overall, 45,723 (3%) children had $1 depression-related entry in
their clinical records. SSRIs were prescribed to 16,925 (1%) of children. SSRI prescription rates decreased from 3.2
(95%CI:3.0,3.3) per 1,000 person-years at risk (PYAR) in 2002 to 1.7 (95%CI:1.7,1.8) per 1,000 PYAR in 2005, but have since
risen to 2.7 (95%CI:2.6,2.8) per 1,000 PYAR in 2009. Prescription rates for CSM-contraindicated SSRIs citalopram, sertraline
and especially paroxetine dropped dramatically after 2002, while rates for fluoxetine and amitriptyline remained stable.
After 2005 rates for all antidepressants, except paroxetine and imipramine, started to rise again. Rates for depression
diagnoses dropped from 3.0 (95%CI:2.8,3.1) per 1,000 PYAR in 2002 to 2.0 (95%CI:1.9,2.1) per 1,000 PYAR in 2005 and have
been stable since. Recording of symptoms saw a steady increase from 1.0 (95%CI:0.8,1.2) per 1,000 PYAR in 1995 to 4.7
(95%CI:4.5,4.8) per 1,000 PYAR in 2009.
Conclusions: The rates of depression diagnoses and SSRI prescriptions showed a significant drop around the time of the
CSM advice, which was not present in the recording of symptoms. This could indicate caution on the part of GPs in making
depression diagnoses and prescribing antidepressants following the CSM advice.
Citation: Wijlaars LPMM, Nazareth I, Petersen I (2012) Trends in Depression and Antidepressant Prescribing in Children and Adolescents: A Cohort Study in The
Health Improvement Network (THIN). PLoS ONE 7(3): e33181. doi:10.1371/journal.pone.0033181
Editor: Kenji Hashimoto, Chiba University Center for Forensic Mental Health, Japan
Received December 15, 2011; Accepted February 5, 2012; Published March 13, 2012
Copyright:  2012 Wijlaars et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: LPW received support from the National Institute of Health Research English National School for Primary Care Research (http://www.nspcr.ac.uk/) for
the submitted work. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: linda.wijlaars.10@ucl.ac.uk
Introduction
Antidepressants (ADs) are commonly prescribed to children and
adolescents for depression, anxiety, and a variety of other disorder
[1]. Selective serotonin reuptake inhibitors (SSRIs), first intro-
duced in the late 1980s, were prescribed to children for depression
on the basis of effectiveness data from trials on adult psychiatric
disorders coupled with other trial data demonstrating the
ineffectiveness of tricyclic antidepressants (TCAs) [2–5]. In the
early 2000s, SSRIs became the preferred treatment for depression
in children rather than tricyclic antidepressants (TCAs) [6].
However, doubts have been cast on the use of specific SSRIs in
children. In October 2002, the BBC aired an episode of the
investigative journalism show ‘Panorama’ which casted doubt on
the safety of the SSRI paroxetine. In response to this, the UK
Medicines and Healthcare Products Regulatory Agency (MHRA)
reanalysed published and unpublished data on paroxetine, and
found that the drug failed to demonstrate significant beneficial
effects, and was associated with a small increase in suicidal
behaviour and ideation [7]. In June 2003, the MHRA hence
advised that paroxetine should not be used to treat depression in
children younger than 18 years [8]. Following this investigation,
the Committee on Safety of Medicines (CSM) reviewed the safety
of all antidepressants in children and adolescents and in December
2003 advised against the initiation of all SSRIs, except fluoxetine
in children [9]. Fluoxetine is the only drug currently licensed to
treat depression in children in the UK as its benefits were deemed
greater than its risks [10,11]. The CSM, however, does
recommend psychotherapies, such as cognitive-behavioural ther-
apy, as first-line treatment for children and adolescents with
depression. The American Food and Drug Authority (FDA)
followed suit in October 2004 and issued a black box warning for
all antidepressants prescribed to children [12].
Following the CSM advice, fewer children and adolescents in
the UK were prescribed antidepressants in primary care [13].
There was a 48% reduction in the initiation of CSM-contraindi-
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cated antidepressants in children between 2002 and 2004.
However, the use of fluoxetine and non-SSRI antidepressants in
children had not significantly risen during the same period. A
similar pattern was found in a study in Australia, where
antidepressant use, and SSRI use in particular, in children and
adolescents decreased between 2002 and 2005 [14]. In stark
contrast, the use of SSRIs and all antidepressants increased
significantly in adults during the same period.
Time trends in antidepressant prescribing in children have been
described for periods leading up to the CSM advice [1,13], but this
is the first comprehensive study which covers trends in the
recording of depression diagnoses and symptoms, and the
prescription of antidepressants in children and adolescents from
1995 to 2009 in a large UK general practice database.
Methods
Ethics statement
The scheme for THIN to obtain and provide anonymous
patient data to researchers was approved by the National Health
Service South-East Multicenter Research Ethics Committee
(MREC) in 2002 and scientific approval for this study was
obtained from CMD Medical Research’s Scientific Review
Committee in March 2011.
Data Source
Approximately 98% of the population in the UK is registered
with a general practitioner [15]. The Health Improvement
Network (THIN) database is one of the largest national collections
of primary care data and is broadly representative of the general
practice (GP) population in terms of demographics and consulta-
tion behaviour [16]. Participating general practitioners from 497
practices enter clinical information on patients, including demo-
graphics data, diagnoses, and prescriptions so as to offer a
longitudinal medical record for each patient which is available to
researchers as anonymised data [17]. Clinical diagnoses recorded
by GPs on THIN have been shown to be accurate compared with
other reliable sources [18]. The database provides the Townsend
score measure of deprivation, a composite measure of social
deprivation in quintiles (owner occupation, overcrowding, car
ownership, and unemployment) [19]. It is based on patient postal
code and linked to UK census data from 2001 for approximately
150 households in that postal area. We analysed data from 1995 to
2009.
Study population
We identified a cohort of children aged up to 18 years who were
registered with a General Practice which was a part of THIN for
at least six months between January 1995 and December 2009.
Children entered the cohort when they registered with a General
Practice, or, the date when their practice joined the THIN scheme
and met standards for acceptable levels of data recording [20].
Children remained in the cohort until aged 18 years, transfer out
of the practice, date of death or date of last data collection from
the practice.
Measurements
Outcome. We examined entries made of diagnoses and
symptoms of depression. Depression diagnosis codes ranged from
‘dysthymia’ and ‘mild depression’ to ‘recurrent severe major
depression’, but excluded codes that indicated other mental
disorder such as psychosis or anxiety. Depression symptoms relate
to codes indicating depression but are not certain enough to be
classified as a diagnosis, such as ‘symptoms of depression’ or ‘C\O
feeling depressed’. We also examined antidepressants BNF codes
prescribed by the general practitioner at any dose, except for high
dose TCAs (50 mg) that were indicated for nocturnal enuresis [6].
These code lists have been created and used in previous studies
and were developed in line with published methods and reviewed
by a general practitioner [21,22].
Potential confounders. We included information on age,
gender and social deprivation score in our analysis as these are
known to be associated with childhood depression and the
distribution of these variables may change over the 15 year
study period.
Statistical analysis. We described the baseline socio-
demographic characteristics of the cohort using frequency tables.
We calculated annual incidence rates and 95% confidence
intervals (CI) for depression diagnoses, symptoms and
antidepressant prescriptions by dividing the annual number of
incident cases by the total person-years at risk (PYAR) for each
year.
Incidence rate ratios adjusted for gender, age and quintiles of
Townsend deprivation score) were estimated using a Poisson
regression model. The analyses were adjusted for clustering at
practice level.
A Lewis plot [23] was used to explore the association between
time since registration and incidence rates as prior diagnoses might
be registered at or near the time of registration and these ought not
to be included in the incidence rates. The Lewis plots revealed that
there was an increased rate of depression diagnoses, symptoms and
antidepressant prescribing in the first month after registration,
after which the rate of recording dropped to a steady state (results
not shown). To correct for this, we started follow= up one month
after registration.
In order to assess the effects of the CSM advice on
antidepressant prescribing, a segmented regression analysis [24]
was performed using the Jointpoint regression program (version
3.5.1) from the Surveillance Research Program of the US National
Cancer Institute [25]. Jointpoint is statistical software for the
analysis of trends using Jointpoint models [26]. This analysis
allows for identifying points where there is a change in the linear
slope of the trend. The analysis started with the minimum number
of jointpoints (i.e., 0 jointpoints, which is a straight line), and tested
whether one or more jointpoints (up to 4) were statistically
significant and should be added to the model. The models
incorporated estimated variation for each point by using the
standard error of the rate estimate. After identifying the existence
of a change in the trend, a segmented regression was fitted and the
result of the best model was shown graphically. Finally, the
estimated annual percentage of change (APC) and its correspond-
ing 95% CI was computed for each of those trends by fitting a
regression line to the natural logarithm of the rates, using calendar
year as a regression variable [27].
All other analyses were conducted in of Stata, version 11.2
(Stata Corp, College Station, Texas).
Results
In total, 1,502,753 children up to the age of 18 were registered
with their GP for at least one year in The Health Improvement
Network (THIN) UK primary care database. Of these children,
45,723 (3%) children had at least one entry of a depressive
symptom, diagnosis or antidepressant prescription. Of these
children, 17,124 (38%) had a diagnosis of depression, 22,587
(49%) had a record of depressive symptoms, and 25,473 (56%)
were prescribed antidepressants, 16,925 of which were SSRIs
(Figure 1). Most of these antidepressant prescriptions were for
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SSRIs: 16,925 (66%), with TCAs representing 7,777 (31%) and
other antidepressants 771 (3%) of prescriptions (Table 1). Of the
children receiving SSRIs, 4,339 (26%) were not diagnosed with
depression or depression symptoms. Similarly, 7,211 (42%) of
children diagnosed with depression were not prescribed antide-
pressants.
Rates for entries of diagnoses of depression increased from 2.2
(95% CI 1.9–2.5) per 1,000 PYAR in 1995 to 3.0 (95%CI:2.8,3.1)
per 1,000 PYAR in 2002, then dropped to 2.0 (95%CI:1.9,2.1) per
1,000 PYAR in 2005 and have since been relatively constant at
around 2.0 per 1,000 PYAR (Figure 2). Rates for antidepressant
prescribing show a similar pattern: they have gone up from 2.8
(95%CI:2.4,3.1) per 1,000 PYAR in 1995 to 4.5 (95%CI:4.3,4.6)
per 1,000 PYAR in 2002, then dropped to rates similar to the
initial 1995 rates, but have been increasing again since 2005.
Recording of symptoms has seen a dramatic rise from 1.0
(95%CI:0.8,1.2) in 1995 to 4.7 (95%CI:4.5,4.8) per 1,000 PYAR
in 2009.
TCAs were the most common antidepressant prescribed to
children in 1995, but by 1999 SSRIs had overtaken them and have
been the preferred drug type ever since (Figure 3). However, since
2003 there has been a sharp decline in SSRI prescriptions, with
rates decreasing from 3.2 (95%CI:3.0,3.3) per 1,000 PYAR in
2002 to 1.7 (95%CI:1.7,1.8) per 1,000 PYAR in 2005. Since then,
rates have gradually started increasing again. TCA prescription
rates have gradually decreased since 1995, but stopped decreasing
in 2006. Rates for MAOIs and other antidepressants were
negligible (results not shown).
In children aged 3–11 years, girls were less likely than boys to be
diagnosed as depressed (IRR=0.79, 95%CI:0.67,0.92), have
depression symptoms recorded (IRR=0.90, 95%CI:0.84,0.95) or
be prescribed antidepressants (IRR=0.63, 95%CI:0.58,0.69;
Table 2). In children aged 12–18, girls were more likely than boys
to have been diagnosed as depressed (IRR=2.87,
95%CI:2.77,2.97), have symptoms recorded (IRR=2.31,
95%CI:2.23,2.39) or have been prescribed antidepressants
(IRR=2.71, 95%CI:2.63,2.80). When comparing age groups, the
incidence of all three outcomes in the younger age group (3–11 years
old) is only a fraction of that in the older age group (12–18 years old).
Rates for all depression indicators increased with deprivation:
children and adolescents in the most deprived quintile were twice as
likely to be diagnosed as depressed (IRR=2.14, 95%CI:2.03.2.26)
or be prescribed antidepressants (IRR=1.91, 95%CI:1.82,2.00)
compared to children and adolescent in the least deprived quintile.
For depression symptoms, there was an almost 50% increase of
recording in the most deprived compared to the most affluent
children and adolescents (IRR=1.43, 95%CI:1.36,1.50).
Segmented regression analysis
The Jointpoint analysis suggested for SSRIs as a group, there
were two time points were prescription rates changed: 2002 and
2005. Up to 2002 prescription rates for SSRIs had been
significantly increasing nearly 16% from 1995–2002 (Table 3,
Figures 4A & 4B). However, between 2002 and 2005 the rates
were stagnant, followed by a significant increase of nearly 11%
from 2005 to 2009 (Table 3).
Individual SSRIs followed a similar pattern: fluoxetine,
citalopram, paroxetine and sertraline rates all were increasing
from 1995 to the early 2000s before showing a temporary
decrease, or stall, in prescription rates. Paroxetine was the only
SSRI which showed a statistically significant decrease in
prescription rates. Rates for citalopram and sertraline started
increasing again in 2005, while rates for fluoxetine and paroxetine
remained stable (Table 3).
In contrast, rates for TCAs as a group showed a significant
decrease between 1995 and 2006, after which there was no
significant change. Rates for amitriptyline prescriptions showed a
moderate decrease between 1995 and 2006, but started to increase
after this point. Imipramine prescription rates showed a steady
decline over the entire period.
Figure 1. Venn diagram which shows the intersection between depression diagnoses, symptoms and antidepressant prescriptions.
doi:10.1371/journal.pone.0033181.g001
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Discussion
Key Findings
To our knowledge, this is the first large paediatric database
study to compare depression diagnoses, symptoms and antide-
pressant prescriptions and the effects the CSM advice over a
longer time period in the UK. We have found that prescription
rates of SSRIs as a group decreased from 3.2 per 1,000 person-
years in 2002 to 1.7 per 1,000 person-years in 2005. More
specifically, rates for contra-indicated SSRIs, i.e. citalopram,
Table 1. Study population characteristics by antidepressant (AD).
Characteristic of first-time
new users Individuals by AD drug group
SSRI
(n =16925)
TCA
(n=7777) Other (n =769) MAOI (n =2)
Any AD
(n=25473)
Socio-demographic
Girls 12142 (71.7) 4680 (60.2) 488 (63.5) 1 (50.0) 17311 (68.0)
Most commonly
prescribed drug (#
prescriptions)
Fluoxetine (8157) Amitriptyline (4402) Mirtazapine (320) Moclobemide (2) -
Deprivation quintile
1 (most affluent) 3252 (19.2) 1631 (21.0) 144 (18.7) 1 (50.0) 5028 (19.7)
2 3063 (18.1) 1451 (18.7) 105 (13.7) 0 4619 (18.1)
3 3456 (20.4) 1646 (21.2) 139 (18.1) 0 5241 (20.6)
4 3732
(22.1)
1706 (21.9) 182 (23.7) 0 5620 (22.1)
5 (most deprived) 3195
(18.9)
1259 (16.2) 191 (24.8) 1 (50.0) 4646 (18.2)
Not recorded 227 (1.3) 84 (1.1) 8 (1.0) 0 319 (1.3)
Age groups
3–10 years 179 (1.1) 1577 (20.3) 7 (0.9) 0 (0) 1764 (6.9)
11–14 years 1567 (9.3) 1558 (20.0) 53 (6.9) 1 (50.0) 3192 (19.4)
15–18 years 15179 (89.7) 4642 (59.7) 709 (92.2) 1 (50.0) 20652 (80.7)
Values are numbers (column percentages) unless otherwise indicated.
SSRI = selective serotonin reuptake inhibitor; TCA= tricyclic antidepressant; MAOI =mono-amine oxidase inhibitor; other ADs are: mirtazapine, venlafaxine, flupentixol,
duloxetine, nefazodone and reboxetine.
doi:10.1371/journal.pone.0033181.t001
Figure 2. Trends in the incidence of childhood depression, symptoms and antidepressants from 1995 to 2009.
doi:10.1371/journal.pone.0033181.g002
Trends in Depression in Children and Adolescents
PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e33181
236
paroxetine and sertraline, went down during that period, while
rates for fluoxetine remained stable and rates for TCAs were not
affected. The decline in prescription rates was sharpest for
paroxetine. Similar to SSRI prescription rates, rates for depression
diagnoses entries decreased from 3.0 per 1,000 person-years in
2002 to 2.0 per 1,000 person years in 2005. Depression symptom
recording saw a steady increase over the study period, increasing
from 1.0 per 1,000 person-years in 1995 to 4.7 per 1,000 person-
years in 2009. Finally, rates for SSRIs as group and citalopram in
particular, were increasing after 2005.
The decrease in recording of both depression diagnoses and
antidepressant prescriptions after 2002 could indicate caution on
the part of GPs in diagnosing depression and prescribing
antidepressants following the CSM advice. Moreover, GPs might
prefer to record depression symptoms rather than diagnose a child
as depressed. The decrease in contra-indicated SSRIs as opposed
Figure 3. Rates of prescription of Tricyclic Antidepressants (TCA) and Selective Serotonin Reuptake Inhibitors (SSRI) in children.
doi:10.1371/journal.pone.0033181.g003
Table 2. Incidence rate ratios (IRR) for diagnosis and symptoms of depression and antidepressant prescriptions stratified by
gender, age group and deprivation.
Multivariablea: stratified by
age group: 3–11
Multivariablea: stratified by
age group: 12–18
Multivariablea: stratified by
deprivation:
Townsend 1 & 2c
Multivariablea: stratified by
deprivation:
Townsend 4 & 5c
IRR (95% CI) Pb IRR (95% CI) Pb IRR (95% CI) Pb IRR (95% CI) Pb
Diagnosed depression
Gender
Boy Reference Reference Reference Reference
Girl 0.79 (0.67–0.92) 0.003 2.87 (2.77–2.97) ,0.001 2.58 (2.44–2.73) ,0.001 2.93 (2.78–3.09) ,0.001
Symptoms of depression
Gender
Boy Reference Reference Reference Reference
Girl 0.90 (0.84–0.95) 0.001 2.31 (2.23–2.39) ,0.001 1.75 (1.67–1.83) ,0.001 2.12 (2.02–2.22) ,0.001
Antidepressant prescription
Gender
Boy Reference Reference Reference Reference
Girl 0.63 (0.58–0.69) ,0.001 2.71 (2.63–2.80) ,0.001 2.26 (2.16–2.36) ,0.001 2.57 (2.47–2.69) ,0.001
aAdjusted for calendar year, gender, deprivation, age and for clustering by general practitioner practice using robust standard errors.
bP based on Wald test.
cA Townsend score of 1 or 2 represents the most affluent patients, while patients with a Townsend score of 4 or 5 live in the most deprived areas.
doi:10.1371/journal.pone.0033181.t002
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to fluoxetine strengthens the possibility of a link with the CSM
advice.
Although the Jointpoint program points to 2002 as the time point
where SSRI rates changed, the observed data shows that rates did
not decrease until after 2003, the year when the CSM advice was
issued. However, prescription rates could have started decreasing
prior to the CSM advice as information regarding the safety and
effectiveness of SSRIs was circulating in the specialist community
before the advice was issued and could have influenced changes in
prescription recommendations. Similarly, the program does not
qualify the small dip in fluoxetine rates around 2005 as statistically
significant. This dip might be related to the requirement of the US
Food and Drug Administration (FDA) to add a black box warning to
all antidepressants, including fluoxetine and TCAs, about an
increased risk of suicidal behaviour in 2004 [12].
The sharp decline in paroxetine prescription rates could be
related to the advice by the MHRA against the prescribing of
paroxetine specifically. This advice was issued in June 2003,
preceding the overall SSRI advice in December of the same year.
It followed a review of randomised controlled trials that showed
higher rates of suicidal thought and behaviour (but not completed
suicides) in patient who took paroxetine (25 out of 738; 3%),
compared to those who took placebo (8 out of 647; 1%; p for
difference = 0.01) [8].
The BBC programme that initially started the controversy
implied that paroxetine (brand name Seroxat) was addictive, had
severe withdrawal symptoms and could increase the risk of suicidal
behaviour [28]. This might have led to patients being biased
against taking paroxetine as a first line of treatment, and making it
difficult to determine whether the sharp decline in paroxetine
Figure 4. Observed and modelled prescription rates for individual (A) Selective Serotonin Reuptake Inhibitors (SSRIs) and (B)
Tricyclic Antidepressants (TCAs).
doi:10.1371/journal.pone.0033181.g004
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prescriptions in primary care was due to a negative public opinion
of the drug in response to the issues raised in the programme, or
the advice issued by the CSM half a year later.
The increase in SSRI prescription rates after 2005 could
indicate that concerns about a possible suicidality risk associated
with SSRIs have waned. Several studies found no increased risk of
suicidality for SSRIs [29,30], or increases in suicide rates that
coincided with decreases in SSRI prescription rates [31]. In the
US, 2004 saw the largest single-year increase in suicide rates in
adolescents aged 10–19 years [32]. From 1990 to 2003 suicide
rates had been decreased by 28%, but in 2004 they had increased
with 15% from 6.78 to 7.32 per 100,000 people. This might have
led GPs to revaluate prescribing SSRIs to children and
adolescents, although doubts continue to exist regarding the safety
and effectiveness of SSRIs [33,34].
Comparison to other studies
The antidepressant prescription rates we found are similar in
size and trend to those found by a General Practice Research
Database study which studied prescription rates from 1992 to
2001 [1]. We also found similar age and gender effects. Our results
also confirm findings by Murray et al. who found a decrease in
SSRI prescribing in between 2003 and 2004, while prescribing
rates for fluoxetine remained stable [13]. However, the study by
Murray et al. did not assess data for individual drugs, apart from
fluoxetine, whereas our study did take different SSRIs into
account.
A study based on Australian data also found a decrease in
antidepressant use in children, in particular of SSRIs [14]. They
also saw a sharp rise of fluoxetine over time, which we did not find
in the UK. This might be explained by sertraline being the most
commonly prescribed antidepressant in Australia before the SSRI
controversy started, whereas fluoxetine was already the drug of
first choice in the UK before the CSM advice.
Main Strengths and Limitations
The main strength of this study is its sample size that enables
examination of outcomes separately for girls and boys, and by
drug. There is no clear reason to believe the results would differ for
the entire population of UK children.
However, there are also limitations. In using data from general
practices, few children might have been missed out if their
depression was not severe enough to warrant a visit to a GP, or if
they were diagnosed outside a general practice setting, e.g. by a
child psychiatrist. However, a study on depression in adults found
that although incidence rates in the THIN database are lower than
depression rates found in epidemiological studies, associations with
covariates such as gender and deprivation were similar [35]. Also,
non-psychiatric physician’s recognition of depression has been
found to have a limited sensitivity, but a high specificity [36,37].
Childhood depression rates might have been underestimated in
this study, but trends and associations with other variables are
likely to be representative of the general population. Moreover, as
we were specifically interested in the effects of the CSM advice in
primary care settings, this limitation will have only a minimal
effect on our results.
While data on prescriptions is available in the THIN database,
there is no information on dispensing and treatment compliance.
Thus the antidepressant prescription rates we found might not
reflect antidepressant use. However, we aimed to study prescrip-
tion rates in primary care, so this does not affect our estimates.
Conclusions
After 2002, general practitioners decreased their prescribing of
contra-indicated SSRIs, particularly paroxetine. Rates for fluox-
etine, the only SSRI not to be contra-indicated, remained stable.
Depression diagnoses mirrored prescription rates and decreased
between 2002 and 2005, suggesting caution on the side of GPs.
The timing and direction of these trends imply that GPs followed
the CSM advice, although it cannot be ruled out that these trends
resulted from the negative media attention SSRIs received around
the same time. After 2005, rates for all antidepressants, except
paroxetine, started recovering. This is in line with results from
observational studies that found no increased risk of suicidal
behaviour with SSRIs.
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Table 3. Annual percentage change (APC) for selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) as
groups and individual drugs.
APC 1 (95% CI) Period APC 2 (95% CI) Period APC 3 (95% CI) Period
SSRIs 15.8* (8.5–23.6) 1995–2002 219.7 (236.2–1.0) 2002–2005 10.6* (3.1–18.8) 2005–2009
Fluoxetine 11.6 (20.4–25.1) 1995–2001 21.8 (24.8–1.3) 2001–2009
Citalopram1 37.7 (24.7–98.9) 1999–2002 222.0 (251.1–45.4) 2002–2005 29.0* (14.4–45.4)2005–2009
Paroxetine2 67.9 (227.1–286.9) 1995–1997 22.2 (212.2–9.1) 1997–2002 269.1* (284.2–
39.5)
2002–2005
Sertraline3 20.5* (6.1–37.0) 1996–2002 229.4 (254.2–9.0) 2002–2005 4.3 (211.3–22.6)2005–2009
TCAs 29.5* (210.3–8.7) 1995–2006 6.5 (1.0–12.2) 2006–2009
Amitriptyline 21.8 (23.8–0.3) 1995–2006 11.9* (2.3–22.3) 2006–2009
Imipramine 217.1* (218.6–15.6) 2006–2009
*Annual percentage change (APC) is statistically significant (p,0.05) different from 0.
1Observations start in 1999 for citalopram as prescription rates were negligible (,10 prescriptions a year) before this year.
2Observations stop in 2005 for paroxetine as it is only prescribed sporadically (,5 prescriptions a year) after this time point.
3Observations start in 1996 for sertraline as prescription rates were negligible (,10 prescriptions a year) before this year.
doi:10.1371/journal.pone.0033181.t003
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Appendix G
Scientific approval
SRC Feedback 
 
Researcher Name: Dr Irene Petersen 
Organisation: UCL 
SRC Reference Number: 11-005A 
Date: 10/05/2011 
Study title: Trends in the incidence of childhood depression in the United Kingdom 
Committee opinion: Amendment approved 
______________________________________________________________ 
 
The following feedback has been supplied by the SRC.  
 
Notes from the Chair:  
 
I am happy to approve this amendment to the original proposal. I have no fundamental 
concerns and I am happy to approve the revision. 
 
I have made two further suggestions which the applicants may find useful. However these are 
not compulsory revisions, only suggestions. 
 
IDENTIFICATION OF OUTCOME EVENTS (SUICIDES) 
 
My understanding is that there is some difficulty in ascertaining whether deaths are suicides 
in electronic primary care records. (1) There may be problems in identification of some 
diagnoses in electronic primary care records. (2) However there are methods for identification 
of suicides in electronic primary care records and it would be useful for the authors to refer to 
these methods. (3) 
 
PRELIMINARY ANALYSIS 
 
There may be a problem of confounding associated with prescription. It is likely that more 
severely depressed children are more likely to be prescribed antidepressants (or 
antidepressants unlicensed for use in adolescents) and are also more likely to commit 
suicide. 
 
The authors might like to consider a matched case control study as an initial investigation of 
the relationship between antidepressant drug prescription and suicide. Cases are children 
with a diagnosis of suicide identified using a previously described methodology (ref 3) and 
who have been prescribed an antidepressant in the 6 months prior to diagnosis. Controls are 
age and sex matched who have also been prescribed an antidepressant in the 6 months prior 
to diagnosis. Odds ratios can be determined by conditional logistic regression analysis. These 
will give an indication whether there is a difference in frequency of exposure to a specific type 
of antidepressants prior to suicide. 
 
This is a more rapid analysis than a retrospective cohort study and may help decide if there is 
prima facie evidence of an association between. Including only persons prescribed an 
antidepressant removes some of the confounding associated with prescription.  
 
Ref: 
 
1) Hall G. Validation of death and suicide recording on the THIN UK primary care 
database Pharmacoepidemiology and Drug Safety 2009 Feb;18(2):120-131 
2) Khan NF et al Validity of diagnostic coding within GPRD: a systematic review BJGP 
2010 Mar;60(572):e128-36. 
3) Arana A et al An algorithm for the diagnosis of suicide in the THIN database 
Pharmacoepidemiology and Drug Safety 2010 18:S1-347 
 
______________________________________________________________ 
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We are pleased to inform that you can proceed with the study as amendment is now 
approved.  
 
Once the study has been completed and published, you must let CSD Medical Research 
know in order for your reference number to be closed.  
 
CSD Medical Research will let the relevant Ethics committee know this study has been 
approved by the SRC and will inform them of study completion (when known) on your behalf.  
 
I wish you and your team all the best with the study progression.  
 
Kind Regards,  
 
 
Mustafa Dungarwalla  
Research Associate 
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Page 1 
SRC Feedback 
 
Researcher Name: Linda Wijlaars 
Organisation: UCL 
SRC Reference Number: 12-032 
Date: 20/08/2012 
Study title: Trends in sleep disorders and sleeping drug treatment in children and the 
association with depression 
Committee opinion: Approved 
______________________________________________________________ 
 
The following feedback has been supplied by the SRC.  
 
Notes from the Chair:  
 
The protocol appears to be of a reasonably good standard. The proposed methods are valid 
and the objectives may be feasibly addressed using THIN data. 
The overall response therefore is to approve the protocol.  The comments given in the advice 
section are to help the researcher to fine-tune their methods. 
 
Advice  
(General advice for the researchers as information only) 
Overall, the protocol is well written, expressing clearly the aims, methods and potential 
limitations.  The first two objectives may be readily addressed using THIN data; the third 
objective may also be addressed using THIN data, although consider how to handle the 
potential limitations highlighted in the comments below.  The methods are appropriate for 
addressing the study questions.  Some specific comments/ suggestions: 
1. The background section highlights well the lack of previous research in this area.  However, 
could you provide more detail in the background of the need/motivation for the research and 
perceived value of the research in terms of the potential public health/ clinical benefit? 
2. The third objective could be more precisely expressed 
3. Clarify why the population comprises children aged 3 to 18 years, while the children enter 
the cohort from age 5 years. 
4. When defining start and end dates for follow-up, consider use of data quality control dates 
(e.g. AMR date). 
5. Townsend score is included in the analyses.  Consider pre-specifying how to handle patients 
with missing Townsend score.  Will practices with no Townsend data be excluded? 
6. Sleeping problems due to physical illness e.g asthma/ sickle cell will be excluded.  How will 
these cases be identified? Are there specific codes for sleeping problems due to asthma or will 
all patients with asthma be excluded? 
7. Consider whether there may be other possible confounders than Townsend score.  If these 
factors are not available in THIN, how might not adjusting for the confounders affect the 
results? 
8. Sleeping disorders and depression may recur. How will repeated episodes be handled in the 
analyses? Will patients who have prior episodes at baseline be excluded? 
9. Clarify how the proportional hazards assumption will be tested. 
10. Have preliminary analyses been carried out to estimate the size (number of children) in the 
cohort?  How many children are likely to have sleep disorders in THIN? 
11. Could individual likelihood to consult lead to bias in the association between sleep disorders 
and depression (children/ parents may differ in their likelihood to consult their GP in general - 
those who consult more may be more likely to consult for both depression and sleep disorders 
than those who don't which could lead to overestimation of an association). 
12. For the oldest children, is up to one year long enough to allow people to get depression 
after their sleep disorders? 
13. Might the cohort be limited by the number of variables you are choosing to match on? It 
may be better to control for some of these variables in the analysis instead. 
14. It may be difficult to determine the temporal relationship between sleep disorders and 
depression. The researchers may need to derive rules to distinguish between the exposure and 
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outcome occuring contemperaneously and when they are truly occuring before or after each 
other. 
15. The list of physical disorders which may give rise to secondary sleep conditions needs to be 
carefully developed 
16. The researchers list some important limitations to the work which will always need to be 
considered during analysis, write-up and dissemination. The prescription of antihistamines for 
indications other than sleep is particularly important. Is it worth developing codelists for the 
most common alternative diagnoses for which antihistamines are prescribed? 
17. The researchers list some important limitations to the work which will always need to be 
considered during analysis, write-up and dissemination. The prescription of antihistamines for 
indications other than sleep is particularly important. Is it worth developing codelists for the 
most common alternative diagnoses for which antihistamines are prescribed?    
 
 
______________________________________________________________ 
 
We are pleased to inform that you can proceed with the study as this is now approved.  
 
Once the study has been completed and published, you must let CSD Medical Research 
know in order for your reference number to be closed.  
 
CSD Medical Research will let the relevant Ethics committee know this study has been 
approved by the SRC and will inform them of study completion (when known) on your behalf.  
 
I wish you and your team all the best with the study progression.  
 
Kind Regards,  
 
 
Mustafa Dungarwalla  
Research Associate 
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SRC Feedback 
 
Researcher Name: Linda PMM Wijlaars 
Organisation: UCL 
SRC Reference Number: 13-041 
Date: 15
th
 July 2013 
Study title: A longitudinal study on the association between parental depression in the first 
postpartum year and adolescent depression 
Committee opinion: Approved 
______________________________________________________________ 
 
The following feedback has been supplied by the SRC.  
 
Notes from the Chair:  
 
While we approve the protocol, I hope the attached comments will prove useful to the 
investigators 
 
Advice  
(General advice for the researchers as information only – for advice only) 
A) Triads that move out may differ from those who remain, despite the statement at the top of 
page 7. I am not certain about the literature on "movers" but suspect they may be more 
deprived and possibly more subject to depression (their depression may lead to relationship 
breakdown leading to re-housing, and after a move, a family may become at greater risk of 
depression - the former phenomenon is likely to be more of an issue for this project) 
B) Parental divorce may impact more strongly on adolescent depression than parental 
depression. Yet because of divorce, fewer episodes of depression may come to light (especially 
among fathers who are more likely to move out) - is parental divorce thus a collider rather 
than a confounder? 
C) Inclusion criteria in penultimate para on page 2 mentions children born from 1994-2011, 
but page 5 says all children with 15 years of follow-up (so presumably children born before 
1997 ?). Will this still provide sufficient sample size? 
D) Rev 2:-  
(i)I'd imagine that the composite "internalizing behavior" as a mediator of depression is a 
particularly challening diagnosis to confirm, and there potentially could be exposure 
misclassification.  Has any preliminary work been conducted to assess the charactecteristics of 
this classification in terms of predicting depression in adolescents?   
(ii)Is there the possibility for confounder misclassification regarding child abuse, drug abuse,a 
nd alcohol abuse?  How would this affect the IPW analysis suggested?  Could additional  
sensitivity analyses assess this effect? 
(iii)Is will follow-up time be adequate to assess the outcome of interest for the birth cohort? 
Have any preliminary sample size calculations   [NB from chair: I think comment (iii) is like my 
own comment C) above.] 
Re point A above: do a descriptive comparison of triads who move versus those who stay. This 
is among families whose child should have reached adolescence by the end point of data 
collection (?? born earlier than 1997) 
 
Re point B: I am confident the range of statistical models proposed by the authors can address 
the concern outlined above, even if my hunch is correct - I would only ask the investigators to 
consider the point. 
 
I am very impressed by the innovative use of statistical methods such as marginal structural 
models. I was only curious about the IPW (lower half of page 4): is it really desirable that a 
rare confounder should receive high weight in an analysis? 
 
Rev 1:- 
This is a very interesting study and the team obviously have a good understanding of the 
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strengths and weaknesses of the data, as well as the clinical problem. 
I thought there might be other explanations for any positive findings in the pathway analysis if 
so-called internalising behaviours proved important. These conditions might be markers for 
other things. In addition, these internalising conditions will be more frequently recorded in 
some patients than others, perhaps including those with depression. 
I was worried that life events would not be well recorded  
[NB from chair: the comment on "internalising behaviours" may have overlap with Reviewer 1's 
comment D)(i) above] 
 
Rev 2:- 
In general, this is a well-constructed research proposal, designed by a research team that is 
familiar with THIN and has done some similar research in this database previously.  I have 
some minor concerns listed above not as "fundamental issues" that should inhibit the approval 
of this proposal per se, but perhaps would be best used as questions to think about in 
conducting the study.  Additional sensitivity analyses may be useful to explore the effects of 
confounder and mediator misclassification on the relationship between the exposure and 
outcome.    
 
 
______________________________________________________________ 
 
We are pleased to inform that you can proceed with the study as this is now approved. CSD 
Medical Research will let the relevant Ethics committee know this study has been approved 
by the SRC. 
 
Once the study has been completed and published, it is important for you to inform CSD 
Medical Research in order for us to advise the SRC and your reference number to be closed. 
 
References to all published studies are added to our website enabling other researchers to 
become aware of your work. Copies of publication(s), where available, will be appreciated.  
 
I wish you and your team all the best with the study progression.  
 
Mustafa Dungarwalla  
Research Associate 
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